Cycloalkyl- or haloalkyl-containing compounds

Novel compounds targeting the EGFR pathway effectively address drug resistance in lung cancer by inhibiting the C797S mutation, improving treatment efficacy against EGFR-TKI resistance.

JP2024543127APending Publication Date: 2024-11-19CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024531016
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-25
Filing Date
2022-11-30
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing EGFR-TKI drugs like Osimertinib face significant resistance issues due to the EGFR C797S mutation, necessitating the development of more effective inhibitors to overcome drug resistance in tumors, particularly in lung cancer.

Method used

Development of novel compounds represented by Formula I and its stereoisomers or pharmaceutically acceptable salts, which target the EGFR pathway, inhibiting tyrosine kinase activity to combat drug resistance, including the C797S mutation.

Benefits of technology

The compounds demonstrate superior kinase and cellular activity against wild-type and mutant forms of EGFR, enhancing in vivo and in vitro metabolic stability and efficacy in treating EGFR-mediated diseases such as lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543127000001_ABST
    Figure 2024543127000001_ABST
Patent Text Reader

Abstract

The present invention relates to a compound containing cycloalkyl or haloalkyl, and specifically discloses a compound represented by formula I″, its stereoisomer, or a pharma- ceutically acceptable salt thereof, a method for preparing the same, a pharmaceutical composition containing the same, and its use in tumor treatment. JPEG2024543127000211.jpg64105
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to and benefit of Chinese patent application no. 202111441498.1 filed on November 30, 2021, Chinese patent application no. 202111638379.5 filed on December 29, 2021, Chinese patent application no. 202210564004.7 filed on May 23, 2022, Chinese patent application no. 202210889925.0 filed on July 27, 2022, and Chinese patent application no. 202211492694.6 filed on November 25, 2022, all of which are hereby incorporated by reference in their entireties. [Technical Field]

[0002] The present invention relates to compounds containing cycloalkyl or haloalkyl, and specifically discloses a compound represented by formula I″, its stereoisomer, or a pharmaceutically acceptable salt thereof, a method for preparing the same, a pharmaceutical composition containing the compound, and its use in tumor treatment. [Background technology]

[0003] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are small molecule inhibitors that competitively bind to EGFR via endogenous ligands, inhibiting tyrosine kinase activation and thereby blocking the EGFR signaling pathway. These inhibitors ultimately produce a series of biological effects, including inhibition of tumor cell proliferation and metastasis and promotion of tumor cell apoptosis, making them a major target for lung cancer treatment.

[0004] Osimertinib (AZD9291), a third-generation EGFR-TKI drug, has demonstrated a high response rate against drug resistance caused by the T790M mutation. However, patients may still develop drug resistance. Previous studies have shown that the acquisition of a third mutation, the EGFR C797S mutation, is one of the main mechanisms causing resistance to osimertinib, accounting for approximately 40% of cases. Providing patients with safer and more effective fourth-generation EGFR C797S / T790M inhibitors is of great research value. Summary of the Invention

[0005] According to one aspect, the present invention relates to a compound represented by the following formula I″ (hereinafter also referred to as “formula I″ compound”), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: JPEG2024543127000002.jpg64105 (in the formula, R 1 is C 3~5 Cycloalkyl, C 3~5 Cycloalkyl-C 1~3 Alkyl-, HaloC 1~6 Alkyl, or C 1~6 selected from alkyl, R 2 are hydrogen, halogens, OH, NH2, C 1~8 Alkyl, or C 1~8 alkoxy, wherein C 1~8 Alkyl or C 1~8 The alkoxy is optionally substituted by one or more R'; R' is selected from halogen, OH, cyano, NH2, or nitro; R 3 are halogens, cyano, nitro, NH2, OH, C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3-10 membered heterocyclyl, C 6~10Aryl, 5-10 membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH2, -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O)2H, -S(O)2R a , -S(O)2NH2, -S(O)2NR a R b , -NHS(O)2R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a , or -NHC(O)NHR a and C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3-10 membered heterocyclyl, C 6~10 The aryl or 5- to 10-membered heteroaryl may optionally be one or more R c is replaced by R c is oxo, OH, NH2, halogen, cyano, nitro, C 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 alkyl)2, -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NR a R b , -NHS(O)2R a , -C1~6 Alkyl-S(O)2-C 1~6 Alkyl, or optionally OH, halogen or C 1~6 3- to 8-membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; R a and R b are each independently a group optionally substituted by one or more R″: C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6~10 aryl, or 5- to 10-membered heteroaryl; R'' is independently halogen, oxo, deuterium, NH2, OH, cyano, nitro, C 1~8 Alkyl, HaloC 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 alkyl)2, -NH(C 1~8 alkyl), C 3~6 cycloalkyl, or optionally C 1~8 selected from 3- to 10-membered heterocycloalkyl substituted by alkyl; n is selected from 0, 1, 2, 3, or 4; R 4 is C 1~6 Alkyl or C 3~5 cycloalkyl, However, R 1 C 1~6 When selected from alkyl, R 4 is C 3~5 cycloalkyl.

[0006] In another aspect, the present invention relates to a compound represented by the following formula I′ (hereinafter also referred to as “formula I′ compound”), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. JPEG2024543127000003.jpg69100 (in the formula, R 1 is C 3~5Cycloalkyl, C 3~5 Cycloalkyl-C 1~3 Alkyl-, HaloC 1~6 Alkyl, or C 1~6 selected from alkyl, R 2 is hydrogen, C 1~8 Alkyl, or C 1~8 alkoxy, wherein C 1~8 Alkyl or C 1~8 The alkoxy is optionally substituted by one or more R'; R' is selected from halogen, OH, cyano, NH2, or nitro; R 3 are halogens, cyano, nitro, NH2, OH, C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3-10 membered heterocyclyl, C 6~10 Aryl, 5-10 membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH2, -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O)2H, -S(O)2R a , -S(O)2NH2, -S(O)2NR a R b , -NHS(O)2R a , -NHC(O)OR a , or -N(C 1~4 alkyl)C(O)OR a and C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10Cycloalkyl, 3-10 membered heterocyclyl, C 6~10 The aryl or 5- to 10-membered heteroaryl may optionally be one or more R c is replaced by R c is oxo, halogen, cyano, nitro, C 1~8 Alkoxy, -N(C 1~8 alkyl)2, -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NR a R b , -NHS(O)2R a or optionally OH, halogen or C 1~6 3- to 8-membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; R a and R b are each independently a group optionally substituted by one or more R″: C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6~10 aryl, or 5- to 10-membered heteroaryl; R'' is independently halogen, NH2, OH, cyano, nitro, C 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 alkyl)2, -NH(C 1~8 alkyl), C 3~6 cycloalkyl, or 3- to 10-membered heterocycloalkyl; n is selected from 0, 1, 2, 3, or 4; R 4 is C 1~6 Alkyl or C 3~5cycloalkyl, However, R 1 C 1~6 When selected from alkyl, R 4 is C 3~5 cycloalkyl.

[0007] In some embodiments, R 1 is C 3~5 Cycloalkyl, C 3~5 Cycloalkyl-C 1~3 Alkyl- or haloC 1~6 is selected from alkyl. In some embodiments, R 1 is C 3~4 Cycloalkyl, C 3~4 Cycloalkyl-C 1~2 Alkyl- or haloC 1~3 is selected from alkyl. In some embodiments, R 1 is selected from cyclopropyl, cyclopropyl-CH2-, or halomethyl.

[0008] In some embodiments, R 1 is selected from cyclopropyl, cyclopropyl-CH2-, or methyl substituted with one or more fluorines. In some embodiments, R 1 is selected from cyclopropyl. In some embodiments, R 1 is selected from cyclopropyl-CH2-.

[0009] In some embodiments, R 1 is selected from -CH2F, -CHF2, or -CF3. In some embodiments, R 1 is selected from methyl. In some embodiments, R 1 is C 3~4 Cycloalkyl, C 3~4 Cycloalkyl-C 1~2 Alkyl-, HaloC1~3 Alkyl, or C 1~3 is selected from alkyl.

[0010] In some embodiments, R 1 is selected from cyclopropyl, cyclopropyl-CH2-, halomethyl, or methyl. In some embodiments, R 1 is selected from cyclopropyl, cyclopropyl-CH2-, methyl substituted with one or more fluorines, or methyl. In some embodiments, R 2 are hydrogen, halogens, OH, NH2, C 1~6 Alkyl, or C 1~6 alkoxy, wherein C 1~6 Alkyl or C 1~6 The alkoxy is optionally substituted by one or more R'.

[0011] In some embodiments, R 2 are hydrogen, halogens, OH, NH2, C 1~3 Alkyl, or C 1~3 alkoxy, wherein C 1~3 Alkyl or C 1~3 The alkoxy is optionally substituted by one or more R'. In some embodiments, R 2 are hydrogen, fluorine, chlorine, bromine, C 1~3 Alkyl, or C 1~3 Selected from alkoxy. In some embodiments, R 2 is fluorine, chlorine, bromine, or C 1~3 is selected from alkyl. In some embodiments, R 2 is selected from fluorine or methyl.

[0012] In some other embodiments, R 2 is hydrogen, C 1~6 Alkyl, or C 1~6 alkoxy, wherein C1~6 Alkyl or C 1~6 The alkoxy is optionally substituted with one or more R'. In some further embodiments, R 2 is hydrogen, C 1~3 Alkyl, or C 1~3 alkoxy, wherein C 1~3 Alkyl or C 1~3 The alkoxy is optionally substituted by one or more R'.

[0013] In some other embodiments, R 2 is hydrogen, C 1~3 Alkyl, or C 1~3 Selected from alkoxy. In some other embodiments, R 2 is C 1~3 is selected from alkyl. In some other embodiments, R 2 is selected from methyl.

[0014] In some embodiments, R' is selected from halogen. In some embodiments, R 3 are halogens, cyano, nitro, NH2, OH, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3-8 membered heterocyclyl, C 6~10 Aryl, 5-6 membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH2, -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O)2H, -S(O)2R a, -S(O)2NH2, -S(O)2NR a R b , -NHS(O)2R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a , or -NHC(O)NHR a and C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3-8 membered heterocyclyl, C 6~10 The aryl or 5- to 6-membered heteroaryl may optionally be one or more R c has been replaced by

[0015] In some embodiments, R 3 are halogens, cyano, nitro, NH2, OH, C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH2, -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O)2H, -S(O)2R a , -S(O)2NH2, -S(O)2NR a R b , -NHS(O)2R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a , or -NHC(O)NHR a and C1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl may optionally be one or more R c has been replaced by

[0016] In some embodiments, R 3 are halogens, cyano, NH2, OH, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3-8 membered heterocyclyl, -NHR b , -NR a R b , -OR a , -SR a , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -NHS(O)2R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a , or -NHC(O)NHR a and C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 The cycloalkyl or 3- to 8-membered heterocyclyl may optionally be one or more R c has been replaced by

[0017] In some embodiments, R 3 is a halogen, C 1~4 Alkyl, C 2~4 Alkenyl, 4-6 membered heterocycloalkyl, -NHR b , -NR a R b , -OR a , -SR a , -OC(O)R a , -NHC(O)Ra , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a , or -NHC(O)NHR a and C 1~4 Alkyl, C 2~4 The alkenyl, or 4- to 6-membered heterocycloalkyl may optionally be one or more R c has been replaced by

[0018] In some embodiments, R 3 are fluorine, chlorine, bromine, C 1~3 Alkyl, C 2~4 Alkenyl, 4-5 membered azacycloalkyl, -NHR b , -NR a R b , -OR a , -SR a , -OC(O)R a , -NHC(O)R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a , or -NHC(O)NHR a and C 1~3 Alkyl, C 2~4 The alkenyl or 4- to 5-membered azacycloalkyl may optionally be one or more R c has been replaced by

[0019] In some embodiments, R 3 is bromine, methyl, butenyl, azetidinyl, pyrrolidinyl, -NHR b , -NR a R b , -OR a , -NHC(O)R a , or -NHC(O)NHR a wherein said methyl, butenyl, azetidinyl, or pyrrolidinyl is optionally selected from one or more R c has been replaced by

[0020] In some embodiments, R3 is bromine, JPEG2024543127000004.jpg1997-NHR b , -NR a R b , -OR a , -NHC(O)R a , or -NHC(O)NHR a Selected from.

[0021] In some specific embodiments, R 3 -NHR b , -NR a R b , -OR a , -NHC(O)R a , or -NHC(O)NHR a Selected from. In some specific embodiments, R 3 -NHR b , or -NR a R b In some specific embodiments, R 3 -OR a In some specific embodiments, R 3 is -NHC(O)R a , or -NHC(O)NHR a Selected from.

[0022] In some embodiments, R 3 is bromine, JPEG2024543127000005.jpg124107JPEG2024543127000006.jpg103120, or R 3 teeth, Selected from JPEG2024543127000007.jpg59107.

[0023] In some specific embodiments, R 3 teeth, Selected from JPEG2024543127000008.jpg111108JPEG2024543127000009.jpg77106.

[0024] In some other embodiments, the R 3 are fluorine, chlorine, bromine, C 1~4 Alkyl, C 2~4 Alkenyl, 5-6 membered heterocyclyl, -NHR b , -NR a R b , -OR a , -SR a , -OC(O)R a , -NHC(O)R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a , or -NHC(O)NHR a and C 1~4 Alkyl, C 2~4 The alkenyl or 5- or 6-membered heterocyclyl may optionally be one or more R c has been replaced by

[0025] In some other embodiments, the R 3 is bromine, methyl, butenyl, pyrrolidinyl, -NHR b , -NR a R b , -OR a , -NHC(O)R a , or -NHC(O)NHR a wherein said methyl, butenyl, or pyrrolidinyl is optionally selected from one or more R c has been replaced by

[0026] In some other embodiments, the R 3 is bromine, JPEG2024543127000010.jpg1879-NHR b , -NR a R b , -OR a , -NHC(O)R a, or -NHC(O)NHR a Selected from.

[0027] In some other embodiments, the R 3 is bromine, Selected from JPEG2024543127000011.jpg140107.

[0028] In some other embodiments, R 3 are halogens, cyano, nitro, NH2, OH, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3-8 membered heterocyclyl, C 6~10 Aryl, 5-6 membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH2, -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O)2H, -S(O)2R a , -S(O)2NH2, -S(O)2NR a R b , -NHS(O)2R a , -NHC(O)OR a , or -N(C 1~4 alkyl)C(O)OR a and C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3-8 membered heterocyclyl, C 6~10 The aryl or 5- to 6-membered heteroaryl may optionally be one or more R c has been replaced by

[0029] In some other embodiments, R 3 are halogens, cyano, nitro, NH2, OH, C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH2, -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O)2H, -S(O)2R a , -S(O)2NH2, -S(O)2NR a R b , -NHS(O)2R a , -NHC(O)OR a , or -N(C 1~4 alkyl)C(O)OR a and C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 The cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl may optionally be one or more R c has been replaced by

[0030] In some other embodiments, R 3 are halogens, cyano, nitro, NH2, OH, C 1~3 Alkyl, C 2~3 Alkenyl, C 2~3 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl, -NHR b , -NR aR b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH2, -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~3 alkyl)C(O)R a , -S(O)2H, -S(O)2R a , -S(O)2NH2, -S(O)2NR a R b , -NHS(O)2R a , -NHC(O)OR a , or -N(C 1~3 alkyl)C(O)OR a and C 1~3 Alkyl, C 2~3 Alkenyl, C 2~3 Alkynyl, C 3~6 The cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl may optionally be one or more R c has been replaced by

[0031] In some other embodiments, R 3 is halogen, cyano, NH2, OH, or -NHR b Selected from. In some other embodiments, R 3 is fluorine, chlorine, bromine, or -NHR b Selected from.

[0032] In some other embodiments, R 3 is bromine, Selected from JPEG2024543127000012.jpg1385.

[0033] In some embodiments, R c is OH, NH2, oxo, halogen, cyano, nitro, C 1~6 Alkyl, C 1~6Alkoxy, -N(C 1~6 alkyl)2, -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NR a R b , -NHS(O)2R a , -C 1~6 Alkyl-S(O)2-C 1~6 Alkyl, or optionally OH, halogen or C 1~4 and 3- to 6-membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0034] In some embodiments, R c is OH, NH2, oxo, halogen, cyano, nitro, C 1~4 Alkyl, C 1~4 Alkoxy, -N(C 1~4 alkyl)2, -NH(C 1~4 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NR a R b , -NHS(O)2R a , -C 1~4 Alkyl-S(O)2-C 1~4 Alkyl, or optionally OH, halogen or C 1~3 and 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0035] In some embodiments, R c OH, NH2, halogen, cyano, C 1~4 Alkyl, -C1~4 Alkoxy, -N(C 1~4 alkyl)2, -NH(C 1~4 alkyl), -C 1~4 Alkyl-S(O)2-C 1~4 Alkyl, or optionally OH, halogen or C 1~3 and 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0036] In some embodiments, R c OH, C 1~3 Alkyl, -N(C 1~3 alkyl)2, -C 1~3 Alkyl-S(O)2-C 1~3 Alkyl, or optionally OH, halogen or C 1~3 and 6-membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0037] In some embodiments, R c OH, C 1~3 Alkyl, -N(C 1~3 alkyl)2, -C 1~3 Alkyl-S(O)2-C 1~3 alkyl, or optionally one or more C 1~3 piperazinyl substituted by alkyl.

[0038] In some embodiments, R c is OH, methyl, Selected from JPEG2024543127000013.jpg4285.

[0039] In some other embodiments, the R c is oxo, OH, NH2, halogen, cyano, nitro, C 1~8 Alkoxy, -N(C 1~8 alkyl)2, -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NRa R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NR a R b , -NHS(O)2R a or optionally OH, halogen or C 1~6 and 3-8 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0040] In some other embodiments, the R c is OH, NH2, oxo, halogen, cyano, nitro, C 1~6 Alkoxy, -N(C 1~6 alkyl)2, -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NR a R b , -NHS(O)2R a or optionally OH, halogen or C 1~4 and 3- to 6-membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0041] In some other embodiments, the R c is OH, NH2, oxo, halogen, cyano, nitro, C 1~4 Alkoxy, -N(C 1~4 alkyl)2, -NH(C 1~4 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NRa R b , -NHS(O)2R a or optionally OH, halogen or C 1~3 and 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0042] In some other embodiments, the R c OH, NH2, halogen, cyano, C 1~4 Alkoxy, -N(C 1~4 alkyl)2, -NH(C 1~4 alkyl), or optionally OH, halogen or C 1~3 and 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0043] In some other embodiments, the R c is OH, -N(C 1~3 alkyl)2, or optionally OH, halogen or C 1~3 and 6-membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0044] In some other embodiments, the R c is OH, -N(C 1~3 alkyl)2 or optionally one or more C 1~3 piperazinyl substituted by alkyl.

[0045] In some other embodiments, the R c OH, Selected from JPEG2024543127000014.jpg4055.

[0046] In some other embodiments, the R c is oxo, halogen, cyano, nitro, C 1~6 Alkoxy, -N(C 1~6 alkyl)2, -NH(C 1~8 alkyl), -C(O)Ra , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NR a R b , -NHS(O)2R a or optionally OH, halogen or C 1~4 and 3- to 6-membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0047] In some other embodiments, the R c is oxo, halogen, cyano, nitro, C 1~4 Alkoxy, -N(C 1~4 alkyl)2, -NH(C 1~4 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NR a R b , -NHS(O)2R a or optionally OH, halogen or C 1~3 and 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0048] In some other embodiments, the R c is oxo, halogen, cyano, C 1~4 Alkoxy, -N(C 1~4 alkyl)2, -NH(C 1~4 alkyl), or optionally OH, halogen or C 1~3 and 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl.

[0049] In some embodiments, R a and R b are each independently a group optionally substituted by one or more R″: C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, 3-8 membered heterocycloalkyl, C 6~10 It is selected from aryl, or 5- to 6-membered heteroaryl.

[0050] In some embodiments, R a and R b are each independently a group optionally substituted by one or more R″: C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 It is selected from cycloalkyl, or 3- to 8-membered heterocycloalkyl.

[0051] In some embodiments, R a and R b are each independently a group optionally substituted by one or more R″: C 1~8 Alkyl, C 3~8 In some specific embodiments, R is selected from the group consisting of cycloalkyl, 3- to 8-membered heterocycloalkyl, and 3- to 8-membered heterocycloalkyl. a and R b are each independently a group optionally substituted by one or more R″: C 1~6 Alkyl, C 3~6 It is selected from cycloalkyl, or 3- to 6-membered heterocycloalkyl.

[0052] In some embodiments, R a and R b are each independently a group optionally substituted by one or more R″: C 1~5 Alkyl, C 3~6 It is selected from cycloalkyl, or 4- to 6-membered heterocycloalkyl.

[0053] In some embodiments, R a and R b are each independently selected from the group: methyl, ethyl, propyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydropyranyl, or piperidinyl, optionally substituted with one or more R″.

[0054] In some embodiments, R a and R b each independently represents C optionally substituted by one or more R″ 3~6 In some embodiments, R is selected from the group consisting of cycloalkyl, 4- to 6-membered heterocycloalkyl, and 4- to 6-membered heterocycloalkyl. a and R b each independently represents C optionally substituted by one or more R″ 1~5 In some embodiments, the R a and R b each independently represents C optionally substituted by one or more R″ 3~6 In some embodiments, the R a and R b are each independently selected from 4-6 membered heterocycloalkyl optionally substituted with one or more R″. In some specific embodiments, the R a and R b are each independently selected from the group: methyl, ethyl, propyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with one or more R″. In some specific embodiments, the R a and R b are each independently selected from the group: propyl, or cyclohexyl, optionally substituted with one or more R″. In some specific embodiments, the R a and R bare each independently selected from propyl optionally substituted with one or more R″. In some specific embodiments, the R a and R b are each independently selected from cyclohexyl optionally substituted with one or more R″.

[0055] In some other embodiments, the R a and R b are each independently a group optionally substituted by one or more R″: C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 It is selected from cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl.

[0056] In some other embodiments, the R a and R b are each independently a group optionally substituted by one or more R″: C 1~4 alkyl, or 3- to 6-membered heterocycloalkyl.

[0057] In some other embodiments, the R a and R b are each independently selected from the group: propyl, ethyl, or oxetanyl, optionally substituted with one or more R″.

[0058] In some embodiments, the —N(C 1~8 alkyl)2 is -N(C 1~8 alkyl)2, and -N(deuterated C 1~8 alkyl)2. In some embodiments, each R″ is independently selected from halogen, oxo, deuterium, NH, OH, cyano, nitro, C 1~8 Alkyl, HaloC 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8Alkyl)2, -N(deuterated C 1~8 alkyl)2, -NH(C 1~8 alkyl), C 3~6 cycloalkyl, or optionally C 1~8 It is selected from 3- to 10-membered heterocycloalkyl substituted by alkyl.

[0059] In some embodiments, each R″ is independently selected from halogen, oxo, deuterium, NH, OH, cyano, nitro, C 1~8 Alkyl, HaloC 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 Alkyl)2, -N(deuterated C 1~6 alkyl)2, -NH(C 1~8 alkyl), C 3~6 cycloalkyl, or optionally C 1~8 It is selected from 3- to 10-membered heterocycloalkyl substituted by alkyl.

[0060] In some embodiments, each R″ is independently selected from halogen, oxo, deuterium, NH, OH, cyano, nitro, C 1~6 Alkyl, HaloC 1~6 Alkyl, C 1~6 Alkoxy, -N(C 1~6 Alkyl)2, -N(deuterated C 1~6 alkyl)2, -NH(C 1~6 alkyl), C 3~6 cycloalkyl, or optionally C 1~6 In some specific embodiments, each R" is independently selected from the group consisting of 3- to 6-membered heterocycloalkyl substituted with alkyl. 1~6 Alkyl, -N(C 1~6 Alkyl)2, -N(deuterated C 1~6 alkyl)2, -NH(C 1~6 alkyl), C 3~6 cycloalkyl, or optionally C 1~6 In some specific embodiments, each R" is independently selected from the group consisting of 3- to 6-membered heterocycloalkyl substituted with alkyl.1~6 Alkyl, -N(C 1~6 Alkyl)2, -N(deuterated C 1~6 alkyl)2, or optionally C 1~3 In some specific embodiments, each R" is independently selected from the group consisting of 3- to 6-membered heterocycloalkyl substituted with alkyl. 1~4 Alkyl, -N(C 1~4 Alkyl)2, -N(deuterated C 1~4 alkyl)2, or optionally C 1~3 It is selected from 4- to 6-membered heterocycloalkyl substituted by alkyl.

[0061] In some embodiments, each R″ is independently selected from halogen, oxo, deuterium, NH, OH, cyano, nitro, C 1~3 Alkyl, HaloC 1~3 Alkyl, C 1~3 Alkoxy, -N(C 1~3 Alkyl)2, -N(deuterated C 1~3 alkyl)2, -NH(C 1~3 alkyl), C 4~6 cycloalkyl, or optionally C 1~3 It is selected from 3- to 6-membered heterocycloalkyl substituted by alkyl.

[0062] In some embodiments, each R″ is independently selected from fluorine, chlorine, bromine, oxo, deuterium, NH, OH, cyano, C 1~4 Alkyl, Fluoro C 1~4 Alkyl, C 1~4 Alkoxy, -N(C 1~4 Alkyl)2, -N(deuterated C 1~4 alkyl)2, -NH(C 1~4 alkyl), C 5~6 cycloalkyl, or optionally C 1~4 It is selected from 4- to 6-membered heterocycloalkyl substituted by alkyl.

[0063] In some embodiments, each R″ is independently selected from fluorine, OH, oxo, deuterium, —NH2, methyl, ethyl, propyl, trifluoromethyl, —N(CH3)2, —N(CD3)2, —N(CH2CH3)2, —NHCH3, morpholinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 1,4-dioxanyl, or oxetanyl optionally substituted with methyl or ethyl.

[0064] In some embodiments, each R″ is independently selected from halogen, NH, OH, oxo, deuterium, cyano, nitro, C 1~8 Alkyl, HaloC 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 alkyl), -NH(C 1~8 alkyl), C 3~6 cycloalkyl, or optionally C 1~8 selected from 3- to 10-membered heterocycloalkyl substituted by alkyl; In some embodiments, each R″ is independently selected from halogen, oxo, deuterium, NH, OH, cyano, nitro, C 1~6 Alkyl, HaloC 1~6 Alkyl, C 1~6 Alkoxy, -N(C 1~6 alkyl)2, -NH(C 1~6 alkyl), C 3~6 cycloalkyl, or optionally C 1~6 In some specific embodiments, each R" is independently selected from the group consisting of 3- to 6-membered heterocycloalkyl substituted with alkyl. 1~6 Alkyl, -N(C 1~6 alkyl)2, -NH(C 1~6 alkyl), C 3~6 cycloalkyl, or optionally C 1~6 In some specific embodiments, each R" is independently selected from the group consisting of 3- to 6-membered heterocycloalkyl substituted with alkyl. 1~6 Alkyl, -N(C 1~6 alkyl)2, or optionally C 1~3In some specific embodiments, each R" is independently selected from the group consisting of 3- to 6-membered heterocycloalkyl substituted with alkyl. 1~4 Alkyl, -N(C 1~4 alkyl)2, or optionally C 1~3 It is selected from 4- to 6-membered heterocycloalkyl substituted by alkyl.

[0065] In some embodiments, each R″ is independently selected from halogen, oxo, deuterium, NH, OH, cyano, nitro, C 1~3 Alkyl, HaloC 1~3 Alkyl, C 1~3 Alkoxy, -N(C 1~3 alkyl)2, -NH(C 1~3 alkyl), C 4~6 cycloalkyl, or optionally C 1~3 It is selected from 3- to 6-membered heterocycloalkyl substituted by alkyl.

[0066] In some embodiments, each R″ is independently selected from fluorine, chlorine, bromine, oxo, deuterium, NH, OH, cyano, C 1~4 Alkyl, Fluoro C 1~4 Alkyl, C 1~4 Alkoxy, -N(C 1~4 alkyl)2, -NH(C 1~4 alkyl), C 5~6 cycloalkyl, or optionally C 1~4 It is selected from 4- to 6-membered heterocycloalkyl substituted by alkyl.

[0067] In some embodiments, each R″ is independently selected from fluorine, OH, oxo, deuterium, —NH2, methyl, ethyl, propyl, trifluoromethyl, —N(CH3)2, —N(CH2CH3)2, —NHCH3, morpholinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 1,4-dioxanyl, or oxetanyl optionally substituted with methyl or ethyl.

[0068] In some specific embodiments, each R″ is independently selected from halogen, OH, oxo, C 1~6 Alkyl, HaloC 1~6 Alkyl, or -N(C 1~4 In some specific embodiments, each R″ is independently selected from halogen, OH, oxo, C 1~4 Alkyl, HaloC 1~4 Alkyl, or -N(C 1~2 In some specific embodiments, each R″ is independently selected from fluorine, OH, oxo, methyl, ethyl, propyl, trifluoromethyl, or —N(CH 3 ) 2 .

[0069] In some other embodiments, each R″ is independently selected from halogen, NH, OH, cyano, nitro, C 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 alkyl)2, -NH(C 1~8 alkyl), C 3~6 It is selected from cycloalkyl, or 3- to 10-membered heterocycloalkyl. In some other embodiments, each R″ is independently selected from halogen, NH, OH, cyano, nitro, C 1~6 Alkyl, C 1~6 Alkoxy, -N(C 1~6 alkyl)2, -NH(C 1~6 alkyl), C 3~6 It is selected from cycloalkyl, or 3- to 6-membered heterocycloalkyl.

[0070] In some other embodiments, each R″ is independently selected from halogen, NH, OH, cyano, nitro, C 1~3 Alkyl, C 1~3 Alkoxy, -N(C 1~3 alkyl)2, -NH(C 1~3 alkyl), C 4~6 It is selected from cycloalkyl, or 3- to 6-membered heterocycloalkyl.

[0071] In some other embodiments, each R″ is independently selected from fluorine, chlorine, bromine, NH, OH, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, -N(C 1~4 alkyl)2, -NH(C 1~4 alkyl), C 5~6 In some further embodiments, each R" is independently selected from fluorine, -NH2, methyl, ethyl, propyl, -N(CH3)2, -N(CH2CH3)2, -NHCH3, morpholinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 1,4-dioxanyl, or oxetanyl. In some further embodiments, each R" is independently selected from halogen or 3- to 6-membered heterocycloalkyl.

[0072] In some further embodiments, each R'' is independently selected from fluorine, chlorine, bromine, or 6-membered heterocycloalkyl. In some further embodiments, each R'' is independently selected from fluorine or morpholinyl.

[0073] In some embodiments, R a and R b are each independently methyl, CD3, Selected from JPEG2024543127000015.jpg119106, or R a and R b are each independently Selected from JPEG2024543127000016.jpg61105.

[0074] In some other embodiments, the R a and R b are each independently methyl, Selected from JPEG2024543127000017.jpg92105.

[0075] In some other embodiments, the Ra and R b are each independently Selected from JPEG2024543127000018.jpg25100.

[0076] In some embodiments, n is selected from 0, 1, 2, or 3. In some embodiments, n is selected from 0, 1, or 2. In some embodiments, n is selected from 1 or 2. In some specific embodiments, n is selected from 1.

[0077] In some embodiments, R 4 is C 1~3 Alkyl or C 3~4 cycloalkyl. In some embodiments, R 4 is selected from methyl, ethyl, cyclopropyl, or cyclobutyl.

[0078] In some embodiments, R 4 is selected from methyl, or cyclopropyl. In some specific embodiments, R 4 is selected from cyclopropyl. In some specific embodiments, R 4 is selected from methyl.

[0079] In some embodiments, R 1 is Haro C 1~6 Alkyl, or C 3~4 cycloalkyl, or R 1 is selected from halomethyl, or cyclopropyl; R 2 is C 1~3 alkyl, or R 2 is selected from methyl, R 3 -NHR b , or -NR a R b Selected from R a and R bare each independently a group optionally substituted by one or more R″: C 1~6 Alkyl, C 3~6 cycloalkyl, or 3- to 6-membered heterocycloalkyl; or R a and R b are each independently a group optionally substituted by one or more R″: C 1~5 Alkyl, C 3~6 cycloalkyl, or 4- to 6-membered heterocycloalkyl; or R a and R b are each independently selected from the group: methyl, ethyl, propyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydropyranyl, or piperidinyl, optionally substituted with one or more R″; or R a and R b are each independently selected from the group: methyl, ethyl, propyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with one or more R″; or R a and R b are each independently selected from the group: propyl, or cyclohexyl, optionally substituted with one or more R″; R'' is independently fluorine, chlorine, bromine, oxo, deuterium, NH2, OH, cyano, C 1~4 Alkyl, Fluoro C 1~4 Alkyl, C 1~4 Alkoxy, -N(C 1~4 Alkyl)2, -N(deuterated C 1~4 alkyl)2, -NH(C 1~4 alkyl), C 5~6 cycloalkyl, or optionally C 1~4or each R" is independently selected from fluorine, OH, oxo, deuterium, -NH2, methyl, ethyl, propyl, trifluoromethyl, -N(CH3)2, -N(CD3)2, -N(CH2CH3)2, -NHCH3, morpholinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 1,4-dioxanyl, or oxetanyl optionally substituted with methyl or ethyl; R 4 is C 1~3 alkyl, or R 4 is selected from methyl.

[0080] In some embodiments, the Formula I" compound of the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is selected from a Formula I"A compound or a Formula I"B compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. JPEG2024543127000019.jpg41108 (where n, R 1 , R 2 , R 3 , or R 4 The definition of is as above.)

[0081] In some embodiments, the compound of formula I' according to the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is selected from a compound of formula I'A or a compound of formula I'B, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. JPEG2024543127000020.jpg3693 (where n, R 1 , R 2 , R 3 , or R 4 The definition of is as above.)

[0082] In some embodiments, the compound of Formula I′, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof of the present invention is selected from the compound of Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. JPEG2024543127000021.jpg5679 (where n, R1 , R 2 , or R 3 The definition of is as above.)

[0083] In some embodiments, in the compound of Formula I, R 1 is C 3~5 Cycloalkyl, C 3~5 Cycloalkyl-C 1~3 Alkyl- or haloC 1~6 selected from alkyl, R 2 is hydrogen, C 1~8 Alkyl, or C 1~8 alkoxy, wherein C 1~8 Alkyl or C 1~8 The alkoxy is optionally substituted by one or more R'; R' is selected from halogen, hydroxy, cyano, amino, or nitro; R 3 are halogens, cyano, nitro, NH2, OH, C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3-10 membered heterocyclyl, C 6~10 Aryl, 5-10 membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH2, -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O)2H, -S(O)2R a , -S(O)2NH2, -S(O)2NR a R b , -NHS(O)2R a , -NHC(O)OR a, or -N(C 1~4 alkyl)C(O)OR a and C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3-10 membered heterocyclyl, C 6~10 The aryl or 5- to 10-membered heteroaryl may optionally be one or more R c is replaced by R c is oxo, halogen, cyano, nitro, C 1~8 Alkoxy, -N(C 1~8 alkyl)2, -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O)2R a , -S(O)NR a R b , -NHS(O)2R a or one or more hydroxy, halogen, or optionally C 1~6 selected from 3- to 8-membered heterocycloalkyl substituted by alkyl; R a and R b are each independently a group optionally substituted by one or more R″: C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6~10 aryl, or 5- to 10-membered heteroaryl; R'' is independently halogen, NH2, OH, cyano, nitro, C 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 alkyl)2, -NH(C 1~8 alkyl), C 3~6cycloalkyl, or 3- to 10-membered heterocycloalkyl; n is selected from 0, 1, 2, 3, or 4.

[0084] In some embodiments, heteroatoms in a heterocycloalkyl, heterocyclyl, or heteroaryl of the present invention are selected from N, O, or S, and the remaining ring atoms are selected from carbon; in some embodiments, heteroatoms in a heterocycloalkyl, heterocyclyl, or heteroaryl of the present invention are selected from N or O, and the remaining ring atoms are selected from carbon; in some embodiments, the number of heteroatoms in a heterocycloalkyl, heterocyclyl, or heteroaryl of the present invention is selected from 1, 2, 3, 4, or 5; in some embodiments, the number of heteroatoms in a heterocycloalkyl, heterocyclyl, or heteroaryl of the present invention is selected from 1, 2, or 3.

[0085] In some embodiments, the Formula I' compounds, Formula I'A compounds, Formula I'B compounds, Formula I compounds, stereoisomers thereof, or pharmaceutically acceptable salts thereof of the present invention are selected from Formula IA compounds or Formula IB compounds, stereoisomers thereof, or pharmaceutically acceptable salts thereof. JPEG2024543127000022.jpg42112 (where n, R 1 , R 2 , or R 3 The definition of is as above.)

[0086] In some embodiments, the Formula I' compounds, Formula I'A compounds, Formula I'B compounds, Formula I compounds, Formula IA compounds, Formula IB compounds, stereoisomers thereof, or pharmaceutically acceptable salts thereof of the present invention are selected from Formula I-1 compounds, Formula I-1A compounds, Formula I-1B compounds, Formula I-2 compounds, Formula I-2A compounds, Formula I-2B compounds, Formula II compounds, Formula IIA compounds, Formula IIB compounds, Formula II-1 compounds, Formula II-1A compounds, Formula II-1B compounds, Formula II-2 compounds, Formula II-2A compounds, or Formula II-2B compounds, stereoisomers thereof, or pharmaceutically acceptable salts thereof. JPEG2024543127000023.jpg145122 (in the formula, R b , R 1 , R 2 , and R 3 The definition of is as above.)

[0087] In some embodiments, the compounds of formula I', I'A, I'B, stereoisomers thereof, or pharmaceutically acceptable salts thereof of the present invention are selected from compounds of formula III-1, III-1A, III-1B, III-2, III-2A, III-2B, IV, IVA, IVB, IV-1, IV-1A, IV-1B, IV-2, IV-2A, or IV-2B, stereoisomers thereof, or pharmaceutically acceptable salts thereof. JPEG2024543127000024.jpg136110 (in the formula, R b , R 1 , R 2 , and R 3 The definition of is as above.)

[0088] In some embodiments, the present invention includes the variables and embodiments thereof defined above, and any combination thereof. Any embodiment of the compounds of the present invention as described above, and the specific n, R in the above compounds of the present invention. 1 , R 2 , R 3 and R 4 It should be understood that any of the specific substituents described herein with respect to substituents can be independently combined with other embodiments and / or compound substituents of the invention to form embodiments of the invention not specifically described above. Furthermore, in certain embodiments and / or claims, any particular n, R 1 , R 2 , R 3 and R 4Where a list of substituents is disclosed for a substituent, it is understood that one or more substituents may be deleted from that list and the remainder of the substituent list is considered to be embodiments of the invention.

[0089] In some embodiments, the present invention provides the following compounds, stereoisomers thereof, or pharmaceutically acceptable salts thereof: JPEG2024543127000025.jpg182107JPEG2024543127000026.jpg167110JPEG2024543127000027.jpg162109JPEG2024543127000028.jpg187109 JPEG2024543127000029.jpg179109JPEG2024543127000030.jpg159109JPEG2024543127000031.jpg154109JPEG2024543127000032.jpg166109

[0090] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of the present invention (e.g., a compound of Formula I", Formula I', or Formula I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition of the present invention also further comprises a pharmaceutically acceptable auxiliary material.

[0091] In another aspect, the present invention relates to a method of treating an EGFR-mediated disease in an individual (e.g., a mammal), comprising administering to the individual, preferably a human, in need of such treatment a therapeutically effective amount of a compound according to the present invention (e.g., a compound of Formula I'', Formula I' or Formula I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0092] In another aspect, the present invention relates to the use of a compound of the present invention (e.g., a compound of Formula I'', Formula I' or Formula I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the manufacture of a medicament for preventing or treating an EGFR-mediated disease.

[0093] In another aspect, the present invention relates to the use of a compound of the present invention (e.g., a compound of Formula I'', Formula I' or Formula I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the prevention or treatment of an EGFR-mediated disease.

[0094] In another aspect, the present invention relates to a compound of the present invention (e.g., a compound of Formula I'', Formula I' or Formula I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for preventing or treating an EGFR-mediated disease.

[0095] In some embodiments, the EGFR-mediated disease of the present invention is selected from EGFR mutation-mediated diseases, wherein the mutation is one, two, three, or four selected from L858R, T790M, d19, and C797S. In some embodiments, the mutation is two mutations selected from L858R and T790M. In some embodiments, the mutation is a double mutation selected from d19 and T790M. Further, in some embodiments, the mutation includes a C797S mutation. Furthermore, the mutation is a triple mutation selected from L858R, T790M, and C797S. Alternatively, the mutation is a triple mutation selected from d19, T790M, and C797S.

[0096] In some embodiments, the EGFR-mediated disease of the present invention is selected from cancer. In some embodiments, the EGFR-mediated disease of the present invention is selected from lung cancer. In some embodiments, the EGFR-mediated disease of the present invention is selected from non-small cell lung cancer.

[0097] The compounds of the present invention have one or more advantages of excellent kinase and cellular activity (including wild-type and mutant forms, e.g., d19, T790M, C797S, and L858R), in vivo and in vitro metabolic stability, and excellent in vivo efficacy.

[0098] [Definition] Unless otherwise specified, the following terms used herein have the following meanings: Certain terms should not be considered uncertain or unclear in the absence of a specific definition, but should be understood according to their ordinary meaning in the art. When a trade name appears herein, it is intended to refer to the corresponding trade name or its active ingredient.

[0099] The term "substituted" means that any one or more hydrogen atoms on a particular atom may be replaced by a substituent, provided that the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (=O), this means that two hydrogen atoms have been replaced, and no oxo is present in aromatic groups.

[0100] The term "optionally" or "optionally / optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes both cases where said event or circumstance occurs and cases where said event or circumstance does not occur. For example, "optionally" ethyl substituted with halogen means that ethyl may be unsubstituted (CH2CH3), monosubstituted (e.g., CH2CH2F), polysubstituted (e.g., CHFCH2F, CH2CHF2), or fully substituted (CF2CF3). Those skilled in the art will understand that sterically impossible and / or synthetically impossible substitutions or substitution patterns will not be introduced into any group that contains one or more substituents.

[0101] In some embodiments, "one or more" according to the present invention is selected from 1, 2, 3, 4, 5, or 6. In some embodiments, the "one or more" is selected from 1, 2, or 3. In some embodiments, the "one or more" is selected from 1 or 2.

[0102] As used herein, C m~nis a moiety having an integer number of carbon atoms in a given range, and any carbon present in a substituent of the moiety is C m~n It is not included in the m to n carbon atoms. For example, "C 1~6 " means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms.

[0103] When any variable (e.g., R) occurs more than once in a composition or structure of a compound, its definition at each occurrence is independent. Thus, for example, if a group is substituted by two R, there is a separate option for each R.

[0104] When the number of linking groups is 0, such as -(CH2)0-, it means that the linking group is a covalent single bond. When one of the variables is selected from a single bond, it means that the two groups it connects are directly linked.

[0105] When a bond of a substituent connects two atoms on a ring through a cross-connection, the substituent may be bonded to any atom on the ring. For example, the structural unit JPEG2024543127000033.jpg2592 indicates that substitution can occur at any position on the cyclohexyl or cyclohexadiene.

[0106] JPEG2024543127000034.jpg1223 indicates that the substituent is attached to another structure. For example, R 1 The heterocycloalkyl If selected from JPEG2024543127000035.jpg2729, JPEG2024543127000036.jpg2420 is concatenated to L Showing JPEG2024543127000037.jpg2829.

[0107] The term "halo" or "halogen" refers to fluorine, chlorine, bromine, and iodine. When a group according to the present invention has a halo group, the number of halo groups can be one or more. In some embodiments, the "one or more" according to the present invention is selected from one, two, three, four, five, or six. In some embodiments, the "one or more" is selected from one, two, or three. In some embodiments, the "one or more" is selected from one or two. For example, halo C according to the present invention can be 1~6 Alkyl includes C substituted by 1, 2, 3, 4, 5 or 6 halogen atoms. 1~6 Contains alkyl.

[0108] The term "hydroxy" refers to the group --OH. The term "cyano" refers to the group --CN. The term "amino" refers to the group --NH.sub.2. The term "nitro" refers to the group --NO.sub.2.

[0109] The term "alkyl" refers to a group of the general formula C n H 2n+1 The alkyl group may be a straight chain or a branched chain. For example, "C 1~6 The term "alkyl" refers to an alkyl containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl). Similarly, the alkyl portions (i.e., alkyl) of alkoxy, alkylamino, dialkylamino, alkylsulfonyl, and alkylthio have the same definition as above.

[0110] The term "alkoxy" refers to --O-alkyl. The term "alkylamino" refers to -NH-alkyl. The term "dialkylamino" refers to -N(alkyl)2. The term "alkylsulfonyl" refers to -SO2-alkyl.

[0111] The term "alkenyl" refers to a straight or branched chain unsaturated aliphatic hydrocarbon group composed of carbon and hydrogen atoms and having at least one double bond. Alkenyl is a C group having 2, 3, 4, 5, 6, 7, or 8 carbon atoms. 2~8 It may be alkenyl. Non-limiting examples of alkenyl include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, 1,3-butadienyl, and the like.

[0112] The term "alkynyl" refers to a straight or branched chain unsaturated aliphatic hydrocarbon group composed of carbon and hydrogen atoms and having at least one triple bond. Alkynyl is a C group having 2, 3, 4, 5, 6, 7, or 8 carbon atoms. 2~8 It may be an alkynyl. Non-limiting examples of alkynyl include, but are not limited to, ethynyl (-C≡CH), 1-propynyl (-C≡C-CH), 2-propynyl (-CH-C≡CH), 1,3-butadiynyl (-C≡CC≡CH), and the like.

[0113] The term "cycloalkyl" refers to a fully saturated carbocyclic ring which can exist as a monocyclic, bridged, or spirocyclic ring. Unless otherwise specified, the carbocyclic ring is typically 3- to 10-membered (e.g., 3-, 4-, 5-, 6-, 7-, or 8-membered) ring. Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, and the like.

[0114] The term "heterocycloalkyl" refers to a fully saturated cyclic group that can exist as a monocyclic, bridged, or spirocyclic ring. Unless otherwise specified, the heterocycle is typically a 3- to 10-membered (e.g., 3-, 4-, 5-, 6-, 7-, or 8-membered) ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen, and / or nitrogen. Examples of 3-membered heterocycloalkyls include, but are not limited to, oxiranyl, thiiranyl, and aziranyl. Non-limiting examples of 4-membered heterocycloalkyls include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Examples of 5-membered heterocycloalkyls include, but are not limited to, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, imidazolidinyl, and tetrahydropyrazolyl. Examples of 6-membered heterocycloalkyl include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, piperazinyl, 1,4-thioxanyl, 1,4-dioxanyl, thiomorpholinyl, 1,3-dithianyl, and 1,4-dithianyl. Examples of 7-membered heterocycloalkyl include, but are not limited to, azepanyl, oxipanyl, and thiepanyl. Monocyclic heterocycloalkyls having 5 or 6 ring atoms are preferred.

[0115] The term "heterocyclyl" refers to a non-aromatic ring (e.g., heterocycloalkyl) that is fully saturated or partially unsaturated (but not fully unsaturated heteroaromatic) and can exist as a monocyclic, bridged, or spirocyclic ring. Unless otherwise specified, the heterocycle is typically a 3- to 10-membered (e.g., 3-, 4-, 5-, 6-, 7-, or 8-membered) ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen, and / or nitrogen. Non-limiting examples of heterocyclyl include, but are not limited to, oxiranyl, oxetanyl, tetrahydrofuryl, 1,4-dioxanyl, dihydrofuryl, pyrrolidinyl, N-methylpyrrolidyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyrazolidinyl, 4H-pyranyl, morpholinyl, thiomorpholinyl, tetrahydrothiophenyl, and the like.

[0116] The term "aryl" refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated π-electron system. For example, an aryl may have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 (e.g., 6, 7, 8, 9, 10, 11, or 12) carbon atoms. Non-limiting examples of aryl include, but are not limited to, phenyl, naphthyl, anthracenyl, and 1,2,3,4-tetralin.

[0117] The term "heteroaryl" refers to a monocyclic or fused polycyclic ring system containing at least one ring atom selected from N, O, or S, with the remaining ring atoms being C, and having at least one aromatic ring. Preferred heteroaryls have a single 4-8 membered ring, particularly a 5-8 membered ring, or multiple fused rings containing 6-14, particularly 6-10, ring atoms. Non-limiting examples of heteroaryls include, but are not limited to, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, triazolyl, triazinyl, benzofuranyl, benzothienyl, indolyl, isoindolyl, and the like.

[0118] The term "treating" means administering a compound or formulation according to the invention to ameliorate or eliminate a disease or one or more symptoms associated with said disease, and (i) inhibiting the disease or condition, i.e., arresting its progression; (ii) Alleviating the disease or condition, i.e., eliminating the disease or condition.

[0119] The term "prevention" means administering a compound or formulation according to the invention to prevent a disease or one or more symptoms associated with said disease, and includes preventing the occurrence of a disease or condition in an individual (e.g., a mammal), particularly where such mammal is susceptible to the condition but has not yet been diagnosed with the condition.

[0120] The term "effective amount" refers to the amount of a compound of the present invention used to (i) treat or prevent a particular disease, condition, or disorder, (ii) reduce, ameliorate, or eliminate one or more symptoms of a particular disease, condition, or disorder, or (iii) prevent or delay the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of a compound of the present invention used that constitutes an "effective amount" varies depending on the compound, the condition and its severity, the method of administration, and the age of the mammal being treated, but can be determined routinely by one of ordinary skill in the art based on their own knowledge and the present invention.

[0121] The term "pharmaceutically acceptable" refers to compounds, materials, compositions and / or dosage forms that are suitable for use in contact with the tissues of humans and animals, within the bounds of sound medical judgment, without excessive toxicity, irritation, anaphylaxis, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0122] Pharmaceutically acceptable salts include, for example, metal salts, ammonium salts, salts formed with organic bases, salts formed with inorganic acids, salts formed with organic acids, salts formed with basic or acidic amino acids, and the like.

[0123] The term "pharmaceutical composition" refers to a mixture of one or more compounds according to the invention or their salts with pharmaceutically acceptable auxiliary materials. The purpose of a pharmaceutical composition is to facilitate the administration of the compounds according to the invention to an organism.

[0124] The term "pharmaceutically acceptable auxiliary material" means an auxiliary material that has no obvious irritating effect on the living organism and does not impair the biological activity and performance of the active compound. Suitable auxiliary materials are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0125] The term "individual" includes mammals such as humans, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals. In some embodiments, the individual is a human.

[0126] The words "comprise" or "comprise" and their English variants, such as comprises or comprising, are to be understood in an open and non-exclusive sense, including but not limited to.

[0127] The compounds and intermediates of the present invention may exist in different tautomeric forms, and all such forms are included within the scope of the present invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as proton transfer tautomers) include tautomers resulting from proton migration, such as keto-enol isomers and imine-enamine isomerizations. A specific example of a proton tautomer is the imidazole moiety, where a proton can migrate between the two ring nitrogens. Valence tautomers also include tautomers in which some of the bonding electrons have been reconfigured.

[0128] The present invention also includes isotopically labeled compounds of the present invention that are the same as those described herein, but in which one or more atoms are replaced with an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature. Examples of isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, which can be, for example, 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 123 I, 125 I, and 36 Cl, etc.

[0129] Certain isotopically labeled compounds according to the present invention (e.g., 3 H and 14 C) can be used for tissue distribution analysis of compounds and / or substrates. 3 H) isotopes and carbon-14 (i.e., 14 C) Isotopes are particularly preferred because they are easy to prepare and detectable. 15 O. 13 N, 11 C, and 18 Positron-emitting isotopes such as F can be used to measure substrate occupancy in positron emission tomography (PET) studies. Isotopically labeled compounds according to the present invention can generally be prepared by following procedures similar to those disclosed in the following schemes and / or examples, substituting isotopically labeled reagents for non-isotopically labeled reagents.

[0130] Additionally, (e.g., deuterium (i.e., 2Substitution with heavier isotopes, such as H), may be preferable in some circumstances because they may offer certain therapeutic advantages resulting from increased metabolic stability (such as increased in vivo half-life or reduced dosage requirements). Deuterium substitution can be partial or complete, with partial deuterium substitution meaning that at least one hydrogen is replaced with at least one deuterium.

[0131] The compounds of the present invention may be asymmetric, e.g., have one or more stereoisomers. Unless otherwise specified, all stereoisomers include, e.g., enantiomers and diastereomers. Compounds of the present invention containing asymmetric carbon atoms can be isolated in optically pure or racemic form. Optically pure forms can be resolved from racemic mixtures or synthesized using chiral starting materials or chiral reagents.

[0132] The pharmaceutical compositions of the present invention can be prepared by combining the compounds of the present invention with suitable pharmaceutically acceptable auxiliary materials, and can be formulated into solid, semi-solid, liquid, or gaseous preparations, such as tablets, pills, capsules, powders, granules, plasters, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres, and aerosols.

[0133] Typical routes of administration of the compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0134] The pharmaceutical compositions of the present invention can be manufactured by conventional mixing, dissolving, granulating, dragee-coating, pulverizing, emulsifying, lyophilizing or other methods well known in the art.

[0135] In all methods of administration of the compounds described herein, the daily dose is 0.01 to 200 mg / kg body weight, either as an individual dose or as separate doses.

[0136] The compounds according to the present invention can be prepared by a number of synthetic methods familiar to those skilled in the art, including the specific embodiments listed below, embodiments formed by combination with other chemical synthetic methods, and equivalent substitution methods familiar to those skilled in the art, and preferred embodiments include, but are not limited to, the examples according to the present invention.

[0137] The chemical reactions of specific embodiments of the present invention are carried out in suitable solvents appropriate for the chemical transformations of the present invention and the reagents and materials required therefor. To obtain compounds of the present invention, one skilled in the art may need to modify or select synthetic steps or reaction sequences based on existing embodiments.

[0138] One of the important considerations in planning synthetic routes in this field is the selection of appropriate protecting groups for reactive functional groups; see, for example, Greene's Protective Groups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley & Sons, Inc., all references cited therein are incorporated herein in their entirety.

[0139] In some embodiments, compounds of the general formula according to the present invention can be prepared by one skilled in the art of organic synthesis by the following routes. JPEG2024543127000038.jpg66112 (in the formula, R 1 , R 2 , R 3 , R 4 , n is defined as above.)

[0140] Preparation of intermediate I-2: Compound I-1 and JPEG2024543127000039.jpg2636 (in the formula, R 1are as defined herein.) in the presence of a suitable solvent (e.g., N,N-dimethylformamide) and an inorganic alkali (e.g., potassium carbonate) to prepare intermediate I-2. The reaction is carried out at about 25°C to about 50°C.

[0141] Preparation of intermediate I-3: Compound I-2 is reacted in the presence of a suitable solvent (e.g., dichloromethane) and an organic alkali (e.g., triethylamine) to prepare intermediate I-3. The reaction is carried out at about 0°C to about 20°C.

[0142] Preparation of intermediate I-4: Compound I-3 and JPEG2024543127000040.jpg4136 (in the formula, R 2 , R 4 are as defined herein.) in the presence of a suitable solvent (e.g., N,N-dimethylformamide) and an inorganic alkali (e.g., potassium carbonate) to prepare intermediate I-4. The reaction is carried out at about 50°C to about 80°C.

[0143] Preparation of intermediate I-5: Compound I-4 was reacted in the presence of a suitable solvent (e.g., methanol) and a catalyst (e.g., Raney nickel) to prepare intermediate I-5. The reaction was carried out at about 0°C to about 30°C.

[0144] Preparation of Intermediate I-6: Intermediate I-6 was prepared by reacting compound I-5 with cyanogen bromide in the presence of a suitable solvent (e.g., dichloromethane / t-butanol, etc.). The reaction was carried out at about 0°C to about 30°C.

[0145] Preparation of intermediate I-7: Compound I-6 was reacted in the presence of a suitable solvent (e.g., tetrahydrofuran) and an inorganic alkali (e.g., sodium hydroxide) to prepare intermediate I-7. The reaction was carried out at about 0°C to about 30°C.

[0146] Preparation of intermediate I-8: Compound I-7 was reacted in the presence of a suitable solvent (e.g., dichloromethane) and a condensing agent (e.g., TBTU) to prepare intermediate I-8. The reaction was carried out at about 0°C to about 30°C.

[0147] Preparation of Intermediate I: Compound I-8 was reacted in the presence of a suitable solvent (e.g., t-amyl alcohol), an alkali (e.g., potassium t-butoxide), a ligand (e.g., 2-(di-t-butylphosphine)biphenyl), and a catalyst (e.g., Pd2(dba)3) to prepare Intermediate I. The reaction was carried out at about 70°C to about 110°C.

[0148] The present invention uses the following abbreviations: Pd(dppf)Cl2CH2Cl2 is [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane complex, HATU is O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, TBTU is 2-[(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate, Pd2(dba)3 is tris(dibenzylideneacetone)dipalladium(0), and Pd(dppf)Cl2 is represents [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), X-Phos represents 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, SEM represents 2-(trimethylsilyl)ethoxymethyl, Boc represents tert-butoxycarbonyl, LiAlH4 represents lithium aluminum hydride, and Cbz represents benzyloxycarbonyl. DETAILED DESCRIPTION OF THE INVENTION

[0149] For clarity, examples are further used to illustrate the present application, but these examples are not intended to limit the scope of the present invention. All reagents used in this application are commercially available and are used without further purification. [Example]

[0150] JPEG2024543127000041.jpg121121

[0151] (1) Method for producing compound A Methyl 2-chloro-6-methylisonicotinate (20.0 g), 1-methyl-5-hydroxypyrazole (21.4 g), Pd(dppf)Cl2CH2Cl2 (2.64 g), and sodium carbonate (25.125 g) were dissolved in anisole (400 mL). The reaction mixture was purged with argon three times and stirred at 130 °C for approximately 10 h. After the reaction was complete, the mixture was cooled to room temperature, suction filtered, and the filter cake was rinsed with 80 mL of toluene. 60 mL of methanol was added to the filtrate, and 40 mL of 4 M hydrogen chloride in dioxane was slowly added dropwise. After the addition was complete, the mixture was stirred at room temperature for 2 h. After stirring, the mixture was suction filtered, and the filter cake was rinsed with 40 mL of toluene. The title compound was obtained and dried under vacuum at 50 °C for 8 h. Compound A (18.3 g) was obtained. ESI-MS: m / z = 248.26 [M+H] + .

[0152] (2) Method for producing compound B (S)-4-Benzyl-2-oxazolidinone (10.0 g), cyclopropylacetic acid (7.3 g), and 4-dimethylaminopyridine (7.6 g) were dispersed in dichloromethane (150 mL). 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (21.6 g) was added at 20-25 °C. After the addition was complete, the mixture was stirred at 20-25 °C for 12 h to complete the reaction. 50 mL of dichloromethane was added to the reaction mixture, and the dichloromethane phase was washed sequentially with water (100 mL), 1 M hydrochloric acid (100 mL x 2), and 1 M sodium bicarbonate solution (100 mL x 2). The dichloromethane phase was retained, dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. Compound B (7.65 g) was obtained by column chromatography. ESI-MS: m / z = 260.16 [M+H] + .

[0153] (3) Method for producing compound C Compound B (4.0 g) was dispersed in tetrahydrofuran (50 mL), purged with nitrogen gas three times, and cooled (temperature set to -78 °C). When the internal temperature reached -70 °C, sodium bis(trimethylsilyl)amide (2 M, 11.6 mL) was added dropwise over 15 min. The mixture was stirred for 1 h while maintaining the temperature at -70 °C or below. 3-Bromopropene (3.7 g) was then added dropwise, and the mixture was stirred for 1 h while maintaining the temperature at -70 °C or below. The mixture was then slowly warmed to room temperature and stirred for 12 h to complete the reaction. The reaction mixture was poured into ammonium chloride solution (1 M, 400 mL) and extracted with ethyl acetate (30 mL x 2). The combined ethyl acetate phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound C (2.8 g) was obtained by column chromatography. ESI-MS: m / z = 300.18 [M+H] + .

[0154] (4) Method for producing compound D Compound C (1.0 g) was dispersed in tetrahydrofuran (10 mL) and cooled to 0-5 °C in an ice bath. A solution of lithium hydroxide monohydrate (240 mg) in water (2 mL) was added and stirred for 5 min. After stirring, hydrogen peroxide (30%, 1.34 mL) was added and the mixture was incubated at 0-5 °C and stirred for 1 h to complete the reaction. To the reaction mixture, sodium sulfite solution (15 mL) and sodium bicarbonate solution (1 M, 15 mL) were added, and the mixture was extracted with dichloromethane (15 mL × 2). The aqueous phase was retained and adjusted to pH 1-2 with 4 M hydrochloric acid. The combined dichloromethane phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound D (3.34 mmol) was obtained, which was used directly in the next step without further purification.

[0155] (5) Method for producing compound E Compound D (3.34 mmol) was dissolved in dichloromethane (10 mL), and dibenzylamine (659 mg), N,N-diisopropylethylamine (1.3 g), and HATU (1.5 g) were added in that order. After the addition was complete, the mixture was stirred at 20-25°C for 12 hours to complete the reaction. The reaction mixture was washed with water (10 mL x 2), and the dichloromethane phase was retained, dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. Compound E (800 mg) was obtained by column chromatography. ESI-MS: m / z = 320.30 [M+H] + .

[0156] (6) Method for producing compound F Compound E (800 mg) was dispersed in tetrahydrofuran (10 mL), and 9-borabicyclo[3.3.1]nonane (0.5 M, 12.5 mL) was added. The mixture was stirred at 20-25°C for 1 h. The reaction was then cooled to 0-5°C in an ice bath, and a solution of sodium hydroxide (200 mg) in water (2 mL) and hydrogen peroxide (30%, 1.42 mL) were added sequentially. The mixture was stirred at 20-25°C for 2 h to complete the reaction. The reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (10 mL x 2). The combined ethyl acetate phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound F (700 mg) was obtained and used directly in the next step without further purification. ESI-MS: m / z = 338.30 [M+H] + .

[0157] (7) Method for producing compound G Compound F (700 mg) was dispersed in tetrahydrofuran (10 mL) and cooled to 0-5°C. Lithium aluminum hydride (1 M, 4.1 mL) was added dropwise. After the addition was complete, the mixture was stirred at 20-25°C for 2 hours to complete the reaction. Saturated sodium sulfate solution was added dropwise to the reaction mixture until gas release ceased. Anhydrous sodium sulfate was then added to dry the mixture, filtered, and concentrated until no liquid flowed out. Compound G (630 mg) was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 324.35 [M+H] + .

[0158] (8) Method for producing compound H Compound G (630 mg) was dispersed in methanol (10 mL), Pd / C (10%, 50 mg) was added, and the mixture was purged with hydrogen gas three times. The mixture was stirred in a water bath at 40-45°C for 2 h. After completion of the reaction, the reaction mixture was filtered and concentrated until no more liquid flowed out, yielding compound H (1.948 mmol), which was used directly in the next step without further purification.

[0159] (9) Method for producing compound I Compound H (1.948 mmol) was dissolved in N,N-dimethylformamide (10 mL), 4-bromo-1-fluoro-2-nitrobenzene (428 mg), and potassium carbonate (592 mg) were added in that order. The reaction was completed by stirring in a 40-45°C water bath for 6 hours. The reaction mixture was poured into 50 mL of water and extracted with ethyl acetate (10 mL x 2). The combined ethyl acetate phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound I (470 mg) was obtained by column chromatography. ESI-MS: m / z = 343.14 [M+H] + .

[0160] (10) Method for producing compound J Compound I (470 mg) was dissolved in dichloromethane (8 mL), triethylamine (208 mg) was added, and the mixture was cooled to 0-5°C. A solution of methylsulfonyl chloride (188 mg) in dichloromethane (2 mL) was added dropwise. After the addition was complete, the mixture was reacted at 20-25°C for 1 h to complete the reaction. The reaction mixture was washed with sodium bicarbonate solution (1 M, 10 mL x 2), and the dichloromethane phase was retained, dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out, to obtain compound J (1.369 mmol), which was used directly in the next step without further purification.

[0161] (11) Method for producing compound K Compound J (1.369 mmol), compound A (339 mg), and potassium carbonate (416 mg) were dispersed in N,N-dimethylformamide (10 mL) and reacted at 60 °C for 6 hours. The reaction was completed. The reaction mixture was poured into 50 mL of water and extracted with ethyl acetate (10 mL x 2). The ethyl acetate phases were combined, and the organic phase was washed once with water. The organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound K (650 mg) was obtained by column chromatography. ESI-MS: m / z = 572.16 [M+H] + .

[0162] (12) Method for producing compound L Compound K (650 mg) was dissolved in methanol (5 mL), Raney nickel (20 mg) was added, and the mixture was purged with hydrogen gas three times. The reaction was completed by reacting at 25 °C for 5 h. The reaction solution was filtered, and the filtrate was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound L (1.135 mmol), which was used directly in the next step without further purification.

[0163] (13) Method for producing compound M Compound L (1.135 mmol) was dissolved in t-butanol (1 mL) and dichloromethane (4 mL), and a solution of cyanogen bromide (144 mg) in dichloromethane (1 mL) was added dropwise. The reaction was allowed to proceed at 25 °C for 12 h, completing the reaction. Sodium bicarbonate solution (1 M, 10 mL) was added to the reaction mixture, and the mixture was separated. The dichloromethane phase was retained and the organic phase was washed with sodium bicarbonate solution (1 M, 10 mL x 2). The organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound M (460 mg), which was used directly in the next step without further purification. ESI-MS: m / z = 567.17 [M+H] + .

[0164] (14) Method for producing compound N Compound M (460 mg) was dissolved in tetrahydrofuran (3 mL), and a solution of sodium hydroxide (130 mg) in water (3 mL) was added. The reaction was stirred at 20-25°C for 45 min to complete the reaction. The pH was adjusted to 5-6 with 6 M hydrochloric acid, and tetrahydrofuran and water were removed by evaporation under reduced pressure. Dichloromethane (10 mL) and triethylamine (246 mg) were added and stirred until the mixture was clear. The mixture was then dried over anhydrous sodium sulfate, filtered, and concentrated until no liquid flowed out. Compound N (0.811 mmol) was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 553.16 [M+H] + .

[0165] (15) Method for producing compound O Compound N (0.811 mmol) was redissolved in dichloromethane (5 mL), TBTU (312 mg) was added, and the mixture was allowed to react at 20-25°C for 16 hours. The reaction was then completed. The reaction mixture was washed with water (10 mL x 3), the organic phase was dried over anhydrous sodium sulfate, and the mixture was concentrated until no liquid flowed out. Compound O (310 mg) was obtained by column chromatography. ESI-MS: m / z = 535.22 [M+H] + .

[0166] (16) Manufacturing Method of Example 1 Compound O (100 mg), 3-oxetanamine (16 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed out, and purified by preparative liquid chromatography to obtain Example 1 (20 mg). ESI-MS: m / z = 528.48 [M+H] + .

[0167] 11H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.36 (d, J = 8.7 Hz, 1H), 6.64 (d, J = 2.1 Hz, 1H), 6.48 (dd, J = 8.7, 2.2 Hz, 1H), 6.38 (d, J = 6.0 Hz, 1H), 4.85 (t, J = 6.2 Hz, 2H), 4.49 (q, J = 6.2 Hz, 1H), 4.44 (td, J = 5.9, 4.1 Hz, 2H), 4.31 - 4.25 (m, 1H), 4.21 (dd, J = 14.0, 3.5 Hz, 1H), 4.07 - 3.98 (m, 2H), 3.72 (s, 3H), 2.54 (s, 3H), 2.19 (q, J = 6.7 Hz, 1H), 2.13 (dt, J = 10.4, 5.1 Hz, 1H), 1.97 (dd, J = 11.7, 6.5 Hz, 1H), 1.80 (t, J = 8.5 Hz, 1H), 1.69 (q, J = 6.9, 5.5 Hz, 1H), 0.62 - 0.53 (m, 1H), 0.29 (dt, J = 9.4, 4.8 Hz, 1H), -0.07 (dq, J = 9.5, 4.9 Hz, 1H), -0.18 (tt, J = 9.5, 4.5 Hz, 1H), -0.62 (dq, J = 9.6, 4.8 Hz, 1H).

Example

[0168] JPEG2024543127000042.jpg2887 Compound O (100 mg), (S)-trifluoroisopropylamine hydrochloride (32 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (10 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 50 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (50 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 2 (10 mg). ESI-MS: m / z = 568.48 [M+H] + .

[0169] 11H NMR (500 MHz, DMSO-d6) δ 12.44 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.55 (s, 1H), 7.37 (d, J = 8.7 Hz, 1H), 6.93 (d, J = 2.2 Hz, 1H), 6.73 (dd, J = 8.8, 2.3 Hz, 1H), 5.99 (d, J = 8.6 Hz, 1H), 4.29 (d, J = 7.5 Hz, 1H), 4.22 (dq, J = 8.1, 5.1, 4.3 Hz, 2H), 4.03 (td, J = 9.5, 4.3 Hz, 2H), 3.73 (s, 3H), 2.54 (s, 3H), 2.20 (q, J = 6.7, 6.3 Hz, 1H), 2.13 (dq, J = 9.0, 4.4, 3.8 Hz, 1H), 1.98 (td, J = 9.9, 9.2, 4.5 Hz, 1H), 1.80 (d, J = 9.3 Hz, 1H), 1.70 (tt, J = 8.6, 3.7 Hz, 1H), 1.33 (d, J = 6.7 Hz, 3H), 0.59 (tt, J = 8.6, 3.6 Hz, 1H), 0.30 (dt, J = 8.9, 4.4 Hz, 1H), -0.03 - -0.09 (m, 1H), -0.18 (dt, J = 9.1, 4.4 Hz, 1H), -0.61 (dd, J = 9.4, 4.8 Hz, 1H).

Example

[0170] JPEG2024543127000043.jpg3194 Compound O (110 mg), 4-(2-aminoethyl)morpholine (40 mg), Pd2(dba)3 (47 mg), 2-(di-t-butylphosphine)biphenyl (31 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (10 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. The reaction was then completed. 50 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (50 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 3 (30 mg). ESI-MS: m / z = 585.49 [M+H] + .

[0171] 1H NMR (500 MHz, DMSO-d6) δ 12.39 (s, 1H), 8.34 (s, 1H), 8.16 (s, 1H), 7.91 (s, 1H), 7.55 (d, J = 1.3 Hz, 1H), 7.34 (d, J = 8.7 Hz, 1H), 6.76 (d, J = 2.2 Hz, 1H), 6.61 (dd, J = 8.7, 2.2 Hz, 1H), 4.33 - 4.26 (m, 1H), 4.22 (dd, J = 13.9, 3.4 Hz, 1H), 4.02 (dt, J = 14.3, 8.2 Hz, 2H), 3.73 (s, 3H), 3.61 (t, J = 4.6 Hz, 4H), 3.13 (t, J = 6.7 Hz, 2H), 2.54 (s, 6H), 2.44 (s, 3H), 2.21 (t, J = 6.8 Hz, 1H), 2.14 (dt, J = 10.4, 5.4 Hz, 1H), 2.03 - 1.94 (m, 1H), 1.80 (d, J = 10.0 Hz, 1H), 1.70 (dd, J = 11.1, 5.9 Hz, 1H), 0.58 (dt, J = 9.8, 5.2 Hz, 1H), 0.30 (dt, J = 9.3, 4.7 Hz, 1H), -0.06 (dq, J = 9.5, 4.8 Hz, 1H), -0.17 (dt, J = 9.1, 4.7 Hz, 1H), -0.61 (dt, J = 9.6, 4.8 Hz, 1H).

Example

[0172] JPEG2024543127000044.jpg125122

[0173] (1) Method for producing compound A-1-1 Cyclopropylhydrazine hydrochloride (5.0 g) was dispersed in methanol (50 mL), and methyl trans-3-methoxyacrylate (5.34 g) was added dropwise at 20-25°C. The mixture was then heated to 50-60°C and reacted for 3.5 hours, completing the reaction. The reaction mixture was concentrated, and tetrahydrofuran (60 mL) was added to the residue. The mixture was stirred at room temperature for 2 hours. After stirring, the mixture was filtered under suction, rinsed with 20 mL of tetrahydrofuran, and vacuum-dried at 50°C for 8 hours. Compound A-1-1 (6.4 g) was obtained. ESI-MS: m / z = 125.08 [M+H] + .

[0174] (2) Method for producing compound A-1-2 Compound A-1-1 (6.0 g) and sodium methoxide (2.02 g) were dispersed in methanol (60 mL) and stirred at 20-25°C for 2 h to react. The reaction solution was concentrated, tetrahydrofuran (50 mL × 2) was added, and the solvent was evaporated using a rotary evaporator. Tetrahydrofuran (100 mL) was added, and the mixture was stirred at 20-25°C for 1 h, suction filtered, and concentrated to dryness. Tetrahydrofuran (60 mL), triphenylphosphine (12.7 g), and benzyl alcohol (4.85 g) were added in that order, and the temperature was lowered to 0-10°C. Diisopropyl azodicarboxylate (10.6 g) was added dropwise, and the mixture was allowed to react for 2 h to complete the reaction. Water (100 mL) and ethyl acetate (100 mL) were added to the reaction mixture, and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed out, and purified by column chromatography to give compound A-1-2 (7.0 g). ESI-MS: m / z = 215.10 [M+H] + .

[0175] (3) Method for producing compound A-1-3 Compound A-1-2 (7.0 g) was dispersed in dichloromethane (70 mL), N-iodosuccinimide (7.35 g) was added, and the mixture was stirred at 20-25°C for 2 hours to complete the reaction. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (50 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed out, and subjected to column chromatography to obtain compound A-1-3 (5.9 g). ESI-MS: m / z = 341.04 [M+H] + .

[0176] (4) Method for producing compound A-1-4 Compound A-1-3 (5.9 g) was dispersed in tetrahydrofuran (60 mL) and cooled to -20 to -10 °C under nitrogen gas protection. Isopropyl magnesium chloride (2 mol / L, 17.34 mL) was added dropwise and the mixture was allowed to react for 2 hours. 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8.07 g) was added dropwise. After the addition was complete, the mixture was allowed to react for another 2 hours. The reaction mixture was poured into ammonium chloride solution (10%, 100 mL) and extracted with ethyl acetate (100 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound A-1-4 (7.2 g) was obtained and used directly in the next step without further purification. ESI-MS: m / z = 341.02 [M+H] + .

[0177] (5) Method for producing compound A-1-5 Compound A-1-4 (3.6 g), methyl 2-bromo-6-methylisonicotinate (2.43 g), potassium carbonate (2.9 g), and Pd(dppf)Cl (0.39 g) were dispersed in N,N-dimethylformamide (30 mL). The atmosphere was purged with nitrogen gas three times and the reaction was carried out at 90-100 °C for 8 h. The reaction was then completed. Water (300 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (150 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed out, and purified by column chromatography to obtain compound A-1-5 (1.06 g). ESI-MS: m / z = 364.25 [M+H]+ .

[0178] (6) Method for producing compound A-1 Compound A-1-5 (1.06 g) was dispersed in tetrahydrofuran (20 mL), Pd / C (10%, 200 mg) was added, and the mixture was purged with hydrogen gas three times. The mixture was stirred at 20-25 °C for 0.5 h. After completion of the reaction, the reaction mixture was filtered and concentrated until no liquid flowed out. Compound A-1 (0.8 g) was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 274.11 [M+H] + .

[0179] (7) Method for producing compound I-1 (R)-5-Amino-4-methyl-1-pentanol (4.65 g), 2-fluoro-5-bromonitrobenzene (8.32 g), and potassium carbonate (11.50 g) were added to N,N-dimethylformamide (85 mL) and reacted at 50 °C for 4 h. After the reaction was complete, the reaction mixture was poured into 500 mL of water and extracted with ethyl acetate (400 mL x 2). The combined ethyl acetate phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound I-1 (4.5 g). This was used directly in the next step without further purification. ESI-MS: m / z = 317.10 [M+H] + .

[0180] (8) Method for producing compound J-1 Compound I-1 (4.31 g) was dissolved in dichloromethane (80 mL), triethylamine (2.75 g) was slowly added, and the mixture was cooled to 0-5°C. p-toluenesulfonyl chloride (2.86 g) was then slowly added dropwise. After the addition was complete, the mixture was allowed to react at 20-25°C for 3 hours, completing the reaction. The reaction mixture was washed with sodium bicarbonate solution (1 M, 100 mL x 2), separated, and the organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound J-1 (5.1 g) was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 471.10 [M+H] + .

[0181] (9) Method for producing compound K-1 Compound J-1 (1.38 g), compound A-1 (0.8 g), and potassium carbonate (1.0 g) were added to N,N-dimethylformamide (10 mL) and reacted at 70 °C for 2.5 h to complete the reaction. The reaction mixture was poured into 150 mL of water and extracted with ethyl acetate (150 mL x 2). The combined ethyl acetate phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound K-1 (0.8 g) was obtained by column chromatography. ESI-MS: m / z = 572.19 [M+H] + .

[0182] (10) Method for producing compound L-1 Compound K-1 (0.8 g) was dissolved in methanol (30 mL), Raney Ni (0.2 g) was slowly added, and the reaction mixture was purged with nitrogen gas twice and then with hydrogen gas three times. The reaction was then allowed to proceed at 25 °C for 2 h, completing the reaction. The reaction mixture was filtered, and the filtrate was concentrated until no liquid flowed out. Compound L-1 (1.40 mmol) was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 542.21 [M+H] + .

[0183] (11) Method for producing compound M-1 Compound L-1 (1.40 mmol) was dissolved in methanol (30 mL), and a solution of cyanogen bromide (0.3 g) in acetonitrile (3 mL) was added dropwise. The reaction was allowed to proceed for 2 h at 40-50 °C, leading to completion. Sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (15 mL x 2). The combined dichloromethane phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Concentrated compound M-1 (0.7 g) was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 567.21 [M+H] + .

[0184] (12) Method for producing compound N-1 Compound M-1 (0.7 g) was dissolved in tetrahydrofuran (30 mL), and a solution of sodium hydroxide (0.2 g) in water (6 mL) was added dropwise. The reaction was allowed to proceed at 20-25°C for 3 hours, leading to completion. The reaction mixture was adjusted to pH 5-6 with 6 M hydrochloric acid, and the tetrahydrofuran and water were removed by evaporation under reduced pressure. Dichloromethane (50 mL) and triethylamine (2.25 g) were added and stirred, and the mixture was dissolved until clear. The mixture was dried and filtered to obtain a dichloromethane solution of compound N-1 (1.23 mmol), which was used directly in the next step without further purification. ESI-MS: m / z = 553.18 [M+H] + .

[0185] (13) Method for producing compound O-1 TBTU (0.47 g) was added to a dichloromethane solution of compound N-1 (1.23 mmol), and the reaction was completed by reacting at 20-25°C for 16 hours. The reaction mixture was washed with water (20 mL x 3), and the organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound O-1 (0.48 g) was obtained by column chromatography. ESI-MS: m / z = 535.23 [M+H] + .

[0186] (14) Manufacturing Method of Example 4 Compound O-1 (100 mg), 3-oxetanamine (21 mg), Pd2(dba)3 (37 mg), 2-(di-t-butylphosphine)biphenyl (23 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 70-75 °C for 2 h. The reaction was then completed. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (50 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 4 (36 mg). ESI-MS: m / z = 528.43 [M+H] + .

[0187] 1H NMR (500 MHz, chloroform-d) δ 12.09 (s, 1H), 8.48 (d, J = 1.3 Hz, 1H), 8.09 (s, 1H), 7.63 (d, J = 1.4 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.56 (dd, J = 8.7, 2.2 Hz, 1H), 6.45 (d, J = 6.0 Hz, 1H), 5.30 (s, 1H), 4.99 (t, J = 6.2 Hz, 2H), 4.62 - 4.38 (m, 4H), 4.29 (d, J = 13.7 Hz, 1H), 4.02 (s, 1H), 3.58 (t, J = 11.8 Hz, 1H), 3.49-3.40 (m, 1H), 2.79 (s, 1H), 2.60 (s, 3H), 2.25 (d, J = 7.1 Hz, 1H), 1.93 (dtd, J = 19.1, 10.2, 9.5, 5.6 Hz, 2H), 1.48 (dq, J = 13.4, 7.1, 5.8 Hz, 1H), 1.40-1.32 (d, J = 10.5 Hz, 1H), 1.16-1.13 (m, 1H), 1.09 - 0.97 (m, 2H), 0.89 (d, J = 6.6Hz, 3H). [Example]

[0188] JPEG2024543127000045.jpg35101 Compound O-1 (100 mg), 4-(2-aminoethyl)morpholine (46 mg), Pd2(dba)3 (37 mg), 2-(di-t-butylphosphine)biphenyl (23 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 70-75 °C for 2 h. The reaction was then completed. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (50 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 5 (15 mg). ESI-MS: m / z = 585.36 [M+H] + .

[0189] 1 H NMR (500 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.44 (s, 1H), 8.16 (s, 1H), 7.87 (s, 1H), 7.55 (s, 1H), 7.44 - 7.41 (m, 1H), 6.77 (d, J = 2.3 Hz, 1H), 6.61 (dd, J = 8.6, 2.2 Hz, 1H), 4.39 (td, J = 9.2, 4.5 Hz, 1H), 4.12 (ddd, J = 25.9, 11.6, 4.0 Hz, 2H), 3.78 (dd, J = 13.6, 10.1 Hz, 1H), 3.60 (t, J = 4.5 Hz, 5H), 3.13 (t, J = 6.7 Hz, 2H), 2.78 (s, 1H), 2.54 (s, 4H), 2.52 (s, 1H), 2.43 (t, J = 4.7 Hz, 3H), 2.23 (t, J = 6.8 Hz, 1H), 2.03 - 1.95 (m, 1H), 1.93 (d, J = 10.9 Hz, 1H), 1.49 - 1.40 (m, 1H), 1.23 (d, J = 5.0 Hz, 1H), 1.17 - 1.14 (m, 1H), 1.03 (t, J = 5.5 Hz, 3H), 0.81 (d, J = 6.5 Hz, 3H).

Example

[0190] JPEG2024543127000046.jpg50118

[0191] (1) Method for producing compound K-2 Compound J (600 mg), compound A-1 (400 mg), and potassium carbonate (433 mg) were added to N,N-dimethylformamide (10 mL) and reacted at 60 °C for 5 hours to complete the reaction. The reaction mixture was poured into 50 mL of water and extracted with ethyl acetate (30 mL x 2). The combined ethyl acetate phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound K-2 (610 mg) was obtained by column chromatography. ESI-MS: m / z = 598.21 [M+H] + .

[0192] (2) Method for producing compound L-2 Compound K-2 (600 mg) was dissolved in methanol (10 mL), Raney Ni (0.1 g) was slowly added, and the reaction mixture was purged with nitrogen gas twice and then with hydrogen gas three times. The reaction was then allowed to proceed at 25 °C for 4 h, completing the reaction. The reaction mixture was filtered, and the filtrate was concentrated until no liquid flowed out. Compound L-2 (1.003 mmol) was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 568.22 [M+H] + .

[0193] (3) Method for producing compound M-2 Compound L-2 (1.003 mmol) was dissolved in t-butanol (2 mL) and dichloromethane (8 mL). A solution of cyanogen bromide (128 mg) in dichloromethane (1 mL) was added dropwise and the mixture was allowed to react at 20-25 °C for 12 h, leading to completion of the reaction. Sodium bicarbonate solution (1 M, 10 mL) was added to the reaction mixture, and the mixture was separated. The dichloromethane phase was retained and the organic phase was washed with sodium bicarbonate solution (1 M, 10 mL x 2). The organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound M-2 (500 mg) was obtained and used directly in the next step without further purification. ESI-MS: m / z = 593.24 [M+H] + .

[0194] (4) Method for producing compound N-2 Compound M-2 (500 mg) was dissolved in tetrahydrofuran (10 mL), and a solution of sodium hydroxide (135 mg) in water (6 mL) was added dropwise. The reaction was allowed to proceed at 20-25°C for 2 hours, leading to completion. The reaction mixture was adjusted to pH 5-6 with 6 M hydrochloric acid, and the tetrahydrofuran and water were removed by evaporation under reduced pressure. Dichloromethane (20 mL) and triethylamine (250 mg) were added and stirred, and the mixture was dissolved until clear. The mixture was dried and filtered to obtain a dichloromethane solution of compound N-2 (0.842 mmol), which was used directly in the next step without further purification. ESI-MS: m / z = 579.20 [M+H] + .

[0195] (5) Method for producing compound O'-2 TBTU (324 mg) was added to a dichloromethane solution of compound N-2 (0.842 mmol), and the reaction was completed by reacting at 20-25°C for 16 hours. The reaction mixture was washed with water (20 mL x 3), and the organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound O'-2 (350 mg) was obtained by column chromatography. ESI-MS: m / z = 561.19 [M+H] + .

[0196] (6) Manufacturing Method of Example 6 Compound O'-2 (100 mg), 3-oxetanamine (16 mg), Pd2(dba)3 (41 mg), 2-(di-t-butylphosphine)biphenyl (27 mg), and potassium t-butoxide (120 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 70-75 °C for 2 h. The reaction was then completed. 50 mL of water was added to the reaction mixture, which was then extracted with dichloromethane (50 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 6 (26 mg). ESI-MS: m / z = 554.31 [M+H] + . [Example]

[0197] JPEG2024543127000047.jpg2996 Compound O'-2 (100 mg), 4-(2-aminoethyl)morpholine (28 mg), Pd2(dba)3 (41 mg), 2-(di-t-butylphosphine)biphenyl (27 mg), and potassium t-butoxide (120 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 70-75 °C for 2 h. The reaction was then completed. 50 mL of water was added to the reaction mixture, and the mixture was extracted with dichloromethane (50 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 7 (15 mg). ESI-MS: m / z = 611.36 [M+H] + . [Example]

[0198] JPEG2024543127000048.jpg56102

[0199] (1) Method for producing compound I-2 Compound H (1.0 g), 2-fluoro-4-bromonitrobenzene (1.54 g), and potassium carbonate (2.12 g) were added to N,N-dimethylformamide (30 mL) and stirred in a water bath at 40-45 °C for 6 h. The reaction was monitored by LC-MS and confirmed to be complete. The reaction mixture was poured into 200 mL of water and extracted with ethyl acetate (30 mL x 2). The combined ethyl acetate phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound I-2 (1.54 g) was obtained by column chromatography. ESI-MS: m / z = 343.15 [M+H] + .

[0200] (2) Method for producing compound J-2 Compound I-2 (1.54 g) was dissolved in dichloromethane (20 mL), triethylamine (681 mg) was slowly added, and the mixture was cooled to 0-5°C. Ethylsulfonyl chloride (692 mg) was then slowly added dropwise. After the addition was complete, the mixture was reacted at 20-25°C for 3 hours to complete the reaction. The reaction mixture was washed with sodium bicarbonate solution (1 M, 20 mL x 2), separated, and the organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound J-2 was obtained, which was used directly in the next step without further purification.

[0201] (3) Method for producing compound K-2 Compound J-2 obtained in the previous step, compound A (1.10 g), and potassium carbonate (1.36 g) were added to N,N-dimethylformamide (20 mL) and reacted at 70 °C for 2.5 h. LC-MS showed the reaction was complete. The reaction mixture was poured into 100 mL of water and extracted with ethyl acetate (20 mL x 2). The combined ethyl acetate phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound K-2 (2.01 g) was obtained by column chromatography. ESI-MS: m / z = 572.20 [M+H] + .

[0202] (4) Method for producing compound L-2 Compound K-2 (2.0 g) was dissolved in methanol (15 mL) and tetrahydrofuran (15 mL), Raney nickel (200 mg) was added, and the mixture was purged with hydrogen gas three times. The mixture was then reacted at 25 °C for 5 h. TLC showed that the reaction was complete. The reaction mixture was filtered, and the filtrate was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound L-2 was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 542.21 [M+H] + .

[0203] (5) Method for producing compound M-2 Compound L-2 obtained in the previous step was dissolved in t-butanol (5 mL) and dichloromethane (20 mL). A solution of cyanogen bromide (444 mg) in dichloromethane (2 mL) was added dropwise and the mixture was allowed to react at 25 °C for 12 h. LC-MS showed the reaction was complete. Sodium bicarbonate solution (1 M, 30 mL) was added to the reaction mixture, the layers were separated, the dichloromethane phase was retained, and the organic phase was washed with sodium bicarbonate solution (1 M, 30 mL x 2). The organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound M-2 (1.80 g), which was used directly in the next step without further purification. ESI-MS: m / z = 567.19 [M+H] + .

[0204] (6) Method for producing compound N-2 Compound M-2 (1.80 g) was dissolved in tetrahydrofuran (10 mL), and a solution of sodium hydroxide (507 mg) in water (10 mL) was added. The reaction was stirred at 20-25 °C for 45 min. LC-MS showed the reaction was complete. The pH was adjusted to 5-6 with 6 M hydrochloric acid, and tetrahydrofuran and water were removed by evaporation under reduced pressure. Dichloromethane (30 mL) and triethylamine (963 mg) were added and stirred until the mixture was clear. The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated until no liquid flowed out. Compound N-2 was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 553.16 [M+H] + .

[0205] (7) Method for producing compound O-2 Compound N-2 obtained in the previous step was dissolved in dichloromethane (30 mL), TBTU (1.20 g) was added, and the mixture was allowed to react at 20-25 °C for 16 h. LC-MS showed the reaction was complete. The reaction mixture was washed with water (30 mL x 3), the organic phase was dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. Compound O-2 (900 mg) was obtained by column chromatography. ESI-MS: m / z = 535.21 [M+H] + .

[0206] (8) Method for producing compound P-2 Compound O-2 (100 mg) was added to N,N-dimethylformamide (2 mL), and 2-(trimethylsilyl)ethoxymethyl chloride (47 mg) and N,N-diisopropylethylamine (48 mg) were added dropwise at 20-25°C. The mixture was purged with nitrogen gas three times and reacted at 60°C for 3 h. LC-MS showed the reaction was complete. The reaction mixture was poured into 15 mL of water and extracted with ethyl acetate (10 mL x 2). The combined ethyl acetate phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound P-2 (90 mg) was obtained by column chromatography. ESI-MS: m / z = 665.20 [M+H] + .

[0207] (9) Method for producing compound Q-2 Compound P-2 (90 mg), potassium trifluoro((4-methylpiperazin-1-yl)methyl)borate (52 mg), X-Phos (15 mg), palladium acetate (3.6 mg), and cesium carbonate (130 mg) were added to 1,4-dioxane (3 mL) and water (0.3 mL). The mixture was purged with nitrogen three times and reacted at 100 °C for 2 h. LC-MS indicated the reaction was complete. The reaction mixture was poured into 15 mL of water and extracted with ethyl acetate (10 mL x 2). The combined ethyl acetate phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound Q-2 (70 mg) was obtained by column chromatography. ESI-MS: m / z = 699.38 [M+H] + .

[0208] (10) Manufacturing Method of Example 8 Compound Q-2 (20 mg) was added to dichloromethane (2 mL), trifluoroacetic acid (0.3 mL) was added dropwise at 20-25°C, and the reaction was allowed to proceed at 35°C for 6 hours. LC-MS showed that the reaction was complete. The reaction mixture was concentrated until no more liquid flowed out, and purified by preparative liquid chromatography to give Example 8 (13 mg). ESI-MS: m / z = 569.35 [M+H] + .

[0209] 1 H NMR (500 MHz, クロロホルム-d) δ 12.05 (s, 1H), 8.41 (s, 1H), 8.15 (s, 1H), 7.66 (s, 1H), 7.40 (s, 1H), 7.27 (d, J = 9.1 Hz, 1H), 7.21 (d, J = 8.1 Hz, 1H), 4.41 (dd, J = 14.2, 3.0 Hz, 1H), 4.38 - 4.32 (m, 1H), 4.03 (dd, J = 14.0, 7.2 Hz, 1H), 3.96 (dd, J = 9.6, 4.7 Hz, 1H), 3.79 (s, 3H), 3.62 (s, 2H), 2.64 (s, 3H), 2.57 - 2.40 (m, 6H), 2.30 (s, 3H), 2.28 (s, 1H), 2.21 (dd, J = 15.5, 7.9 Hz, 3H), 2.01 (d, J = 6.3 Hz, 1H), 1.64 (t, J = 7.5 Hz, 1H), 0.59 - 0.51 (m, 1H), 0.44 (dq, J = 8.9, 4.4 Hz, 1H), 0.04 (d, J = 7.2 Hz, 1H), -0.04 (q, J = 5.3, 4.8 Hz, 1H), -0.37 (dq, J = 9.7, 5.0 Hz, 1H).

Example

[0210] JPEG2024543127000049.jpg68103

[0211] (1) Method for producing compound A-2-1 1-Methyl-5-hydroxypyrazole (30 g) and potassium carbonate (90 g) were added to acetonitrile (900 mL), and 2-(trimethylsilyl)ethoxymethyl chloride (90 mL) was added dropwise at 25°C. After the addition was complete, the mixture was allowed to react at 20-25°C for 16 hours, completing the reaction. The reaction mixture was filtered, and the filtrate was evaporated to dryness. To the residue, methyl t-butyl ether (300 mL) was added, and the mixture was heated to 65°C and dissolved until clear. Further addition of n-heptane (120 mL) resulted in crystallization by natural cooling. The mixture was then vacuum filtered, and the filter cake was baked to obtain compound A-2-1. ESI-MS: m / z = 229.30 [M+H] + .

[0212] (2) Method for producing compound A-2-2 Compound A-2-1 (26 g), N-iodosuccinimide (30.7 g), and benzoic acid (2.8 g) were added to dichloromethane (260 mL) and reacted at 20-25°C for 3 hours to complete the reaction. The reaction mixture was washed with water (500 mL x 2), separated, and the organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound A-2-2 was obtained by column chromatography. ESI-MS: m / z = 355.20 [M+H] + .

[0213] (3) Method for producing compound A-2-3 2-Fluoroisonicotinic acid (20 g), methyl iodide (40.2 g), and potassium carbonate (39 g) were added to N,N-dimethylformamide (200 mL) and reacted at 40 °C for 16 hours to complete the reaction. The reaction mixture was poured into 1500 mL of water and extracted with ethyl acetate (500 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound A-2-3 was obtained by column chromatography. ESI-MS: m / z = 156.08 [M+H] + .

[0214] (4) Method for producing compound A-2-4 Bis(pinacolato)diboron (14.8 g), methoxy(cyclooctadiene)iridium(I) dimer (570 mg), and 4,4-di-t-butylbipyridine (468 mg) were added to cyclohexane (150 mL), purged with nitrogen gas three times, and stirred at 25 °C for 1 h. A solution of compound A-2-3 (9 g) in cyclohexane (30 mL) was then added dropwise. After the addition was complete, the reaction was allowed to proceed at 75 °C for 4 h, completing the reaction. The reaction solution was evaporated to dryness to obtain compound A-2-4, which was used directly in the next step without further purification. ESI-MS: m / z = 199.99 [M+H] + .

[0215] (5) Method for producing compound A-2-5 Compound A-2-2 (5.9 g), compound A-2-4 (5.0 g), Pd(dppf)Cl (1.3 g), and cesium carbonate (8.2 g) were added to N,N-dimethylformamide (50 mL), purged with nitrogen gas three times, and stirred at 100 °C for 4 h to complete the reaction. The reaction solution was poured into 300 mL of water and extracted with dichloromethane (100 mL × 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound A-2-5 was obtained by column chromatography. ESI-MS: m / z = 382.34 [M+H] + .

[0216] (6) Method for producing compound A-2 Compound A-2-5 (5.9 g) was added to a 1,4-dioxane solution of hydrogen chloride (4 M, 20 mL) and stirred at 25 °C for 3 h to complete the reaction. The reaction solution was evaporated to dryness to give compound A-2, which was used directly in the next step without further purification. ESI-MS: m / z = 252.17 [M+H] + .

[0217] (7) Method for producing compound K-3 Compound J (1.0 g), compound A-2 (596 mg), and potassium carbonate (721 mg) were added to N,N-dimethylformamide (20 mL) and reacted at 60 °C for 6 h. LC-MS showed the reaction was complete. The reaction mixture was poured into 100 mL of water and extracted with ethyl acetate (30 mL x 2). The ethyl acetate phases were combined, and the organic phase was washed once with water. The organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound K-3 (1.1 g) was obtained by column chromatography. ESI-MS: m / z = 576.15 [M+H] + .

[0218] (8) Method for producing compound L-3 Compound K-3 (1.1 g) was dissolved in methanol (15 mL), Raney nickel (100 mg) was added, and the mixture was purged with hydrogen gas three times. The mixture was then reacted at 25 °C for 5 h, after which TLC showed the reaction was complete. The reaction mixture was filtered, and the filtrate was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound L-3 was obtained, which was used directly in the next step without further purification.

[0219] (9) Method for producing compound M-3 Compound L-3 obtained in the previous step was dissolved in t-butanol (4 mL) and dichloromethane (16 mL). A solution of cyanogen bromide (243 mg) in dichloromethane (1 mL) was added dropwise and the mixture was allowed to react at 25 °C for 12 h. LC-MS showed the reaction was complete. Sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, the layers were separated, the dichloromethane phase was retained, and the organic phase was washed with sodium bicarbonate solution (1 M, 20 mL x 2). The organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound M-3 (850 mg), which was used directly in the next step without further purification. ESI-MS: m / z = 571.13 [M+H] + .

[0220] (10) Method for producing compound N-3 Compound M-3 (850 mg) was dissolved in tetrahydrofuran (10 mL), and a solution of sodium hydroxide (238 mg) in water (3 mL) was added. The reaction was stirred at 20-25 °C for 45 min. LC-MS showed the reaction was complete. The pH was adjusted to 5-6 with 6 M hydrochloric acid, and tetrahydrofuran and water were removed by evaporation under reduced pressure. Dichloromethane (10 mL) and triethylamine (456 mg) were added and stirred until the mixture was clear. The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated until no liquid flowed out. Compound N-3 was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 557.15 [M+H] + .

[0221] (11) Method for producing compound O-3 Compound N-3 obtained in the previous step was dissolved in dichloromethane (10 mL), TBTU (573 mg) was added, and the mixture was allowed to react at 20-25 °C for 16 h. LC-MS showed the reaction was complete. The reaction mixture was washed with water (10 mL x 3), the organic phase was dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. Compound O-3 (620 mg) was obtained as a gray-brown solid by column chromatography. ESI-MS: m / z = 539.16 [M+H] + .

[0222] (12) Manufacturing Method of Example 9 Compound O-3 (100 mg), (S)-trifluoroisopropylamine hydrochloride (42 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (10 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. LC-MS showed the reaction was complete. The reaction mixture was added with 10 mL of water and extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 9 (12 mg). ESI-MS: m / z = 572.34 [M+H] + .

[0223] 1 1H NMR (500 MHz, DMSO-d6) δ 12.52 (s, 1H), 8.43 (d, J = 2.2 Hz, 1H), 7.87 (s, 1H), 7.40 (d, J = 8.8 Hz, 1H), 7.29 (d, J = 1.9 Hz, 1H), 6.93 (d, J = 2.2 Hz, 1H), 6.75 (dd, J = 8.7, 2.3 Hz, 1H), 6.03 (d, J = 8.6 Hz, 1H), 4.36 - 4.28 (m, 1H), 4.23 (dt, J = 14.1, 3.7 Hz, 2H), 4.06 (td, J = 9.3, 4.1 Hz, 2H), 3.74 (s, 3H), 2.21 (q, J = 6.8, 6.0 Hz, 1H), 2.15 (dt, J = 10.1, 5.0 Hz, 1H), 2.04 - 1.96 (m, 1H), 1.79 (s, 1H), 1.76 - 1.66 (m, 1H), 1.33 (d, J = 6.7 Hz, 3H), 0.63 - 0.56 (m, 1H), 0.30 (tt, J = 9.0, 4.7 Hz, 1H), -0.04 (dq, J = 9.7, 4.7 Hz, 1H), -0.18 (tt, J = 9.6, 4.8 Hz, 1H), -0.62 (dt, J = 9.5, 5.0 Hz, 1H).

Example

[0224] JPEG2024543127000050.jpg2578 Compound O (100 mg), 4-amino-1-methylpiperidine (32 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (10 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 50 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (50 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 10 (30 mg). ESI-MS: m / z = 569.56 [M+H] + .

[0225] 11H NMR (500 MHz, DMSO-d6) δ 12.35 (s, 1H), 8.33 (s, 1H), 8.21 (s, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.32 (d, J = 8.6 Hz, 1H), 6.78 (d, J = 2.2 Hz, 1H), 6.59 (dd, J = 8.7, 2.2 Hz, 1H), 4.28 (q, J = 7.8 Hz, 1H), 4.21 (dd, J = 13.9, 3.5 Hz, 1H), 4.02 (td, J = 14.0, 13.4, 7.5 Hz, 2H), 3.73 (s, 3H), 3.24 - 3.14 (m, 1H), 2.89 (d, J = 11.3 Hz, 2H), 2.54 (s, 3H), 2.30 (s, 3H), 2.27 - 2.19 (m, 3H), 2.16 - 2.08 (m, 1H), 1.97 (dd, J = 13.7, 8.8 Hz, 3H), 1.81 (d, J = 9.2 Hz, 1H), 1.70 (dq, J = 13.7, 6.4, 5.5 Hz, 1H), 1.48 (q, J = 11.2 Hz, 2H), 0.58 (tt, J = 8.6, 3.6 Hz, 1H), 0.30 (tt, J = 9.3, 4.8 Hz, 1H), -0.06 (dq, J = 9.7, 4.9 Hz, 1H), -0.16 (dp, J = 9.4, 4.7 Hz, 1H), -0.59 (dt, J = 9.7, 4.9 Hz, 1H).

Example

[0226] Compound O-2 (60 mg), copper hydroxide (22 mg), and potassium carbonate (30 mg) were added to N,N-dimethylethanolamine (5 mL), the atmosphere was purged with nitrogen gas three times, and the reaction was completed at 130 °C for 18 hours. The reaction mixture was added with 30 mL of water and extracted with ethyl acetate (30 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed out, and purified by preparative liquid chromatography to obtain Example 11 (15 mg). ESI-MS: m / z = 544.41 [M+H] + .

[0227] 1 H NMR (500 MHz, DMSO-d6) δ 12.43 (s, 1H), 8.38 (s, 1H), 7.95 (s, 1H), 7.59 (s, 1H), 7.30 (d, J = 8.5 Hz, 1H), 6.81 (d, J = 2.1 Hz, 1H), 6.61 (dd, J = 8.5, 2.0 Hz, 1H), 4.33 (q, J = 8.1 Hz, 1H), 4.27 (dd, J = 14.1, 3.7 Hz, 1H), 4.09 (td, J = 9.5, 4.5 Hz, 2H), 3.99 (t, J = 5.3 Hz, 2H), 3.77 (s, 3H), 2.59 (s, 3H), 2.53 (t, J = 6.9 Hz, 2H), 2.28 (s, 1H), 2.25 (s, 6H), 2.18 (td, J = 9.6, 4.9 Hz, 1H), 2.04 (tt, J = 13.9, 10.5, 5.0 Hz, 1H), 1.89 (d, J = 9.5 Hz, 1H), 1.78 (tt, J = 13.2, 5.6 Hz, 1H), 0.66 (qd, J = 8.4, 4.2 Hz, 1H), 0.38 (dp, J = 9.2, 4.7 Hz, 1H), 0.00 (dq, J = 9.6, 5.0 Hz, 1H), -0.06 (dp, J = 9.4, 4.7 Hz, 1H), -0.55 (dt, J = 9.6, 4.9 Hz, 1H). [Example]

[0228] JPEG2024543127000052.jpg3093 Compound O-1 (100 mg), 4-amino-1-methylpiperidine (32 mg), Pd2(dba)3 (37 mg), 2-(di-t-butylphosphine)biphenyl (23 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (4 mL), purged with nitrogen gas three times, and reacted at 70-75 °C for 4 h. The reaction was then completed. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (100 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 12 (47 mg). ESI-MS: m / z = 569.45 [M+H] + .

[0229] 1H NMR (500 MHz, クロロホルム-d) δ 12.20 (s, 1H), 8.46 (d, J = 1.4 Hz, 1H), 8.15 (s, 1H), 7.90 (d, J = 1.3 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 6.58 (d, J = 9.5 Hz, 2H), 4.48 (td, J = 9.1, 5.0 Hz, 1H), 4.32 (dd, J = 13.7, 3.3 Hz, 1H), 4.06 - 4.01 (m, 1H), 3.85 (ddt, J = 15.4, 5.2, 3.3 Hz, 2H), 3.79 - 3.75 (m, 2H), 3.73 (s, 3H), 3.69 - 3.61 (m, 2H), 3.52 - 3.46 (m, 2H), 3.14 (dd, J = 12.4, 3.8 Hz, 1H), 3.05 (dd, J = 12.4, 7.5 Hz, 1H), 2.83 (s, 1H), 2.65 (s, 3H), 2.28 (d, J = 7.1 Hz, 1H), 2.12 (ddt, J = 14.1, 9.3, 4.5 Hz, 1H), 1.92 (dtd, J = 19.1, 10.2, 9.5, 5.6 Hz, 2H), 1.50 (dq, J = 13.4, 7.1, 5.8 Hz, 1H), 1.40 - 1.35 (m, 1H), 1.18 - 1.13 (m, 1H), 1.07 - 1.01 (m, 2H), 0.89 (d, J = 6.6 Hz, 3H).

Example

[0230] Compound O-1 (100 mg), (R)-3-aminotetrahydrofuran hydrochloride (35 mg), Pd2(dba)3 (37 mg), 2-(di-t-butylphosphine)biphenyl (23 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (4 mL), purged with nitrogen gas three times, and reacted at 70-75 °C for 4 h. The reaction was then completed. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (100 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 13 (18 mg). ESI-MS: m / z = 542.39 [M+H] + .

[0231] 1H NMR (500 MHz, クロロホルム-d) δ 11.93 (s, 1H), 8.51 (d, J = 1.4 Hz, 1H), 8.10 (s, 1H), 7.66 (d, J = 1.3 Hz, 1H), 7.08 (d, J = 8.5 Hz, 1H), 6.57 (d, J = 8.2 Hz, 2H), 4.47 (dt, J = 9.1, 4.5 Hz, 1H), 4.32 (dd, J = 13.7, 3.4 Hz, 1H), 4.10 - 4.02 (m, 2H), 4.00 - 3.91 (m, 2H), 3.85 (td, J = 8.6, 5.5 Hz, 1H), 3.74 (dd, J = 9.3, 2.8 Hz, 1H), 3.63 (dd, J = 13.7, 9.6 Hz, 1H), 3.48 (tt, J = 7.4, 3.9 Hz, 1H), 2.83 (s, 1H), 2.63 (s, 3H), 2.29 (dtd, J = 10.5, 5.7, 5.0, 2.5 Hz, 2H), 2.14 (td, J = 9.7, 4.9 Hz, 1H), 1.96 (dq, J = 9.6, 4.8 Hz, 1H), 1.89 (dddd, J = 13.0, 8.1, 5.6, 3.1 Hz, 1H), 1.56 - 1.47 (m, 1H), 1.37 (dtd, J = 7.5, 3.9, 2.0 Hz, 1H), 1.19 - 1.14 (m, 1H), 1.10 - 1.01 (m, 2H), 0.92 (d, J = 6.5 Hz, 3H).

Example

[0232] JPEG2024543127000054.jpg34113 Compound O-1 (100 mg), (S)-1,4-dioxane-2-methylamine hydrochloride (43 mg), Pd2(dba)3 (37 mg), 2-(di-t-butylphosphine)biphenyl (23 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (4 mL), purged with nitrogen gas three times, and reacted at 70-75 °C for 4 h. The reaction was then completed. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (100 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 14 (11 mg). ESI-MS: m / z = 572.41 [M+H] + .

[0233] 1H NMR (500 MHz, クロロホルム-d) δ 11.91 (s, 1H), 8.51 (d, J = 1.3 Hz, 1H), 8.09 (s, 1H), 7.66 (d, J = 1.4 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 6.61 (dd, J = 8.6, 2.1 Hz, 1H), 6.57 (d, J = 2.1 Hz, 1H), 4.48 (td, J = 9.1, 5.0 Hz, 1H), 4.32 (dd, J = 13.7, 3.3 Hz, 1H), 4.06 - 4.01 (m, 1H), 3.85 (ddt, J = 15.4, 5.2, 3.3 Hz, 2H), 3.79 - 3.72 (m, 2H), 3.68 - 3.60 (m, 2H), 3.51 - 3.45 (m, 2H), 3.16 (dd, J = 12.4, 3.8 Hz, 1H), 3.07 (dd, J = 12.4, 7.5 Hz, 1H), 2.83 (s, 1H), 2.63 (s, 3H), 2.27 (d, J = 7.1 Hz, 1H), 2.14 (ddt, J = 14.1, 9.3, 4.5 Hz, 1H), 1.96 (dtd, J = 19.1, 10.2, 9.5, 5.6 Hz, 2H), 1.51 (dq, J = 13.4, 7.1, 5.8 Hz, 1H), 1.40 - 1.35 (m, 1H), 1.18 - 1.13 (m, 1H), 1.07 - 1.01 (m, 2H), 0.91 (d, J = 6.6 Hz, 3H).

Example

[0234] JPEG2024543127000055.jpg53104

[0235] (1) Method for producing compound I-4 (R)-5-Amino-4-methyl-1-pentanol (5.58 g), 2-fluoro-4-bromonitrobenzene (9.98 g), and potassium carbonate (13.82 g) were added to N,N-dimethylformamide (85 mL) and reacted at 50 °C for 4 h. After the reaction was complete, the reaction mixture was poured into 500 mL of water and extracted with ethyl acetate (400 mL x 2). The combined ethyl acetate phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound I-4 (5.52 g). This was used directly in the next step without further purification. ESI-MS: m / z = 317.10 [M+H] + .

[0236] (2) Method for producing compound J-4 Compound I-4 (5.52 g) was dissolved in dichloromethane (80 mL), triethylamine (3.52 g) was slowly added, and the mixture was cooled to 0-5°C. p-toluenesulfonyl chloride (3.66 g) was then slowly added dropwise. After the addition was complete, the mixture was allowed to react at 20-25°C for 3 hours, completing the reaction. The reaction mixture was washed with sodium bicarbonate solution (1 M, 100 mL x 2), separated, and the organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound J-4 (6.1 g) was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 471.10 [M+H] + .

[0237] (3) Method for producing compound K-4 Compound J-4 (1.38 g), compound A-1 (0.8 g), and potassium carbonate (1.0 g) were added to N,N-dimethylformamide (10 mL) and reacted at 70 °C for 2.5 h to complete the reaction. The reaction mixture was poured into 150 mL of water and extracted with ethyl acetate (150 mL x 2). The combined ethyl acetate phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound K-4 (0.9 g) was obtained by column chromatography. ESI-MS: m / z = 572.20 [M+H] + .

[0238] (4) Method for producing compound L-4 Compound K-4 (0.8 g) was dissolved in methanol (30 mL), Raney nickel (0.2 g) was slowly added, and the reaction mixture was purged with nitrogen gas twice and then with hydrogen gas three times. The reaction was then allowed to proceed at 25°C for 2 hours, completing the reaction. The reaction mixture was filtered, and the filtrate was concentrated until no more liquid flowed out. Compound L-4 was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 542.24 [M+H] + .

[0239] (5) Method for producing compound M-4 Compound L-4 obtained in the previous step was dissolved in methanol (30 mL), and a solution of cyanogen bromide (0.3 g) in acetonitrile (3 mL) was added dropwise. The reaction was allowed to proceed for 2 h at 40-50 °C, leading to completion. Sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (15 mL x 2). The combined dichloromethane phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding concentrated compound M-4 (0.7 g). ESI-MS: m / z = 567.25 [M+H] + .

[0240] (6) Method for producing compound N-4 Compound M-4 (0.7 g) was dissolved in tetrahydrofuran (30 mL), and a solution of sodium hydroxide (0.2 g) in water (6 mL) was added dropwise. The reaction was allowed to proceed at 20-25°C for 3 hours, leading to completion. The reaction mixture was adjusted to pH 5-6 with 6 M hydrochloric acid, and the tetrahydrofuran and water were removed by evaporation under reduced pressure. Dichloromethane (50 mL) and triethylamine (2.25 g) were added and stirred, and the mixture was dissolved until clear. The mixture was dried and filtered to obtain a dichloromethane solution of compound N-4, which was used directly in the next step without further purification. ESI-MS: m / z = 553.19 [M+H] + .

[0241] (7) Method for producing compound O-4 The dichloromethane solution of compound N-4 obtained in the previous step was added with TBTU (0.47 g) and reacted at 20-25 °C for 16 h to complete the reaction. The reaction mixture was washed with water (20 mL x 3), the organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed out, and compound O-4 (0.51 g) was obtained by column chromatography. ESI-MS: m / z = 535.27 [M+H] + .

[0242] (8) Manufacturing Method of Example 15 Compound O-4 (50 mg), 4-amino-1-methylpiperidine (13 mg), Pd(dba) (21 mg), 2-(di-t-butylphosphine)biphenyl (14 mg), and potassium t-butoxide (61 mg) were added to t-amyl alcohol (3 mL). The mixture was purged with nitrogen gas three times and reacted at 70-75 °C for 4 h. The reaction was then completed. Water (10 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 15 (5 mg). ESI-MS: m / z = 569.49 [M+H] + .

[0243] 1H NMR (500 MHz, DMSO-d6) δ 12.38 (s, 1H), 8.44 (s, 1H), 8.15 (s, 1H), 7.87 (s, 1H), 7.54 (s, 1H), 7.23 (d, J = 8.6 Hz, 1H), 6.68 (d, J = 2.0 Hz, 1H), 6.54 (dd, J = 8.6, 2.0 Hz, 1H), 4.40 (td, J = 9.3, 4.5 Hz, 1H), 4.13 (ddd, J = 18.7, 11.6, 4.0 Hz, 2H), 3.85 - 3.81 (m, 1H), 3.64 - 3.62 (m, 1H), 3.28 (s, 1H), 2.81 - 2.73 (m, 3H), 2.54 (s, 3H), 2.24 (s, 1H), 2.20 (s, 3H), 2.09 (t, J = 11.2 Hz, 2H), 2.03 - 1.98 (m, 1H), 1.96 - 1.89 (m, 3H), 1.46 (s, 1H), 1.44 - 1.35 (m, 2H), 1.20 - 1.14 (m, 1H), 1.03 (ddd, J = 11.6, 7.7, 3.7 Hz, 3H), 0.82 (d, J = 6.5 Hz, 3H). [Example]

[0244] JPEG2024543127000056.jpg35103 Compound O-4 (50 mg), (S)-3-pyrrolidinol (10 mg), Pd2(dba)3 (21 mg), 2-(di-t-butylphosphine)biphenyl (14 mg), and potassium t-butoxide (61 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 70-75 °C for 4 h. The reaction was then completed. Water (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 16 (10 mg). ESI-MS: m / z = 542.26 [M+H] + .

[0245] 1 1H NMR (500 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.35 (s, 1H), 7.91 (s, 1H), 7.55 (s, 1H), 7.34 (d, J = 8.6 Hz, 1H), 6.69 (d, J = 2.2 Hz, 1H), 6.47 (dd, J = 8.7, 2.2 Hz, 1H), 4.98 (s, 1H), 4.43 (dq, J = 7.0, 3.4 Hz, 1H), 4.29 (q, J = 8.2, 7.6 Hz, 1H), 4.22 (dd, J = 14.0, 3.7 Hz, 1H), 4.14 (dd, J = 13.8, 9.1 Hz, 1H), 4.04 (dt, J = 7.0, 4.6 Hz, 1H), 3.46 (dd, J = 10.0, 5.0 Hz, 1H), 3.12 (dd, J = 10.0, 2.5 Hz, 1H), 2.79 (s, 1H), 2.60 (s, 3H), 2.25 (d, J = 7.1 Hz, 1H), 2.09 (t, J = 11.2 Hz, 2H), 2.03 - 1.98 (m, 1H), 1.96 - 1.89 (m, 3H), 1.48 (dq, J = 13.4, 7.1, 5.8 Hz, 1H), 1.40-1.32 (d, J = 10.5 Hz, 2H), 1.16-1.13 (m, 1H), 1.09 - 0.97 (m, 2H), 0.89 (d, J = 6.6 Hz, 3H).

Example

[0246] Compound O-4 (70 mg), N,N-dimethylethylenediamine (23 mg), Pd2(dba)3 (24 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 80 °C for 2 h. The reaction was then completed. Water (10 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 17 (20 mg). ESI-MS: m / z = 543.43 [M+H] + .

[0247] 1 H NMR (500 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.45 (s, 1H), 8.19 (d, J = 2.6 Hz, 1H), 7.88 (d, J = 3.4 Hz, 1H), 7.55 (d, J = 1.2 Hz, 1H), 7.26 (d, J = 8.5 Hz, 1H), 6.73 (d, J = 2.1 Hz, 1H), 6.57 (dd, J = 8.6, 2.1 Hz, 1H), 4.40 (dt, J = 9.5, 4.8 Hz, 1H), 4.18 - 4.10 (m, 2H), 3.84 (dd, J = 13.6, 10.2 Hz, 1H), 3.65 - 3.61 (m, 1H), 3.21 (t, J = 6.4 Hz, 2H), 2.81 (s, 1H), 2.63 (t, J = 6.5 Hz, 2H), 2.55 (d, J = 3.6 Hz, 3H), 2.33 (d, J = 4.7 Hz, 6H), 2.25 (s, 1H), 2.01 (d, J = 13.8 Hz, 1H), 1.97 - 1.89 (m, 1H), 1.47 (s, 1H), 1.16 (ddd, J = 9.1, 4.6, 2.7 Hz, 1H), 1.09 - 1.01 (m, 3H), 0.84 (t, J = 5.2 Hz, 3H). [Example]

[0248] JPEG2024543127000058.jpg34108 Compound O (100 mg), (R)-3-aminotetrahydropyran hydrochloride (31 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 50 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 18 (69 mg). ESI-MS: m / z = 556.46 [M+H] + .

[0249] 11H NMR (500 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.24 (d, J = 8.6 Hz, 1H), 6.82 (d, J = 2.1 Hz, 1H), 6.58 (dd, J = 8.6, 2.1 Hz, 1H), 5.45 (s, 1H), 4.28 (td, J = 8.5, 5.2 Hz, 1H), 4.21 (dd, J = 13.9, 3.7 Hz, 1H), 4.12 - 4.01 (m, 2H), 3.92 (ddd, J = 10.9, 4.0, 1.6 Hz, 1H), 3.73 (s, 3H), 3.45 (s, 1H), 3.38 - 3.33 (m, 1H), 3.12 (dd, J = 11.0, 8.4 Hz, 1H), 2.54 (s, 3H), 2.21 (dd, J = 13.3, 6.6 Hz, 1H), 2.13 (tt, J = 8.8, 4.9 Hz, 1H), 2.00 (td, J = 13.4, 5.0 Hz, 2H), 1.84 (d, J = 9.9 Hz, 1H), 1.71 (dq, J = 12.2, 3.7 Hz, 2H), 1.59 (dtd, J = 17.7, 10.0, 8.3, 4.4 Hz, 1H), 1.50 - 1.42 (m, 1H), 0.86 - 0.83 (m, 1H), 0.67 - 0.58 (m, 1H), 0.32 (dp, J = 9.2, 4.7 Hz, 1H), -0.05 (dq, J = 9.6, 4.8 Hz, 1H), -0.13 (dq, J = 9.3, 4.9 Hz, 1H), -0.57 (dt, J = 9.6, 4.8 Hz, 1H).

Example

[0250] JPEG2024543127000059.jpg35110 Compound O (100 mg), (S)-1,4-dioxane-2-methylamine hydrochloride (43 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 19 (13 mg). ESI-MS: m / z = 572.34 [M+H] + .

[0251] 1H NMR (500 MHz, クロロホルム-d) δ 11.93 (s, 1H), 8.39 (s, 1H), 8.15 (s, 1H), 7.65 (s, 1H), 7.15 (d, J = 9.1 Hz, 1H), 6.57 (d, J = 6.5 Hz, 2H), 4.35 (tt, J = 8.8, 4.5 Hz, 2H), 3.98 - 3.90 (m, 2H), 3.84 (ddd, J = 17.8, 9.9, 4.1 Hz, 3H), 3.78 (s, 3H), 3.76 (d, J = 10.1 Hz, 1H), 3.66 (td, J = 11.4, 3.0 Hz, 1H), 3.51 (dd, J = 11.4, 9.8 Hz, 1H), 3.22 (dd, J = 12.4, 3.8 Hz, 1H), 3.13 (dd, J = 12.3, 7.5 Hz, 1H), 2.64 (s, 3H), 2.27 (q, J = 7.8, 7.4 Hz, 1H), 2.18 (p, J = 9.2, 7.5 Hz, 2H), 1.81 (q, J = 7.8, 7.1 Hz, 2H), 0.87 (dtt, J = 10.5, 6.6, 3.0 Hz, 1H), 0.52 (dq, J = 8.6, 4.8, 3.6 Hz, 1H), 0.44 (tt, J = 8.9, 4.9 Hz, 1H), 0.12 (tt, J = 9.0, 5.1 Hz, 1H), -0.03 (d, J = 4.8 Hz, 1H), -0.32 (dq, J = 9.9, 5.1 Hz, 1H).

Example

[0252] JPEG2024543127000060.jpg41113 Compound O-2 (100 mg), 4-amino-1-methylpiperidine (26 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 20 (35 mg). ESI-MS: m / z = 569.45 [M+H] + .

[0253] 11H NMR (500 MHz, DMSO-d6) δ 12.35 (s, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.23 (d, J = 8.5 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 6.53 (dd, J = 8.8, 1.9 Hz, 1H), 5.35 (s, 1H), 4.32 - 4.26 (m, 1H), 4.22 (dd, J = 13.9, 3.8 Hz, 1H), 4.03 (td, J = 13.9, 13.1, 7.1 Hz, 2H), 3.73 (s, 3H), 3.24 (d, J = 9.9 Hz, 1H), 2.75 (d, J = 11.4 Hz, 2H), 2.54 (s, 3H), 2.26 - 2.21 (m, 1H), 2.17 (s, 3H), 2.12 (dq, J = 9.2, 4.3 Hz, 1H), 2.07 - 1.95 (m, 3H), 1.90 (t, J = 13.1 Hz, 2H), 1.81 (s, 1H), 1.72 (dd, J = 13.6, 6.4 Hz, 1H), 1.39 (dtd, J = 24.7, 11.5, 11.1, 5.6 Hz, 2H), 0.59 (dq, J = 8.5, 5.1, 3.5 Hz, 1H), 0.33 (td, J = 9.1, 5.0 Hz, 1H), -0.04 (dt, J = 9.4, 4.6 Hz, 1H), -0.13 (dp, J = 9.5, 4.6 Hz, 1H), -0.54 (dq, J = 9.6, 4.8 Hz, 1H).

Example

[0254] JPEG2024543127000061.jpg37107 Compound O-2 (60 mg), (S)-3-pyrrolidinol hydrochloride (17 mg), Pd2(dba)3 (25 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (75 mg) were added to t-amyl alcohol (10 mL), purged with nitrogen gas three times, and reacted at 85-95 °C for 3 h. The reaction was then completed. The temperature was lowered to room temperature, the palladium catalyst was removed by suction filtration, 30 mL of water was added to the filtrate, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 21 (25 mg). ESI-MS: m / z = 542.41 [M+H] + .

[0255] 11H NMR (500 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.35 (s, 1H), 7.91 (s, 1H), 7.55 (s, 1H), 7.34 (d, J = 8.6 Hz, 1H), 6.69 (d, J = 2.2 Hz, 1H), 6.47 (dd, J = 8.7, 2.2 Hz, 1H), 4.98 (s, 1H), 4.43 (dq, J = 7.0, 3.4 Hz, 1H), 4.29 (q, J = 8.2, 7.6 Hz, 1H), 4.22 (dd, J = 14.0, 3.7 Hz, 1H), 4.14 (dd, J = 13.8, 9.1 Hz, 1H), 4.04 (dt, J = 7.0, 4.6 Hz, 1H), 3.73 (s, 3H), 3.46 (dd, J = 10.0, 5.0 Hz, 1H), 3.12 (dd, J = 10.0, 2.5 Hz, 1H), 2.54 (s, 3H), 2.25 - 2.18 (m, 1H), 2.16 - 2.06 (m, 2H), 2.03 - 1.98 (m, 2H), 1.94 - 1.84 (m, 2H), 1.72 (dt, J = 13.6, 6.1 Hz, 1H), 1.50 - 1.42 (m, 1H), 0.63 (dd, J = 9.8, 5.3 Hz, 1H), 0.31 (tt, J = 9.3, 4.6 Hz, 1H), -0.05 (dt, J = 9.5, 4.7 Hz, 1H), -0.14 (tt, J = 9.1, 4.6 Hz, 1H), -0.56 (dd, J = 9.5, 5.0 Hz, 1H).

Example

[0256] JPEG2024543127000062.jpg34107 Compound O (70 mg), 4-aminomethyltetrahydropyran (23 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. 50 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (50 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 22 (35 mg). ESI-MS: m / z = 570.41 [M+H] + .

[0257] 1H NMR (500 MHz, DMSO-d6) δ 12.37 (s, 1H), 8.34 (s, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.23 (d, J = 8.6 Hz, 1H), 6.71 (d, J = 2.3 Hz, 1H), 6.55 (dd, J = 8.6, 2.0 Hz, 1H), 4.28 (q, J = 7.7 Hz, 1H), 4.22 (dd, J = 14.0, 3.6 Hz, 1H), 4.10 - 4.01 (m, 2H), 3.89 - 3.83 (m, 2H), 3.73 (s, 3H), 3.25 (td, J = 9.3, 4.6 Hz, 2H), 2.96 (qd, J = 12.7, 6.7 Hz, 2H), 2.54 (s, 3H), 2.21 (q, J = 7.7, 6.4 Hz, 1H), 2.13 (dq, J = 14.2, 7.7, 6.2 Hz, 1H), 2.05 - 1.97 (m, 1H), 1.87 - 1.77 (m, 2H), 1.75 - 1.66 (m, 3H), 1.29 - 1.20 (m, 2H), 0.61 (tq, J = 8.4, 4.4, 3.4 Hz, 1H), 0.32 (dp, J = 9.4, 4.7 Hz, 1H), -0.04 (dt, J = 9.7, 4.8 Hz, 1H), -0.13 (tt, J = 9.3, 4.7 Hz, 1H), -0.57 (dq, J = 9.6, 4.8 Hz, 1H).

Example

[0258]

Example

[0259] JPEG2024543127000063.jpg33113

[0260] (1) Method for producing compound (3-Fluorum Fructus) Fructus 1,3-Dibromopropane (90 mmol), triphenylphosphine (25 g), and toluene (260 mL) were added to the reaction flask in this order and reacted at 110 °C for 4 h. The reaction mixture was then suction filtered, and the filter cake was rinsed with 40 mL of cyclohexane to obtain the compound (3-bromopropyl)triphenylphosphine. This was used directly in the next step without further purification. ESI-MS: m / z = 383.01 [M] + .

[0261] (2) Method for producing compound R Compound (3-bromopropyl)triphenylphosphine (5 g), methanol (26 mL), and dimethylamine (40 mmol) were added to the reaction flask in this order, stirred at room temperature for 1 h, then heated to 65 °C and reacted for 4 h. The reaction mixture was concentrated until no liquid flowed out, yielding compound R (4.0 g). This was used directly in the next step without further purification. ESI-MS: m / z = 348.40 [M] + .

[0262] (3) Method for producing compound S Compound O-2 (165 mg), N-formylsaccharin (131 mg), palladium acetate (7 mg), 1,4-bis(diphenylphosphino)butane (20 mg), triethylsilane (58 mg), and sodium carbonate (66 mg) were added to N,N-dimethylformamide (5 mL). The mixture was purged with nitrogen three times and reacted at 80 °C for 4 h. The reaction mixture was poured into 20 mL of water and extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound S, which was used directly in the next step without further purification. ESI-MS: m / z = 485.33 [M+H] + .

[0263] (4) Manufacturing Method of Examples 23 / 24 Compound R (323 mg) was added to tetrahydrofuran (5 mL), purged with nitrogen gas three times, cooled to -78 ° C, n-butyllithium (0.5 mL) was added, and the mixture was stirred at -78 ° C for 3 h. A solution of compound S obtained in the previous step in tetrahydrofuran (5 mL) was added to the reaction mixture, and the temperature was gradually raised to 60 ° C. The reaction was continued for 3 h, completing the reaction. The mixture was cooled to room temperature, poured into 20 mL of ice water, and the tetrahydrofuran was removed by evaporation under reduced pressure. The mixture was extracted with dichloromethane (50 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed out, and purified by preparative liquid chromatography to obtain Example 23 (15 mg). ESI-MS: m / z = 554.46 [M+H] + and Example 24 (20 mg), ESI-MS: m / z = 554.46 [M+H] + Example 23: 11H NMR (500 MHz, DMSO-d6) δ 8.41 (s, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.60 (dd, J = 9.1, 1.3 Hz, 2H), 7.56 (d, J = 8.2 Hz, 1H), 7.21 (dd, J = 8.3, 1.4 Hz, 1H), 6.61 (dd, J = 11.7, 2.1 Hz, 1H), 5.72 (dt, J = 11.6, 6.6 Hz, 1H), 4.38 - 4.32 (m, 2H), 4.26 - 4.22 (m, 1H), 4.10 (d, J = 5.6 Hz, 1H), 3.78 (s, 3H), 2.60 (s, 3H), 2.52 - 2.45 (m, 2H), 2.22 (s, 6H), 2.05 (ddt, J = 14.1, 10.8, 5.0 Hz, 2H), 1.90 (s, 1H), 1.81 - 1.72 (m, 1H), 1.34 - 1.25 (m, 3H), 0.68 (dd, J = 11.7, 7.1 Hz, 1H), 0.34 (dq, J = 8.9, 4.7 Hz, 1H), 0.00 (dq, J = 9.7, 5.0 Hz, 1H), -0.19 (tt, J = 9.1, 4.7 Hz, 1H), -0.63 (dq, J = 9.7, 4.8 Hz, 1H). Example 24: 11H NMR (500 MHz, DMSO-d6) δ 8.43 (s, 1H), 8.34 (s, 1H), 7.99 (s, 1H), 7.77 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 1.2 Hz, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.32 (dd, J = 8.4, 1.5 Hz, 1H), 6.60 (d, J = 15.8 Hz, 1H), 6.39 (dt, J = 15.8, 6.8 Hz, 1H), 4.39 - 4.33 (m, 2H), 4.29 - 4.26 (m, 1H), 4.14 - 4.10 (m, 1H), 3.80 (s, 3H), 3.45 (t, J = 6.5 Hz, 2H), 2.62 (s, 3H), 2.55 (d, J = 7.3 Hz, 1H), 2.46 (t, J = 7.5 Hz, 2H), 2.32 (s, 6H), 2.08 (dt, J = 13.0, 4.6 Hz, 1H), 1.96 (d, J = 9.5 Hz, 1H), 1.83 - 1.75 (m, 1H), 1.64 - 1.54 (m, 1H), 0.71 (dq, J = 9.8, 5.3, 4.2 Hz, 1H), 0.37 (dq, J = 9.4, 5.0 Hz, 1H), 0.01 (dt, J = 9.7, 5.0 Hz, 1H), -0.18 (dq, J = 9.0, 4.7 Hz, 1H), -0.59 (dq, J = 9.5, 4.8 Hz, 1H).

Example

[0264]

Example

[0265] JPEG2024543127000064.jpg24114 Compound O (100 mg), N,N-dimethyl-1,4-cyclohexanediamine (30 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), the atmosphere was purged with nitrogen gas three times, and the reaction was completed at 100°C for 2 hours. The reaction mixture was added with 1M aqueous sodium bicarbonate (20 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The product was purified by preparative chromatography (liquid phase conditions: column: YMC-TA-C18 250 x 50 mm, 10 μm; mobile phase: A: 0.1% formic acid / water, C: acetonitrile, gradient: 20% C to 50% C (0-60 min); flow rate: 60 mL / min; wavelength: 254 nm) to obtain Example 25 (13 mg, retention time: 14.2 min). ESI-MS: m / z = 597.44 [M+H] + , and Example 26 (19 mg, retention time: 19.6 min), ESI-MS: m / z = 597.44 [M+H] + Example 25: 1H NMR (500 MHz, クロロホルム-d) δ 12.15 (s, 1H), 8.51 (s, 1H), 8.41 (s, 1H), 8.15 (s, 1H), 7.70 (s, 1H), 7.15 (d, J = 8.5 Hz, 1H), 6.54 (d, J = 7.8 Hz, 2H), 4.40 - 4.32 (m, 2H), 3.95 (p, J = 5.9 Hz, 2H), 3.79 (s, 3H), 3.16 (d, J = 12.0 Hz, 1H), 2.92 (d, J = 12.4 Hz, 1H), 2.62 (d, J = 5.1 Hz, 3H), 2.60 (s, 6H), 2.27 (d, J = 12.3 Hz, 3H), 2.17 - 2.09 (m, 3H), 1.83 - 1.74 (m, 2H), 1.48 (t, J = 10.5 Hz, 2H), 1.26 (t, J = 6.0 Hz, 2H), 0.87 (dt, J = 14.0, 7.0 Hz, 1H), 0.57 - 0.48 (m, 1H), 0.45 (dq, J = 10.0, 5.1 Hz, 1H), 0.12 (dd, J = 10.2, 5.3 Hz, 1H), -0.02 (s, 1H), -0.31 (dq, J = 10.2, 5.0 Hz, 1H). Example 26: 1H NMR (500 MHz, クロロホルム-d) δ 11.98 (s, 1H), 8.53 (s, 1H), 8.39 (s, 1H), 8.15 (s, 1H), 7.67 (s, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.72 (dd, J = 8.7, 2.1 Hz, 1H), 6.60 (d, J = 2.1 Hz, 1H), 4.39 - 4.32 (m, 2H), 3.94 (dq, J = 13.9, 7.4, 6.2 Hz, 2H), 3.78 (s, 3H), 3.69 - 3.64 (m, 1H), 2.83 (d, J = 11.1 Hz, 1H), 2.69 (s, 6H), 2.64 (s, 3H), 2.31 - 2.25 (m, 1H), 2.22 - 2.15 (m, 2H), 2.12 - 2.06 (m, 2H), 1.97 (d, J = 21.7 Hz, 4H), 1.82 - 1.73 (m, 2H), 1.68 - 1.60 (m, 2H), 0.52 (d, J = 12.0 Hz, 1H), 0.44 (dq, J = 8.9, 4.5, 4.1 Hz, 1H), 0.17 - 0.09 (m, 1H), -0.04 (q, J = 4.8 Hz, 1H), -0.31 (dd, J = 9.8, 5.3 Hz, 1H).

Example

[0266] Compound O-2 (60 mg), 3-dimethylaminopropylamine (14 mg), Pd2(dba)3 (25 mg), 2-(di-t-butylphosphine)biphenyl (17 mg), and potassium t-butoxide (75 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. The reaction was then completed. 1M aqueous sodium bicarbonate solution (10 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 27 (20 mg). ESI-MS: m / z = 279.36 [1 / 2M+H] + .

[0267] 11H NMR (500 MHz, DMSO-d6) δ 12.37 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.25 (d, J = 8.6 Hz, 1H), 6.70 (d, J = 2.0 Hz, 1H), 6.53 (dd, J = 8.6, 2.0 Hz, 1H), 4.29 (td, J = 8.4, 5.8 Hz, 1H), 4.22 (dd, J = 14.0, 3.6 Hz, 1H), 4.08 - 4.00 (m, 2H), 3.73 (s, 3H), 3.07 (t, J = 6.9 Hz, 2H), 2.54 (d, J = 1.2 Hz, 4H), 2.33 (t, J = 7.1 Hz, 2H), 2.22 (dt, J = 12.4, 6.9 Hz, 1H), 2.15 (s, 6H), 2.00 (td, J = 7.8, 4.6 Hz, 1H), 1.84 (d, J = 9.3 Hz, 1H), 1.71 (h, J = 6.7 Hz, 3H), 0.60 (td, J = 8.2, 3.5 Hz, 1H), 0.32 (tt, J = 9.3, 4.6 Hz, 1H), -0.05 (dt, J = 9.4, 4.6 Hz, 1H), -0.12 (tt, J = 7.6, 4.4 Hz, 1H), -0.57 (dq, J = 9.5, 4.7 Hz, 1H).

Example

[0268] Compound O-2 (60 mg), N,N-dimethylethylenediamine (12 mg), Pd2(dba)3 (25 mg), 2-(di-t-butylphosphine)biphenyl (17 mg), and potassium t-butoxide (75 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. The reaction was then completed. 1M aqueous sodium bicarbonate solution (10 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 28 (25 mg). ESI-MS: m / z = 272.30 [1 / 2M+H] + .

[0269] 11H NMR (500 MHz, DMSO-d6) δ 12.43 (s, 1H), 8.38 (s, 1H), 7.95 (s, 1H), 7.59 (s, 1H), 7.30 (d, J = 8.5 Hz, 1H), 6.81 (d, J = 2.1 Hz, 1H), 6.61 (dd, J = 8.5, 2.0 Hz, 1H), 5.41 (s, 1H), 4.33 (q, J = 8.1 Hz, 1H), 4.27 (dd, J = 14.1, 3.7 Hz, 1H), 4.09 (td, J = 9.5, 4.5 Hz, 2H), 3.77 (s, 3H), 3.20 (t, J = 5.3 Hz, 2H), 2.59 (s, 3H), 2.53 (t, J = 6.9 Hz, 2H), 2.28 (s, 1H), 2.25 (s, 6H), 2.18 (td, J = 9.6, 4.9 Hz, 1H), 2.05 (tt, J = 13.9, 10.5, 5.0 Hz, 1H), 1.89 (d, J = 9.5 Hz, 1H), 1.76 (tt, J = 13.2, 5.6 Hz, 1H), 0.65 (qd, J = 8.4, 4.2 Hz, 1H), 0.37 (dp, J = 9.2, 4.7 Hz, 1H), 0.00 (dq, J = 9.6, 5.0 Hz, 1H), -0.07 (dp, J = 9.4, 4.7 Hz, 1H), -0.51 (dt, J = 9.6, 4.9 Hz, 1H).

Example

[0270] JPEG2024543127000067.jpg34103 Compound O (100 mg), 3-methyloxetan-3-amine (20 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 29 (20 mg). ESI-MS: m / z = 542.37 [M+H] + .

[0271] 11H NMR (500 MHz, DMSO-d6) δ 12.38 (s, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.29 (d, J = 8.5 Hz, 1H), 6.40 (dd, J = 8.6, 2.1 Hz, 1H), 6.33 (d, J = 2.1 Hz, 1H), 6.11 (s, 1H), 4.63 (dd, J = 15.9, 5.8 Hz, 2H), 4.52 (d, J = 5.8 Hz, 2H), 4.33 - 4.25 (m, 1H), 4.22 (dd, J = 14.0, 3.4 Hz, 1H), 4.07 - 3.97 (m, 2H), 3.72 (s, 3H), 2.54 (s, 3H), 2.22 (dd, J = 13.6, 6.9 Hz, 1H), 2.12 (td, J = 11.3, 10.2, 5.5 Hz, 1H), 2.05 - 1.95 (m, 1H), 1.81 - 1.69 (m, 2H), 1.58 (s, 3H), 0.57 (tt, J = 8.7, 3.6 Hz, 1H), 0.33 (dp, J = 9.3, 4.7 Hz, 1H), -0.05 (dt, J = 9.7, 4.8 Hz, 1H), -0.13 (dp, J = 9.5, 4.7 Hz, 1H), -0.60 (dq, J = 9.7, 4.8 Hz, 1H).

Example

[0272] JPEG2024543127000068.jpg33103 Compound O (50 mg), 2,2-dimethyloxetan-3-amine (19 mg), Pd2(dba)3 (21 mg), 2-(di-t-butylphosphine)biphenyl (14 mg), and potassium t-butoxide (63 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. The reaction was then completed. 30 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 30 (10 mg). ESI-MS: m / z = 556.37 [M+H] + .

[0273] 11H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 6.79 - 6.72 (m, 2H), 5.70 (d, J = 9.2 Hz, 1H), 4.44 (td, J = 5.9, 4.1 Hz, 2H), 4.29 (td, J = 8.7, 6.1 Hz, 1H), 4.23 (dd, J = 14.0, 3.5 Hz, 1H), 4.04 (t, J = 8.3 Hz, 2H), 3.97 (dd, J = 13.9, 9.6 Hz, 1H), 3.73 (s, 3H), 2.54 (s, 3H), 2.29 - 2.19 (m, 1H), 2.17 - 2.09 (m, 1H), 2.00 - 1.95 (m, 1H), 1.84 (t, J = 8.5 Hz, 1H), 1.77 - 1.67 (m, 1H), 1.46 (s, 3H), 1.44 (s, 3H), 0.55 (tt, J = 8.3, 3.1 Hz, 1H), 0.33 (dq, J = 9.5, 4.7 Hz, 1H), -0.04 (dt, J = 9.9, 4.9 Hz, 1H), -0.19 (dp, J = 9.7, 4.8 Hz, 1H), -0.62 (dq, J = 9.7, 4.9 Hz, 1H).

Example

[0274] JPEG2024543127000069.jpg34103 Compound O (70 mg), 2,2,4,4-tetramethyloxetan-3-amine hydrochloride (43 mg), Pd2(dba)3 (24 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 31 (10 mg). ESI-MS: m / z = 584.34 [M+H] + .

[0275] 11H NMR (500 MHz, DMSO-d6) δ 12.42 (s, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 6.78 - 6.70 (m, 2H), 5.76 (d, J = 9.2 Hz, 1H), 4.29 (td, J = 8.7, 6.1 Hz, 1H), 4.23 (dd, J = 14.0, 3.5 Hz, 1H), 4.04 (t, J = 8.3 Hz, 2H), 3.97 (dd, J = 13.9, 9.6 Hz, 1H), 3.73 (s, 3H), 2.54 (s, 3H), 2.29 - 2.19 (m, 1H), 2.17 - 2.09 (m, 1H), 2.00 - 1.95 (m, 1H), 1.84 (t, J = 8.5 Hz, 1H), 1.77 - 1.67 (m, 1H), 1.46 (s, 3H), 1.44 (s, 3H), 1.30 (s, 3H), 1.19 (s, 3H), 0.55 (tt, J = 8.3, 3.1 Hz, 1H), 0.33 (dq, J = 9.5, 4.7 Hz, 1H), -0.04 (dt, J = 9.9, 4.9 Hz, 1H), -0.19 (dp, J = 9.7, 4.8 Hz, 1H), -0.62 (dq, J = 9.7, 4.9 Hz, 1H).

Example

[0276] Compound O (70 mg), 1-tert-butoxycarbonyl-3-aminocyclobutylamine (45 mg), Pd2(dba)3 (24 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL). The mixture was purged with nitrogen three times and incubated at 100 °C for 2 h. The reaction was completed. 1 M aqueous sodium bicarbonate (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed. The crude product obtained by concentrating the filtrate was directly dissolved in 4 M hydrogen chloride-methanol solution (5 mL) and stirred for 30 min. The reaction was monitored by LC-MS and was complete. The reaction mixture was concentrated and then purified by preparative liquid chromatography to give Example 32 (16 mg). ESI-MS: m / z = 527.37 [M+H] + .

[0277] 11H NMR (500 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.30 (d, J = 8.5 Hz, 1H), 6.68 - 6.62 (m, 1H), 6.51 (dd, J = 8.5, 2.0 Hz, 1H), 6.43 (s, 1H), 4.35 (s, 1H), 4.29 (t, J = 4.3 Hz, 1H), 4.19 (dd, J = 14.6, 5.6 Hz, 2H), 4.10 - 4.01 (m, 2H), 3.73 (s, 3H), 3.67 (td, J = 9.8, 4.8 Hz, 2H), 2.54 (s, 3H), 2.26 - 2.18 (m, 1H), 2.13 (dq, J = 13.1, 7.2, 6.1 Hz, 1H), 1.99 (tt, J = 12.4, 5.5 Hz, 2H), 1.82 (d, J = 9.6 Hz, 1H), 1.71 (q, J = 9.0, 6.1 Hz, 1H), 0.60 (dt, J = 9.6, 4.6 Hz, 1H), 0.31 (dt, J = 9.2, 4.5 Hz, 1H), -0.05 (dq, J = 9.9, 5.0 Hz, 1H), -0.18 (tt, J = 9.4, 4.7 Hz, 1H), -0.62 (dq, J = 9.5, 4.8 Hz, 1H).

Example

[0278] JPEG2024543127000071.jpg33104 Compound O (50 mg), 1-methylazetidin-3-amine (30 mg), Pd2(dba)3 (21 mg), 2-(di-t-butylphosphine)biphenyl (14 mg), and potassium t-butoxide (63 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 33 (10 mg). ESI-MS: m / z = 541.41 [M+H] + .

[0279] 1 H NMR (500 MHz, chloroform-d) δ 12.30 (s, 1H), 8.49 (s, 1H), 8.45 (s, 1H), 8.17 (s, 1H), 7.80 (s, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.65 (dd, J = 8.7, 2.0 Hz, 1H), 6.30 (d, J = 2.1 Hz, 1H), 4.40 - 4.32 (m, 2H), 4.06 - 4.00 (m, 1H), 3.95 - 3.90 (m, 2H), 3.81 (s, 1H), 3.79 (s, 3H), 3.67 (t, J = 8.7 Hz, 1H), 2.66 (s, 3H), 2.64 (s, 3H), 2.28 - 2.10 (m, 3H), 1.78 (d, J = 14.6 Hz, 2H), 1.28 (dd, J = 18.1, 8.7 Hz, 2H), 0.49 (td, J = 9.0, 8.5, 4.1 Hz, 1H), 0.41 (dq, J = 8.7, 4.5, 4.0 Hz, 1H), 0.10 - 0.03 (m, 1H), -0.06 (dt, J = 9.7, 5.2 Hz, 1H), -0.40 (dq, J = 10.0, 5.1 Hz, 1H). [Example]

[0280] JPEG2024543127000072.jpg33102 Compound O (70 mg), 1-Boc-3-amino-3-methylacridine (31 mg), Pd2(dba)3 (24 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL). The mixture was purged with nitrogen three times and reacted at 100 °C for 2 h to complete the reaction. 1 M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed. The filtrate was concentrated and the resulting crude product was directly dissolved in a 4 M hydrogen chloride-methanol solution (5 mL) and stirred for 30 min. LC-MS monitoring confirmed the reaction was complete. The reaction mixture was concentrated and purified by preparative liquid chromatography to yield Example 34 (6 mg). ESI-MS: m / z = 541.21 [M+H] + .

[0281] 1H NMR (500 MHz, DMSO-d6) δ 8.34 (s, 1H), 8.29 (s, 2H), 7.91 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.50 - 6.43 (m, 2H), 6.19 (s, 1H), 4.32 - 4.27 (m, 1H), 4.22 (dd, J = 14.0, 3.6 Hz, 1H), 4.16 - 4.11 (m, 1H), 4.06 (s, 1H), 3.92 (s, 2H), 3.73 (s, 3H), 2.64 (s, 3H), 2.28 - 2.19 (m, 1H), 2.17 - 2.10 (m, 1H), 2.02 - 1.97 (m, 1H), 1.81 (s, 1H), 1.73 (t, J = 10.7 Hz, 1H), 1.57 (s, 3H), 1.24 (t, J = 4.6 Hz, 2H), 0.65 - 0.57 (m, 1H), 0.32 (dt, J = 10.4, 5.3 Hz, 1H), -0.02 - -0.08 (m, 1H), -0.19 (d, J = 9.4 Hz, 1H), -0.65 (dd, J = 9.6, 5.0 Hz, 1H). [Example]

[0282] JPEG2024543127000073.jpg31104 Compound O (60 mg), (1-methylpyrrolidin-3-yl)methylamine (14 mg), Pd2(dba)3 (26 mg), 2-(di-t-butylphosphine)biphenyl (17 mg), and potassium t-butoxide (75 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 35 (20 mg). ESI-MS: m / z = 278.66 [1 / 2M+H] + .

[0283] 1 1H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.34 (s, 1H), 8.24 (d, J = 2.3 Hz, 1H), 7.91 (d, J = 2.3 Hz, 1H), 7.54 (s, 1H), 7.25 (d, J = 8.5 Hz, 1H), 6.74 (s, 1H), 6.54 (d, J = 8.5 Hz, 1H), 4.30 (t, J = 7.9 Hz, 1H), 4.21 (dd, J = 14.2, 3.7 Hz, 1H), 4.05 (dt, J = 9.5, 6.0 Hz, 2H), 3.73 (s, 3H), 3.53 (t, J = 7.8 Hz, 2H), 3.28 - 3.21 (m, 4H), 2.78 - 2.70 (m, 1H), 2.54 (s, 3H), 2.39 (s, 3H), 2.22 (s, 1H), 2.14 (s, 1H), 2.00 (d, J = 9.9 Hz, 1H), 1.86 (s, 1H), 1.70 (d, J = 14.3 Hz, 1H), 0.61 (q, J = 7.2, 5.4 Hz, 1H), 0.32 (dq, J = 9.3, 4.8 Hz, 1H), -0.05 (dd, J = 9.7, 4.9 Hz, 1H), -0.14 (dq, J = 9.2, 4.8 Hz, 1H), -0.59 (dd, J = 9.8, 5.2 Hz, 1H).

Example

[0284] JPEG2024543127000074.jpg32102 Compound O (70 mg), 3-aminomethyloxetane (14 mg), Pd2(dba)3 (24 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1 M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 36 (32 mg). ESI-MS: m / z = 542.35 [M+H] + .

[0285] 11H NMR (500 MHz, DMSO-d6) δ 12.39 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.25 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 2.1 Hz, 1H), 6.53 (dd, J = 8.6, 2.0 Hz, 1H), 4.68 (ddd, J = 7.5, 5.9, 1.6 Hz, 2H), 4.34 (td, J = 5.9, 2.2 Hz, 2H), 4.29 (dt, J = 8.4, 4.2 Hz, 1H), 4.22 (dd, J = 14.0, 3.6 Hz, 1H), 4.10 - 4.01 (m, 2H), 3.73 (s, 3H), 3.36 (d, J = 7.4 Hz, 2H), 3.24 - 3.19 (m, 1H), 2.54 (s, 3H), 2.21 (dd, J = 13.0, 6.9 Hz, 1H), 2.14 (dq, J = 9.7, 4.9, 4.3 Hz, 1H), 2.04 - 1.97 (m, 1H), 1.85 (d, J = 10.8 Hz, 1H), 1.76 - 1.67 (m, 1H), 0.67 - 0.58 (m, 1H), 0.32 (dp, J = 9.2, 4.5 Hz, 1H), -0.05 (dq, J = 9.5, 4.9 Hz, 1H), -0.14 (tt, J = 9.3, 4.7 Hz, 1H), -0.59 (dq, J = 9.7, 5.0 Hz, 1H).

Example

[0286] JPEG2024543127000075.jpg34104 Compound O (70 mg), 1-(oxetan-3-yl)ethan-1-amine (16 mg), Pd2(dba)3 (24 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 37 (10 mg). ESI-MS: m / z = 556.39 [M+H] + .

[0287] 1H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.36 (s, 1H), 7.93 (s, 1H), 7.57 (s, 1H), 7.26 (d, J = 8.5 Hz, 1H), 6.86 (d, J = 12.8 Hz, 1H), 6.58 (d, J = 8.3 Hz, 1H), 5.36 (dd, J = 23.0, 8.6 Hz, 1H), 4.65 (ddt, J = 18.1, 14.3, 7.2 Hz, 2H), 4.40 (p, J = 6.0 Hz, 2H), 4.36 - 4.28 (m, 1H), 4.24 (d, J = 13.7 Hz, 1H), 4.15 - 4.03 (m, 2H), 3.89 (q, J = 7.4, 6.6 Hz, 1H), 3.75 (s, 3H), 3.07 (p, J = 7.8 Hz, 1H), 2.56 (s, 3H), 2.24 (s, 1H), 2.16 (s, 1H), 2.05 - 1.99 (m, 1H), 1.86 (s, 1H), 1.79 - 1.69 (m, 1H), 1.05 (dd, J = 22.8, 6.2 Hz, 3H), 0.67 - 0.58 (m, 1H), 0.35 (dp, J = 9.2, 4.5 Hz, 1H), -0.05 (dq, J = 9.5, 4.9 Hz, 1H), -0.14 (tt, J = 9.3, 4.7 Hz, 1H), -0.59 (dq, J = 9.7, 5.0 Hz, 1H).

Example

[0288]

Example

[0289] Example 37 (80 mg) was separated by preparative chromatography (separation conditions: column: YMC-SB 250 mm x 30 mm, 10 μm; mobile phase: A: n-hexane, B: ethanol, gradient: 20% C to 70% B (0 to 80 min); flow rate: 20 mL / min; wavelength: 254 nm) to obtain Example 38 (27 mg, retention time: 31.0 min). ESI-MS: m / z = 556.39 [M+H] + and Example 39 (30 mg, retention time: 43.5 min). ESI-MS: m / z = 556.39 [M+H] + Example 38: 11H NMR (500 MHz, DMSO-d6) δ 12.38 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.55 (d, J = 1.2 Hz, 1H), 7.33 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 2.1 Hz, 1H), 6.62 (dd, J = 8.8, 2.2 Hz, 1H), 5.38 (d, J = 8.8 Hz, 1H), 4.62 (ddd, J = 10.9, 7.9, 6.1 Hz, 2H), 4.38 (td, J = 6.2, 4.5 Hz, 2H), 4.29 (q, J = 7.7 Hz, 1H), 4.22 (dd, J = 13.9, 3.5 Hz, 1H), 4.07 - 3.98 (m, 2H), 3.73 (s, 3H), 3.70 (dt, J = 8.9, 6.2 Hz, 1H), 3.05 (dtd, J = 14.4, 8.1, 6.3 Hz, 1H), 2.54 (s, 3H), 2.21 (p, J = 6.7, 6.3 Hz, 1H), 2.13 (dq, J = 13.8, 8.3, 6.7 Hz, 1H), 2.02 - 1.95 (m, 1H), 1.85 - 1.77 (m, 1H), 1.69 (h, J = 7.2 Hz, 1H), 1.04 (d, J = 6.2 Hz, 3H), 0.63 - 0.55 (m, 1H), 0.31 (dq, J = 9.3, 5.1 Hz, 1H), -0.06 (dq, J = 9.5, 4.8 Hz, 1H), -0.15 (dp, J = 9.4, 4.6 Hz, 1H), -0.58 (dq, J = 9.7, 4.9 Hz, 1H). Example 39: 11H NMR (500 MHz, DMSO-d6) δ 12.38 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.55 (s, 1H), 7.33 (d, J = 8.6 Hz, 1H), 6.89 - 6.73 (m, 1H), 6.62 (d, J = 8.7 Hz, 1H), 5.37 (d, J = 8.8 Hz, 1H), 4.63 (dt, J = 10.9, 6.9 Hz, 2H), 4.38 (td, J = 6.2, 3.7 Hz, 2H), 4.29 (q, J = 7.8 Hz, 1H), 4.22 (dd, J = 14.1, 3.5 Hz, 1H), 4.02 (td, J = 13.7, 12.1, 7.2 Hz, 2H), 3.73 (s, 3H), 3.69 (d, J = 7.5 Hz, 1H), 3.05 (q, J = 7.5 Hz, 1H), 2.54 (s, 3H), 2.26 - 2.17 (m, 1H), 2.13 (s, 1H), 2.03 - 1.94 (m, 1H), 1.81 (s, 1H), 1.69 (d, J = 14.8 Hz, 1H), 1.04 (d, J = 6.2 Hz, 3H), 0.59 (d, J = 9.7 Hz, 1H), 0.30 (tt, J = 9.3, 4.7 Hz, 1H), -0.06 (dq, J = 9.6, 4.9 Hz, 1H), -0.14 (dq, J = 13.3, 7.9, 6.2 Hz, 1H), -0.59 (dd, J = 9.8, 5.1 Hz, 1H).

Example

[0290] Compound O (70 mg), 3-methyl-3-aminemethyl-1-oxetane (16 mg), Pd2(dba)3 (24 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. The reaction was then completed. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 40 (41 mg). ESI-MS: m / z = 556.40 [M+H] + .

[0291] 11H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.35 (s, 1H), 7.92 (s, 1H), 7.55 (s, 1H), 7.25 (d, J = 8.5 Hz, 1H), 6.80 (d, J = 2.1 Hz, 1H), 6.62 (dd, J = 8.5, 2.0 Hz, 1H), 5.67 (s, 1H), 4.44 (d, J = 5.5 Hz, 2H), 4.31 - 4.19 (m, 4H), 4.06 (dd, J = 14.2, 9.1 Hz, 2H), 3.73 (s, 3H), 3.27 (d, J = 3.3 Hz, 2H), 2.55 (s, 3H), 2.22 (dt, J = 12.9, 6.8 Hz, 1H), 2.13 (tt, J = 8.8, 4.7 Hz, 1H), 1.99 (ddt, J = 14.2, 9.5, 5.0 Hz, 1H), 1.85 (p, J = 9.3 Hz, 1H), 1.72 (dd, J = 11.8, 6.6 Hz, 1H), 1.35 (s, 3H), 0.60 (tt, J = 8.5, 3.6 Hz, 1H), 0.31 (dp, J = 9.3, 4.6 Hz, 1H), -0.06 (dq, J = 9.7, 4.9 Hz, 1H), -0.15 (dq, J = 9.1, 4.6 Hz, 1H), -0.60 (dq, J = 9.7, 4.8 Hz, 1H).

Example

[0292] JPEG2024543127000078.jpg32104 Compound O (70 mg), 3-methylaminooxetane (14 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 41 (30 mg). ESI-MS: m / z = 542.42 [M+H] + .

[0293] 1 H NMR (500 MHz, DMSO-d6) δ 12.49 (s, 1H), 8.34 (s, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.37 (d, J = 8.7 Hz, 1H), 6.89 (s, 1H), 6.67 (d, J = 8.7 Hz, 1H), 4.79 (q, J = 6.2, 5.6 Hz, 2H), 4.57 (h, J = 5.7 Hz, 2H), 4.48 (t, J = 5.8 Hz, 1H), 4.30 (q, J = 7.9 Hz, 1H), 4.19 (qd, J = 14.1, 6.4Hz, 2H), 4.02 (q, J = 7.3, 6.8 Hz, 1H), 3.73 (s, 3H), 2.83 (s, 3H), 2.54 (s, 3H), 2.18 (d, J = 33.7 Hz, 2H), 2.04 - 1.96 (m, 1H), 1.83 (s, 1H), 1.70 (d, J = 13.3 Hz, 1H), 0.70 - 0.59 (m, 1H), 0.29 (tt, J = 9.2, 4.6 Hz, 1H), -0.08 (dq, J = 9.7, 4.8 Hz, 1H), -0.25 (tt, J = 9.7, 4.7 Hz, 1H), -0.70 (dd, J = 9.4, 5.0 Hz, 1H). [Example]

[0294] JPEG2024543127000079.jpg34105 Compound O (70 mg), N,N-dimethylethylenediamine (23 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 42 (15 mg). ESI-MS: m / z = 543.42 [M+H] + .

[0295] 1 H NMR (500 MHz, chloroform-d) δ 8.41 (s, 1H), 8.15 (s, 1H), 7.72 (s, 1H), 7.13 (d, J = 8.7 Hz, 1H), 6.61 (dd, J = 8.6, 2.1 Hz, 1H), 6.49 (d, J = 2.1 Hz, 1H), 4.35 (dt, J = 10.1, 3.1 Hz, 2H), 3.97 - 3.88 (m, 2H), 3.79 (s, 3H), 3.11 (q, J = 6.4 Hz, 2H), 2.78 (t, J = 5.7 Hz, 2H), 2.63 (s, 3H), 2.42 (s, 6H), 2.30 - 2.23 (m, 1H), 2.20 - 2.11 (m, 2H), 1.83 - 1.74 (m, 2H), 0.50 (tq, J = 8.4, 5.0, 4.2 Hz, 1H), 0.42 (dq, J = 8.8, 4.5 Hz, 1H), 0.09 (tt, J = 9.1, 5.2 Hz, 1H), -0.05 (dt, J = 9.8, 4.8 Hz, 1H), -0.34 (dq, J = 10.0, 5.1 Hz, 1H). [Example]

[0296] JPEG2024543127000080.jpg31100 Compound O (100 mg), (R)-tetrahydrofuran-3-amine hydrochloride (28 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, extracted with ethyl acetate (10 mL × 3), and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Purification by preparative liquid chromatography yielded Example 43 (33 mg). ESI-MS: m / z = 542.39 [M+H] + .

[0297] 1 H NMR (500 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.39 (s, 1H), 7.96 (s, 1H), 7.59 (s, 1H), 7.31 (d, J = 8.5 Hz, 1H), 6.78 (s, 1H), 6.60 (d, J = 8.6 Hz, 1H), 5.89 (d, J = 6.7 Hz, 1H), 4.30 (dd, J = 31.8, 11.0 Hz, 2H), 4.10 (d, J = 9.4 Hz, 2H), 4.01 (t, J = 7.4 Hz, 1H), 3.87 (q, J = 7.7 Hz, 1H), 3.78 (s, 3H), 3.59 (dd, J = 8.9, 3.9 Hz, 1H), 3.47 - 3.28 (m, 2H), 2.59 (s, 3H), 2.33 - 2.11 (m, 3H), 2.10 - 2.00 (m, 1H), 1.92 - 1.71 (m, 3H), 0.72 - 0.62 (m, 1H), 0.36 (dd, J = 11.3, 6.1 Hz, 1H), -0.00 (dt, J = 9.7, 5.0 Hz, 1H), -0.05 - -0.16 (m, 1H), -0.49 - -0.60 (m, 1H). [Example]

[0298] JPEG2024543127000081.jpg33106 Compound O (100 mg), N,N-dimethyl-1,3-diaminopropane (23 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 44 (20 mg). ESI-MS: m / z = 557.44 [M+H] + .

[0299] 1H NMR (500 MHz, クロロホルム-d) δ 8.47 (s, 1H), 8.41 (s, 1H), 8.15 (s, 1H), 7.72 (s, 1H), 7.13 (d, J = 8.6 Hz, 1H), 6.62 (dd, J = 8.7, 2.1 Hz, 1H), 6.48 (d, J = 2.1 Hz, 1H), 4.38 - 4.33 (m, 2H), 3.97 - 3.94 (m, 1H), 3.93 - 3.89 (m, 1H), 3.79 (s, 3H), 3.10 (dq, J = 13.4, 6.4 Hz, 2H), 3.02 - 2.95 (m, 2H), 2.65 (s, 6H), 2.64 (s, 3H), 2.31 - 2.25 (m, 1H), 2.17 (ddd, J = 23.0, 11.6, 5.1 Hz, 2H), 2.00 (q, J = 7.0 Hz, 2H), 1.78 (t, J = 8.9 Hz, 2H), 0.51 (td, J = 9.1, 4.6 Hz, 1H), 0.42 (tt, J = 9.1, 5.0 Hz, 1H), 0.08 (tt, J = 8.6, 5.0 Hz, 1H), -0.04 (dt, J = 9.6, 5.1 Hz, 1H), -0.35 (dq, J = 9.9, 5.1 Hz, 1H).

Example

[0300] JPEG2024543127000082.jpg3295 Compound O-2 (100 mg), N,N,N'-trimethylethylenediamine (28 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. The reaction was then completed. 1 M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 45 (23 mg). ESI-MS: m / z = 279.37 [1 / 2M+H] + .

[0301] 11H NMR (500 MHz, DMSO-d6) δ 12.42 (s, 1H), 8.35 (s, 1H), 7.91 (s, 1H), 7.55 (s, 1H), 7.34 (d, J = 8.7 Hz, 1H), 6.89 (d, J = 2.3 Hz, 1H), 6.66 (dd, J = 8.8, 2.3 Hz, 1H), 4.30 (q, J = 7.9 Hz, 1H), 4.23 (dd, J = 13.9, 3.6 Hz, 1H), 4.14 (dd, J = 13.9, 9.2 Hz, 1H), 4.03 (dt, J = 9.0, 5.8 Hz, 1H), 3.73 (s, 3H), 3.57 - 3.49 (m, 2H), 3.42 (ddd, J = 14.6, 8.5, 6.0 Hz, 2H), 2.94 (s, 3H), 2.54 (s, 3H), 2.43 (qd, J = 9.1, 7.7, 4.1 Hz, 2H), 2.20 (s, 6H), 2.01 (td, J = 9.5, 4.5 Hz, 1H), 1.84 (d, J = 9.5 Hz, 1H), 1.72 (tt, J = 12.5, 5.2 Hz, 1H), 0.63 (qt, J = 8.6, 5.0 Hz, 1H), 0.31 (tt, J = 9.3, 4.8 Hz, 1H), -0.05 (dq, J = 9.7, 4.9 Hz, 1H), -0.17 (dp, J = 9.5, 4.7 Hz, 1H), -0.60 (dq, J = 9.7, 4.8 Hz, 1H).

Example

[0302] JPEG2024543127000083.jpg32103 Compound O-2 (70 mg), N,N-diethylethylenediamine (18 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. The reaction was then completed. 1 M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 46 (20 mg). ESI-MS: m / z = 571.41 [M+H] + .

[0303] 11H NMR (500 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.54 (s, 1H), 7.27 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 2.1 Hz, 1H), 6.56 (dd, J = 8.6, 2.1 Hz, 1H), 4.33 - 4.26 (m, 1H), 4.22 (dd, J = 14.1, 3.6 Hz, 1H), 4.10 - 4.01 (m, 2H), 3.73 (s, 3H), 3.21 (t, J = 6.7 Hz, 2H), 2.77 (t, J = 6.7 Hz, 2H), 2.69 (q, J = 7.2 Hz, 4H), 2.54 (s, 3H), 2.27 - 2.18 (m, 1H), 2.13 (tt, J = 9.3, 4.8 Hz, 1H), 2.00 (tq, J = 8.9, 4.4, 3.8 Hz, 1H), 1.86 (d, J = 10.2 Hz, 1H), 1.71 (tt, J = 8.8, 3.9 Hz, 1H), 1.03 (t, J = 7.1 Hz, 6H), 0.61 (dt, J = 9.4, 4.9 Hz, 1H), 0.31 (dt, J = 9.0, 4.4 Hz, 1H), -0.05 (dt, J = 9.8, 4.8 Hz, 1H), -0.15 (dp, J = 9.6, 4.7 Hz, 1H), -0.59 (dq, J = 9.7, 4.8 Hz, 1H).

Example

[0304] JPEG2024543127000084.jpg33107 Compound O (75 mg), 1-isopropylpiperidin-4-amine (40 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 47 (20 mg). ESI-MS: m / z = 299.39 [1 / 2M+H] + .

[0305] 1 H NMR (500 MHz, chloroform-d) δ 8.49 (s, 1H), 8.42 (s, 1H), 8.15 (s, 1H), 7.73 (s, 1H), 7.14 (d, J = 8.5 Hz, 1H), 6.59 - 6.53 (m, 2H), 4.36 (dq, J = 8.6, 5.8, 4.6 Hz, 2H), 3.97 - 3.89 (m, 2H), 3.79 (s, 3H), 3.39 - 3.29 (m, 4H), 2.64 (s, 3H), 2.57 (s, 1H), 2.28 (dd, J = 13.4, 6.8 Hz, 1H), 2.24 - 2.13 (m, 4H), 1.98 (dd, J = 25.5, 12.2 Hz, 2H), 1.80 (d, J = 11.9 Hz, 2H), 1.28 (s, 3H), 1.26 (s, 3H), 0.87 (dt, J = 13.2, 6.6 Hz, 1H), 0.51 (dd, J = 10.5, 5.8 Hz, 1H), 0.44 (tt, J = 9.0, 4.9 Hz, 1H), 0.10 (tt, J = 8.8, 4.8 Hz, 1H), -0.01 - -0.08 (m, 1H), -0.34 (dq, J = 10.1, 5.1 Hz, 1H). [Example]

[0306] JPEG2024543127000085.jpg33109 Compound O (75 mg), 1-ethylpiperidin-4-amine dihydrochloride (56 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 48 (10 mg). ESI-MS: m / z = 292.38 [1 / 2M+H] + .

[0307] 1H NMR (500 MHz, クロロホルム-d) δ 8.48 (s, 1H), 8.44 (s, 1H), 8.15 (s, 1H), 7.79 (s, 1H), 7.14 (d, J = 8.5 Hz, 1H), 6.58 - 6.50 (m, 2H), 4.41 - 4.33 (m, 2H), 3.96 (dt, J = 8.9, 5.9 Hz, 1H), 3.89 (dd, J = 13.9, 7.7 Hz, 1H), 3.79 (s, 3H), 3.30 (d, J = 13.3 Hz, 2H), 3.18 (s, 1H), 2.73 (q, J = 7.2 Hz, 2H), 2.64 (s, 3H), 2.34 (d, J = 10.9 Hz, 1H), 2.28 (q, J = 6.5 Hz, 1H), 2.25 - 2.19 (m, 2H), 2.11 (t, J = 8.8 Hz, 3H), 1.84 - 1.77 (m, 3H), 1.21 (t, J = 7.3 Hz, 3H), 0.89 - 0.86 (m, 1H), 0.51 (t, J = 8.5 Hz, 1H), 0.43 (tt, J = 9.1, 5.0 Hz, 1H), 0.09 (tt, J = 9.1, 5.3 Hz, 1H), -0.04 (p, J = 4.9 Hz, 1H), -0.34 (dt, J = 9.6, 5.0 Hz, 1H).

Example

[0308] JPEG2024543127000086.jpg32107 Compound O (75 mg), 3-methylaminopropylamine (15 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 49 (25 mg). ESI-MS: m / z = 272.30 [1 / 2M+H] + .

[0309] 11H NMR (500 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.34 (d, J = 8.7 Hz, 1H), 6.74 (d, J = 2.2 Hz, 1H), 6.60 - 6.57 (m, 1H), 4.32 - 4.26 (m, 1H), 4.22 (dd, J = 13.9, 3.5 Hz, 1H), 4.02 (dd, J = 14.5, 9.3 Hz, 2H), 3.73 (s, 3H), 3.06 (t, J = 6.9 Hz, 2H), 2.73 (t, J = 7.0 Hz, 1H), 2.67 - 2.62 (m, 1H), 2.54 (s, 3H), 2.52 (d, J = 2.1 Hz, 3H), 2.23 - 2.18 (m, 1H), 2.14 (d, J = 9.3 Hz, 1H), 2.03 - 1.96 (m, 2H), 1.83 - 1.76 (m, 2H), 1.71 (d, J = 12.8 Hz, 1H), 0.58 (dd, J = 10.5, 5.8 Hz, 1H), 0.30 (tt, J = 9.0, 4.9 Hz, 1H), -0.06 (tt, J = 8.8, 4.8 Hz, 1H), -0.10 - -0.15 (m, 1H), -0.61 (dq, J = 10.1, 5.1 Hz, 1H).

Example

[0310] Compound O (85 mg), (3-aminopropyl)carbamic acid t-butyl ester (33 mg), Pd2(dba)3 (34 mg), 2-(di-t-butylphosphine)biphenyl (22 mg), and potassium t-butoxide (100 mg) were added to t-amyl alcohol (3 mL). The mixture was purged with nitrogen three times and reacted at 100 °C for 2 h. The reaction was completed. 1 M aqueous sodium bicarbonate (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed. The filtrate was concentrated and the resulting crude product was directly dissolved in 4 M hydrogen chloride-methanol solution (5 mL) and stirred for 30 min. The reaction was monitored by LC-MS and confirmed to be complete. The reaction mixture was concentrated and then purified by preparative liquid chromatography to obtain Example 50 (9 mg). ESI-MS: m / z = 529.31 [M+H] + .

[0311] 11H NMR (500 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.34 (s, 1H), 7.88 (s, 1H), 7.52 (s, 1H), 7.31 (d, J = 8.7 Hz, 1H), 6.72 (d, J = 2.2 Hz, 1H), 6.60 - 6.56 (m, 1H), 4.33 - 4.27 (m, 1H), 4.20 (dd, J = 13.9, 3.5 Hz, 1H), 4.01 (dd, J = 14.5, 9.3 Hz, 2H), 3.73 (s, 3H), 3.04 (t, J = 6.9 Hz, 2H), 2.76 (t, J = 7.0 Hz, 1H), 2.66 - 2.61 (m, 1H), 2.56 (s, 3H), 2.23 - 2.18 (m, 1H), 2.13 (d, J = 9.3 Hz, 1H), 2.02 - 1.97 (m, 2H), 1.82 - 1.76 (m, 2H), 1.67 (d, J = 12.8 Hz, 1H), 0.56 (dd, J = 10.5, 5.8 Hz, 1H), 0.31 (tt, J = 9.0, 4.9 Hz, 1H), -0.05 (tt, J = 8.8, 4.8 Hz, 1H), -0.10 - -0.15 (m, 1H), -0.60 (dq, J = 10.1, 5.1 Hz, 1H).

Example

[0312] Compound O (100 mg), 4-dimethylaminobutylamine (21 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 51 (10 mg). ESI-MS: m / z = 571.44 [M+H] + .

[0313] 1H NMR (500 MHz, クロロホルム-d) δ 8.46 (s, 1H), 8.40 (s, 1H), 8.15 (s, 1H), 7.70 (s, 1H), 7.13 (d, J = 8.7 Hz, 1H), 6.60 (dd, J = 8.6, 2.1 Hz, 1H), 6.52 (d, J = 2.2 Hz, 1H), 4.40 - 4.31 (m, 2H), 3.97 - 3.94 (m, 1H), 3.90 (d, J = 6.4 Hz, 1H), 3.78 (s, 3H), 3.08 (td, J = 6.4, 3.3 Hz, 2H), 2.95 - 2.89 (m, 2H), 2.69 (s, 6H), 2.63 (s, 3H), 2.27 (dt, J = 13.5, 6.9 Hz, 1H), 2.16 (ddt, J = 21.9, 13.5, 7.2 Hz, 2H), 1.87 - 1.73 (m, 4H), 1.68 (p, J = 6.8 Hz, 2H), 0.50 (td, J = 9.8, 8.3, 3.4 Hz, 1H), 0.42 (tt, J = 8.9, 4.9 Hz, 1H), 0.09 (tt, J = 9.1, 4.9 Hz, 1H), -0.04 (dq, J = 9.8, 4.9 Hz, 1H), -0.34 (dq, J = 9.9, 5.1 Hz, 1H).

Example

[0314] Compound O (100 mg), (4-aminobutyl)(methyl)carbamic acid t-butyl ester (47 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL). The mixture was purged with nitrogen three times and reacted at 100 °C for 2 h. The reaction was completed. 1 M aqueous sodium bicarbonate (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed. The crude product obtained by concentrating the filtrate was directly dissolved in 4 M hydrogen chloride-methanol solution (5 mL) and stirred for 30 min. The reaction was monitored by LC-MS and confirmed to be complete. The reaction mixture was concentrated and then purified by preparative liquid chromatography to give Example 52 (22 mg). ESI-MS: m / z = 557.31 [M+H] + .

[0315] 1H NMR (500 MHz, chloroform-d) δ 8.35 (s, 2H), 8.32 (s, 1H), 8.14 (s, 1H), 7.59 (s, 1H), 7.05 (d, J = 8.6 Hz, 1H), 6.62 - 6.54 (m, 2H), 4.29 - 4.21 (m, 2H), 3.90 - 3.86 (m, 1H), 3.76 (d, J = 8.8 Hz, 1H), 3.73 (s, 3H), 3.02 (dt, J = 23.3, 7.0 Hz, 4H), 2.69 (s, 3H), 2.60 (s, 3H), 2.15 (q, J = 6.6 Hz, 1H), 2.08 (d, J = 6.1 Hz, 1H), 2.02 - 1.95 (m, 1H), 1.90 (t, J = 7.7 Hz, 2H), 1.74 - 1.65 (m, 4H), 0.41 (s, 1H), 0.35 (dq, J = 8.6, 4.6, 4.1 Hz, 1H), -0.00 - -0.06 (m, 1H), -0.12 (dt, J = 9.7, 5.0 Hz, 1H), -0.45 (dd, J = 9.7, 5.1 Hz, 1H). [Example]

[0316] JPEG2024543127000090.jpg33106 Compound O (100 mg), 1,4-butanediamine hydrochloride (61 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 53 (25 mg). ESI-MS: m / z = 543.42 [M+H] + .

[0317] 1H NMR (500 MHz, Methanol-d4) δ 8.34 (s, 1H), 8.02 (s, 1H), 7.58 (s, 1H), 7.24 - 7.17 (m, 1H), 6.66 (d, J = 8.4 Hz, 2H), 4.34 - 4.28 (m, 1H), 4.27 - 4.20 (m, 1H), 3.98 (p, J = 5.1 Hz, 1H), 3.84 (d, J = 20.1 Hz, 1H), 3.73 (s, 3H), 3.17 - 3.09 (m, 2H), 2.99 (t, J = 7.4 Hz, 2H), 2.53 (s, 3H), 2.19 (d, J = 13.0 Hz, 2H), 2.00 (d, J = 17.1 Hz, 1H), 1.76 (ddd, J = 36.2, 13.9, 6.7 Hz, 6H), 0.52 - 0.43 (m, 1H), 0.33 (t, J = 8.9 Hz, 1H), -0.08 - -0.17 (m, 2H), -0.60 (d, J = 8.9 Hz, 1H). [Example]

[0318] JPEG2024543127000091.jpg3397 Compound O-2 (70 mg), 1-isopropylpiperidin-4-amine (22 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 54 (43 mg). ESI-MS: m / z = 299.39 [1 / 2M+H] + .

[0319] 11H NMR (500 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.29 (s, 1H), 7.95 (s, 1H), 7.58 (s, 1H), 7.28 (d, J = 8.5 Hz, 1H), 6.78 (s, 1H), 6.60 (d, J = 8.6 Hz, 1H), 4.35 - 4.31 (m, 1H), 4.26 (dd, J = 13.8, 3.5 Hz, 1H), 4.10 - 4.06 (m, 2H), 3.77 (s, 3H), 3.42 (t, J = 10.0 Hz, 1H), 3.03 (p, J = 8.0, 6.7 Hz, 2H), 2.62 (d, J = 10.6 Hz, 2H), 2.58 (s, 3H), 2.26 (dd, J = 13.0, 6.6 Hz, 1H), 2.21 - 2.14 (m, 1H), 2.10 - 2.01 (m, 3H), 1.91 - 1.84 (m, 1H), 1.81 - 1.71 (m, 1H), 1.53 (q, J = 13.9, 13.0 Hz, 2H), 1.13 (d, J = 6.6 Hz, 6H), 0.63 (qd, J = 8.5, 5.2, 3.6 Hz, 1H), 0.36 (tt, J = 9.4, 4.6 Hz, 1H), 0.03 - -0.03 (m, 1H), -0.11 (dt, J = 9.3, 4.3 Hz, 1H), -0.54 (dt, J = 9.7, 4.9 Hz, 1H). [Example]

[0320] JPEG2024543127000092.jpg36102 Compound O-2 (70 mg), 1-ethylpiperidin-4-amine dihydrochloride (32 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 55 (35 mg). ESI-MS: m / z = 292.40 [1 / 2M+H] + .

[0321] 11H NMR (500 MHz, DMSO-d6) δ 12.42 (s, 1H), 8.38 (s, 1H), 8.27 (s, 1H), 7.95 (s, 1H), 7.58 (s, 1H), 7.29 (d, J = 8.6 Hz, 1H), 6.78 (s, 1H), 6.60 (d, J = 8.6 Hz, 1H), 4.33 (d, J = 8.2 Hz, 1H), 4.29 - 4.24 (m, 1H), 4.08 (dt, J = 13.2, 6.7 Hz, 2H), 3.77 (s, 3H), 3.42 (d, J = 10.0 Hz, 1H), 3.07 (t, J = 10.8 Hz, 2H), 2.63 (d, J = 7.1 Hz, 2H), 2.58 (s, 3H), 2.43 (d, J = 12.6 Hz, 2H), 2.31 - 2.23 (m, 1H), 2.20 - 2.13 (m, 1H), 2.05 (d, J = 14.8 Hz, 3H), 1.86 (s, 1H), 1.76 (dt, J = 13.6, 6.6 Hz, 1H), 1.51 (t, J = 12.9 Hz, 2H), 1.12 (t, J = 7.1 Hz, 3H), 0.64 (q, J = 8.1 Hz, 1H), 0.37 (td, J = 9.5, 9.0, 4.6 Hz, 1H), 0.00 (dd, J = 9.6, 4.9 Hz, 1H), -0.09 (dt, J = 9.6, 4.6 Hz, 1H), -0.52 (dd, J = 9.1, 4.9 Hz, 1H).

Example

[0322]

Example

[0323] JPEG2024543127000093.jpg26117 Compound O-2 (70 mg), N-methylethylenediamine (15 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), the atmosphere was purged with nitrogen gas three times, and the reaction was completed at 100°C for 2 hours. The reaction mixture was added with 1M aqueous sodium bicarbonate (20 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Example 56 (12 mg, retention time: 60.4 min) was obtained by preparative chromatography (liquid phase conditions: column: YMC AQ C18 250 mm x 30 mm, 10 μm; mobile phase: A: 0.1% formic acid, B: acetonitrile, gradient: 15% C to 25% B (0-90 min); flow rate: 25 mL / min; wavelength: 254 nm). ESI-MS: m / z = 529.35 [M+H] + and Example 57 (25 mg, retention time: 39.5 min). ESI-MS: m / z = 529.35 [M+H] + Example 56: 11H NMR (500 MHz, DMSO-d6) δ 8.39 (s, 1H), 7.91 (s, 1H), 7.54 (s, 1H), 7.27 (d, J = 8.5 Hz, 1H), 6.80 (d, J = 2.1 Hz, 1H), 6.56 (dd, J = 8.6, 2.0 Hz, 1H), 5.81 (s, 1H), 4.33 - 4.26 (m, 1H), 4.22 (dd, J = 14.0, 3.6 Hz, 1H), 4.12 - 4.01 (m, 2H), 3.73 (s, 3H), 3.28 (t, J = 6.3 Hz, 2H), 2.90 (t, J = 6.3 Hz, 2H), 2.54 (s, 3H), 2.44 (s, 3H), 2.21 (dt, J = 12.2, 5.9 Hz, 1H), 2.13 (tt, J = 8.6, 4.6 Hz, 1H), 2.01 (qd, J = 9.4, 6.1, 5.6 Hz, 1H), 1.85 (s, 1H), 1.76 - 1.66 (m, 1H), 0.62 (tq, J = 8.2, 4.9, 4.3 Hz, 1H), 0.31 (tt, J = 9.4, 4.7 Hz, 1H), -0.05 (dq, J = 9.6, 4.9 Hz, 1H), -0.14 (tt, J = 9.4, 4.6 Hz, 1H), -0.60 (dq, J = 9.7, 4.9 Hz, 1H). Example 57: 1H NMR (500 MHz, DMSO-d6) δ 8.44 (s, 1H), 7.91 (s, 1H), 7.55 (s, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.00 (s, 1H), 6.72 (d, J = 8.8 Hz, 1H), 4.29 (t, J = 7.8 Hz, 1H), 4.21 (d, J = 7.7 Hz, 2H), 4.03 (p, J = 6.2 Hz, 1H), 3.73 (s, 3H), 3.50 (tt, J = 15.3, 8.1 Hz, 2H), 2.94 (s, 3H), 2.87 (t, J = 7.2 Hz, 2H), 2.54 (s, 3H), 2.27 - 2.19 (m, 1H), 2.15 (s, 1H), 2.02 (d, J = 15.6 Hz, 1H), 1.87 (s, 1H), 1.71 (s, 1H), 0.66 (s, 1H), 0.29 (s, 1H), -0.03 - -0.13 (m, 1H), -0.21 (s, 1H), -0.65 (s, 1H). [Example]

[0324] JPEG2024543127000094.jpg3598 Compound O-2 (70 mg), ethylenediamine (20 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 58 (40 mg). ESI-MS: m / z = 258.34 [1 / 2M+H] + . 1H NMR (500 MHz, DMSO-d6) δ 8.43 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.54 (s, 1H), 7.27 (d, J = 8.5 Hz, 1H), 6.80 (d, J = 2.1 Hz, 1H), 6.56 (dd, J = 8.5, 2.0 Hz, 1H), 4.29 (q, J = 7.9 Hz, 1H), 4.22 (dd, J = 14.1, 3.5 Hz, 1H), 4.13 - 4.00 (m, 2H), 3.73 (s, 3H), 3.27 (t, J = 6.4 Hz, 2H), 2.93 (t, J = 6.3 Hz, 2H), 2.54 (s, 3H), 2.21 (dt, J = 11.9, 5.9 Hz, 1H), 2.14 (dt, J = 13.4, 6.4 Hz, 1H), 2.04 - 1.96 (m, 1H), 1.84 (d, J = 9.7 Hz, 1H), 1.72 (dd, J = 12.1, 6.7 Hz, 1H), 0.63 (td, J = 9.5, 8.8, 4.1 Hz, 1H), 0.31 (dp, J = 9.4, 4.6 Hz, 1H), -0.05 (dq, J = 9.7, 4.9 Hz, 1H), -0.14 (td, J = 8.8, 4.5 Hz, 1H), -0.60 (dq, J = 9.9, 4.9 Hz, 1H).

Example

[0325]

Example

[0326] JPEG2024543127000095.jpg65101

[0327] (1) Method for producing compound Ba Titanium tetrachloride (43.9 g) was added to dichloromethane (300 mL) and cooled to 0-2°C. While maintaining the temperature at 0-2°C, tetraisopropyl titanate (19.7 g) was added dropwise. After maintaining the temperature and stirring for 10 minutes, the temperature was maintained at 0-2°C, and N,N-diisopropylethylamine (32.8 g) was added dropwise. After maintaining the temperature and stirring for 10 minutes, the temperature was maintained at 0-2°C, and a solution of compound B (30.0 g) in dichloromethane (100 mL) was added dropwise. After maintaining the temperature and stirring for 2 hours, the temperature was maintained at 0-2°C, and t-butyl acrylate (44.5 g) was added dropwise. The temperature was maintained at 0-2°C, and the reaction was continued for another 4 hours. TLC monitoring indicated that the reaction was complete. The reaction mixture was poured into saturated ammonium chloride solution (600 mL) and extracted with dichloromethane (200 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated until no liquid flowed out, and subjected to column chromatography to obtain compound Ba (19.0 g).

[0328] (2) Method for producing compound Bb Sodium borohydride (1.64 g) was added to tetrahydrofuran (70 mL) and the temperature was lowered to 0-2°C. A solution of compound Ba (15.26 g) in tetrahydrofuran (30 mL) was added dropwise while maintaining the temperature at 0-2°C. After the addition was complete, the ice bath was removed and the reaction was stirred at 20-25°C for 6 hours. TLC monitoring confirmed the completion of the reaction. The reaction solution was poured into saturated ammonium chloride solution (200 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound Bb (1.95 g) was obtained by column chromatography.

[0329] (3) Method for producing compound Bc Compound Bb (1.95 g) was added to tetrahydrofuran (50 mL), purged with nitrogen gas three times, and cooled to 0-2 °C. A 1 M solution of lithium aluminum tetrahydride in tetrahydrofuran (10.9 mL) was added dropwise while maintaining the temperature at 0-2 °C. After the addition was complete, the ice bath was removed and the reaction was stirred at 20-25 °C for 6 h. TLC monitoring confirmed the reaction was complete. The temperature was maintained at 0-5 °C. Water (0.37 mL), 15% sodium hydroxide solution (0.37 mL), and water (1.11 mL) were added dropwise to the reaction mixture, followed by filtration. The filter cake was washed with tetrahydrofuran (20 mL). The filtrate was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound Bc (1.44 g).

[0330] (4) Method for producing compound Bd Compound Bc (1.44 g) was dissolved in dichloromethane (50 mL), triethylamine (5.06 g) and 4-dimethylaminopyridine (10 mg) were slowly added, and the mixture was cooled to 0-5°C. A solution of p-toluenesulfonyl chloride (5.72 g) in dichloromethane (10 mL) was then slowly added dropwise. After the addition was complete, the mixture was allowed to react at 20-25°C for 3 hours to complete the reaction. The reaction mixture was washed with sodium bicarbonate solution (1 M, 20 mL x 2), separated, and the organic phase was dried over anhydrous sodium sulfate. The concentrate was concentrated until no more liquid flowed out, and compound Bd (1.89 g) was obtained by column chromatography.

[0331] (5) Method for producing compounds B-e1 / B-e2 Compound Bd (1.89 g), 5-bromo-1H-benzimidazol-2-amine (888 mg), and 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (1.8 mL) were added to acetonitrile (50 mL), purged with nitrogen gas three times, and reacted at 15–20 °C for 24 h. TLC showed the reaction was complete. The reaction mixture was added with 1 M aqueous sodium bicarbonate (50 mL) and extracted with ethyl acetate (50 mL × 2). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by column chromatography to obtain a mixture of compounds B-e1 and B-e2 (1.44 g). ESI-MS: m / z = 492.18 [M+H] + .

[0332] (6) Method for producing compounds B-f1 / B-f2 Compounds B-e1 / B-e2 (1.44 g), compound A (673 mg), and potassium carbonate (601 mg) were added to acetonitrile (70 mL) and reacted at 80 °C for 16 h. TLC showed the reaction was complete. The reaction mixture was poured into 100 mL of water and extracted with ethyl acetate (40 mL x 2). The ethyl acetate phases were combined, and the organic phase was washed once with water. The organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by column chromatography to obtain the compound B-f1 / B-f2 mixture (853 mg). ESI-MS: m / z = 567.19 [M+H] + .

[0333] (7) Method for producing compounds B-g1 / B-g2 Compounds B-f1 / B-f2 (853 mg) were dissolved in tetrahydrofuran (10 mL), and a solution of sodium hydroxide (183 mg) in water (3 mL) was added. The mixture was stirred at 20-25 °C for 18 h. LC-MS showed the reaction was complete. The pH was adjusted to 5-6 with 6 M hydrochloric acid, and tetrahydrofuran and water were removed by evaporation under reduced pressure. Dichloromethane (10 mL) and triethylamine (456 mg) were added and stirred until the mixture was clear. The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated until no liquid flowed out. The mixture was used directly in the next step without further purification. ESI-MS: m / z = 553.16 [M+H] + .

[0334] (8) Method for producing compounds B-h1 / B-h2 Compounds B-g1 and B-g2 obtained in the previous step were dissolved in dichloromethane (10 mL), TBTU (593 mg) was added, and the mixture was allowed to react at 20-25 °C for 16 h. LC-MS analysis showed the reaction was complete. The reaction mixture was washed with water (10 mL x 3), the organic phase was dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. Compounds B-h1 and B-h2 (817 mg) were obtained by column chromatography. Compound B-h1 (253 mg, retention time: 11.6 min) was obtained by preparative SFC (liquid phase conditions: column: YMC SB 30 mm x 250 mm, 10 μm; mobile phase: carbon dioxide:methanol = 40:60; flow rate: 80 mL / min; wavelength: 254 nm). ESI-MS: m / z = 535.16 [M+H] + and compound B-h2 (207 mg, retention time: 14.0 min). ESI-MS: m / z = 535.16 [M+H] + . Compound B-h1: 1H NMR (500 MHz, クロロホルム-d) δ 12.00 (s, 1H), 8.47 (s, 1H), 8.17 (s, 1H), 7.60 (s, 1H), 7.43 (d, J = 1.7 Hz, 1H), 7.35 (dd, J = 8.4, 1.8 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 4.22 (dd, J = 9.1, 4.1 Hz, 1H), 4.18 - 4.10 (m, 2H), 4.01 (ddd, J = 14.0, 9.5, 4.8 Hz, 1H), 3.82 (s, 3H), 2.61 (s, 3H), 2.31 - 2.23 (m, 1H), 2.09 (ddt, J = 12.6, 9.1, 4.5 Hz, 2H), 1.94 (ddd, J = 12.0, 7.4, 4.3 Hz, 1H), 1.08 (dq, J = 8.6, 4.4 Hz, 1H), 0.90 (dtd, J = 9.9, 5.6, 4.7, 2.3 Hz, 1H), 0.64 (tt, J = 9.0, 4.6 Hz, 1H), 0.56 (tt, J = 8.9, 4.7 Hz, 1H), 0.28 (dq, J = 9.6, 4.8 Hz, 1H), 0.21 (dq, J = 9.3, 4.7 Hz, 1H). Compound B-h2: 1H NMR (500 MHz, chloroform-d) δ 12.04 (s, 1H), 8.46 (s, 1H), 8.17 (s, 1H), 7.59 (s, 1H), 7.49 (s, 1H), 7.40 (dd, J = 8.5, 1.2 Hz, 1H), 7.12 (d, J = 8.5 Hz, 1H), 4.22 (dd, J = 9.2, 4.1 Hz, 1H), 4.19 - 4.09 (m, 2H), 4.00 (ddd, J = 14.1, 9.7, 5.0 Hz, 1H), 3.82 (s, 3H), 2.60 (s, 3H), 2.31 - 2.21 (m, 1H). 2.07 (tt, J = 11.3, 8.4, 3.9 Hz, 2H), 1.92 (ddd, J = 11.7, 7.5, 4.2 Hz, 1H), 1.07 (qt, J = 8.3, 4.3 Hz, 1H), 0.96 - 0.87 (m, 1H), 0.67 - 0.60 (m, 1H), 0.56 (ddt, J = 13.3, 8.9, 4.6 Hz, 1H), 0.28 (dq, J = 9.6, 4.9 Hz, 1H), 0.20 (dq, J = 9.3, 4.8 Hz, 1H).

[0335] (9) Manufacturing Method of Example 59 Compound B-h1 (100 mg), 3-oxetanamine (16 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1 M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 59 (22 mg). ESI-MS: m / z = 528.35 [M+H] + .

[0336] 1H NMR (500 MHz, DMSO-d6) δ 12.34 (s, 1H), 8.42 (s, 1H), 7.94 (s, 1H), 7.55 (s, 1H), 7.35 (d, J = 8.6 Hz, 1H), 6.64 (s, 1H), 6.47 (d, J = 8.5 Hz, 1H), 6.39 (d, J = 5.8 Hz, 1H), 4.85 (t, J = 6.3 Hz, 2H), 4.53 - 4.46 (m, 1H), 4.42 (t, J = 6.0 Hz, 2H), 4.23 (dd, J = 9.3, 4.1 Hz, 1H), 4.19 - 4.10 (m, 2H), 3.97 (s, 1H), 3.78 (s, 3H), 2.55 (s, 3H), 2.25 - 2.16 (m, 1H), 1.23 (d, J = 3.8 Hz, 3H), 1.14 (d, J = 4.1 Hz, 1H), 0.97 (tt, J = 8.5, 3.5 Hz, 1H), 0.54 (ddq, J = 17.6, 9.0, 4.5, 3.7 Hz, 2H), 0.34 (dq, J = 9.5, 4.7 Hz, 1H), 0.21 (dq, J = 8.9, 4.8 Hz, 1H).

[0337] (10) Manufacturing Method of Example 60 Compound B-h2 (100 mg), 3-oxetanamine (16 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1 M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 60 (35 mg). ESI-MS: m / z = 528.35 [M+H] + .

[0338] 1H NMR (500 MHz, DMSO-d6) δ 12.35 (s, 1H), 8.42 (s, 1H), 7.94 (s, 1H), 7.58 - 7.51 (m, 1H), 7.26 (d, J = 8.5 Hz, 1H), 6.60 (d, J = 1.9 Hz, 1H), 6.50 (dd, J = 8.6, 2.0 Hz, 1H), 6.40 (d, J = 7.1 Hz, 1H), 4.90 (t, J = 6.5 Hz, 2H), 4.63 (h, J = 6.7 Hz, 1H), 4.43 (td, J = 6.1, 1.6 Hz, 2H), 4.25 (dd, J = 9.2, 4.1 Hz, 1H), 4.21 - 4.11 (m, 2H), 4.01 - 3.94 (m, 1H), 3.78 (s, 3H), 2.55 (s, 3H), 2.29 - 2.19 (m, 1H), 1.98 - 1.89 (m, 2H), 1.15 (ddt, J = 15.7, 8.7, 3.0 Hz, 2H), 1.04 - 0.97 (m, 1H), 0.56 (dtt, J = 25.5, 8.8, 4.3 Hz, 2H), 0.36 (dt, J = 9.3, 4.6 Hz, 1H), 0.27 - 0.20 (m, 1H).

Example

[0339] JPEG2024543127000096.jpg71102

[0340] (1) Manufacturing method of compound B-5 (S)-4-Benzyl-2-oxazolidinone (14.1 g), 3-cyclopropylpropionic acid (10 g), and 4-dimethylaminopyridine (10.7 g) were added to dichloromethane (200 mL). 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (30.6 g) was added at 20-25 °C. After the addition was complete, the mixture was stirred at 20-25 °C for 12 h to complete the reaction. 75 mL of dichloromethane was added to the reaction mixture, and the dichloromethane phase was washed sequentially with water (150 mL), 1 M hydrochloric acid (150 mL x 2), and 1 M sodium bicarbonate solution (150 mL x 2). The dichloromethane phase was retained, dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. Compound B-5 (19.1 g) was obtained by column chromatography. ESI-MS: m / z = 274.14 [M+H] + .

[0341] (2) Method for producing compound C-5 Compound B-5 (6.0 g) was added to tetrahydrofuran (60 mL), purged with nitrogen gas three times, and cooled (temperature set to -78 °C). When the internal temperature reached -70 °C, sodium bis(trimethylsilyl)amide (2 M, 16.5 mL) was added dropwise over 15 min. The mixture was stirred for 1 h while maintaining the temperature at -70 °C or below. 3-Bromopropene (5.3 g) was then added dropwise, and the mixture was stirred for 1 h while maintaining the temperature at -70 °C or below. The mixture was then slowly warmed to room temperature and stirred for 12 h to complete the reaction. The reaction mixture was poured into ammonium chloride solution (1 M, 400 mL) and extracted with ethyl acetate (50 mL × 2). The combined ethyl acetate phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound C-5 (3.5 g) was obtained by column chromatography. ESI-MS: m / z = 314.19 [M+H] + .

[0342] (3) Method for producing compound D-5 Compound C-5 (2.8 g) was added to tetrahydrofuran (30 mL) and cooled to 0-5 °C in an ice bath. A solution of lithium hydroxide monohydrate (1.1 g) in water (10 mL) was added and stirred for 5 min. After stirring, hydrogen peroxide (30 wt %, 3.65 mL) was added and the mixture was incubated at 0-5 °C and stirred for 1 h to complete the reaction. To the reaction mixture, sodium sulfite solution (30 mL) and sodium bicarbonate solution (1 M, 30 mL) were added, and the mixture was extracted with dichloromethane (30 mL × 2). The aqueous phase was retained and adjusted to pH 1-2 with 4 M hydrochloric acid. The combined dichloromethane phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound D-5, which was used directly in the next step without further purification.

[0343] (4) Method for producing compound E-5 Compound D-5 obtained in the previous step was dissolved in dichloromethane (30 mL), and dibenzylamine (1.8 g), N,N-diisopropylethylamine (4.43 mL), and HATU (4.1 g) were added in that order. After the addition was complete, the mixture was stirred at 20-25 °C for 12 h to complete the reaction. The reaction mixture was washed with water (30 mL x 2), and the dichloromethane phase was retained, dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. Compound E-5 (2.8 g) was obtained by column chromatography. ESI-MS: m / z = 334.30 [M+H] + .

[0344] (5) Method for producing compound F-5 Compound E-5 (2.8 g) was added to tetrahydrofuran (30 mL), and 9-borabicyclo[3.3.1]nonane (0.5 M, 42 mL) was added. The mixture was stirred at 20-25°C for 1 h. The reaction was then cooled to 0-5°C in an ice bath, and a solution of sodium hydroxide (672 mg) in water (5 mL) and hydrogen peroxide (30 wt%, 4.29 mL) were added sequentially. The mixture was stirred at 20-25°C for 2 h to complete the reaction. The reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (30 mL x 2). The combined ethyl acetate phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound F-5 (2.08 g) was obtained by column chromatography. ESI-MS: m / z = 352.30 [M+H] + .

[0345] (6) Method for producing compound G-5 Compound F-5 (2.08 g) was added to tetrahydrofuran (30 mL) and cooled to 0-5°C. Borane dimethyl sulfide (2 M, 10.22 mL) was added dropwise. After the addition was complete, the mixture was stirred at 60°C for 4 h, and the reaction was completed. The temperature was then lowered to 0-5°C in an ice bath, and the reaction mixture was quenched by adding dilute hydrochloric acid (1 M) dropwise. The reaction mixture was evaporated to dryness, and the concentrate was dissolved in ethyl acetate (50 mL). The organic phase was washed with saturated sodium bicarbonate solution (50 mL x 1) and saturated brine (50 mL x 1), dried, concentrated, and then separated using a column to obtain G-5 (1.45 g). ESI-MS: m / z = 338.40 [M+H] + .

[0346] (7) Method for producing compound H-5 Compound G-5 (510 mg) was added to methanol (10 mL), Pd / C (10%, 51 mg) was added, and the mixture was purged with hydrogen gas three times. The mixture was stirred in a water bath at 40-45°C for 2 h. After the reaction was completed, the reaction mixture was filtered and concentrated until no more liquid flowed out, yielding compound H-5, which was used directly in the next step without further purification.

[0347] (8) Method for producing compound I-5 Compound H-5 obtained in the previous step was dissolved in N,N-dimethylformamide (10 mL), 4-bromo-1-fluoro-2-nitrobenzene (333 mg), and potassium carbonate (460 mg) were added in that order. The reaction was completed by stirring in a 40-45°C water bath for 6 hours. The reaction mixture was poured into 50 mL of water and extracted with ethyl acetate (10 mL x 2). The combined ethyl acetate phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound I-5 (387 mg) was obtained by column chromatography. ESI-MS: m / z = 357.14 [M+H] + .

[0348] (9) Method for producing compound J-5 Compound I-5 (387 mg) was dissolved in dichloromethane (8 mL), triethylamine (164 mg) was added, and the mixture was cooled to 0-5°C. A solution of ethylsulfonyl chloride (168 mg) in dichloromethane (5 mL) was added dropwise. After the addition was complete, the mixture was reacted at 20-25°C for 1 h to complete the reaction. The reaction mixture was washed with sodium bicarbonate solution (1 M, 30 mL x 2), and the dichloromethane phase was retained, dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out, yielding compound J-5, which was used directly in the next step without further purification.

[0349] (10) Method for producing compound K-5 Compound J-5 obtained in the previous step, compound A (306 mg), and potassium carbonate (416 mg) were added to N,N-dimethylformamide (20 mL) and reacted at 60 °C for 20 h. The reaction was then completed. The reaction mixture was poured into 50 mL of water and extracted with ethyl acetate (30 mL x 2). The ethyl acetate phases were combined, and the organic phase was washed once with water. The organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound K-5 (450 mg) was obtained by column chromatography. ESI-MS: m / z = 586.22 [M+H] + .

[0350] (11) Method for producing compound L-5 Compound K-5 (450 mg) was dissolved in methanol (5 mL), Raney nickel (20 mg) was added, and the mixture was purged with hydrogen gas three times. The reaction was completed by reacting at 25 °C for 2 h. The reaction solution was filtered, and the filtrate was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound L-5, which was used directly in the next step without further purification.

[0351] (12) Method for producing compound M-5 Compound L-5 obtained in the previous step was dissolved in t-butanol (10 mL) and dichloromethane (10 mL), and a solution of cyanogen bromide (163 mg) in dichloromethane (5 mL) was added dropwise. The reaction was allowed to proceed at 25 °C for 12 h, completing the reaction. Sodium bicarbonate solution (1 M, 10 mL) was added to the reaction mixture, and the mixture was separated. The dichloromethane phase was retained and the organic phase was washed with sodium bicarbonate solution (1 M, 10 mL x 2). The organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound M-5, which was used directly in the next step without further purification. ESI-MS: m / z = 581.19 [M+H] + .

[0352] (13) Method for producing compound N-5 Compound M-5 obtained in the previous step was dissolved in tetrahydrofuran (5 mL), and a solution of sodium hydroxide (123 mg) in water (5 mL) was added. The reaction was allowed to proceed for 45 min at 20-25 °C, after which the reaction was completed. The pH was adjusted to 5-6 with 6 M hydrochloric acid, and tetrahydrofuran and water were removed by evaporation under reduced pressure. Dichloromethane (10 mL) and triethylamine (0.43 mL) were added and stirred until the mixture was clear. The mixture was then dried over anhydrous sodium sulfate, filtered, and concentrated until no liquid flowed out. Compound N-5 was obtained, which was used directly in the next step without further purification. ESI-MS: m / z = 567.18 [M+H] + .

[0353] (14) Method for producing compound O-5 Compound N-5 obtained in the previous step was dissolved in dichloromethane (5 mL), TBTU (297 mg) was added, and the mixture was allowed to react at 20-25 °C for 16 h. The reaction was then completed. The reaction mixture was washed with water (10 mL x 3), the organic phase was dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. Compound O-5 (240 mg) was obtained by column chromatography. ESI-MS: m / z = 549.20 [M+H] + .

[0354] (15) Manufacturing Method of Example 61 Compound O-5 (60 mg), 3-oxetanamine (12 mg), Pd2(dba)3 (25 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (73 mg) were added to t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 61 (8 mg). ESI-MS: m / z = 542.46 [M+H] + .

[0355] 1H NMR (500 MHz, chloroform-d) δ 12.04 (s, 1H), 8.41 (s, 1H), 8.15 (s, 1H), 7.66 (s, 1H), 7.08 (d, J = 8.6 Hz, 1H), 6.50 (dd, J = 8.5, 2.1 Hz, 1H), 6.43 (d, J = 2.2 Hz, 1H), 5.04 (t, J = 6.6 Hz, 2H), 4.63 (d, J = 7.8 Hz, 1H), 4.55 (t, J = 6.1 Hz, 2H), 4.45 - 4.34 (m, 2H), 4.01 (q, J = 7.6 Hz, 1H), 3.79 (s, 3H), 2.73 (s, 1H), 2.64 (s, 3H), 2.34 (dt, J = 13.8, 6.9 Hz, 1H), 2.13 - 2.06 (m, 1H), 2.01 (d, J = 6.4 Hz, 1H), 1.86 (q, J = 7.2, 6.0 Hz, 2H), 1.31 (s, 2H), 0.65 - 0.57 (m, 1H), 0.41 (ddt, J = 13.3, 8.7, 4.6 Hz, 2H), -0.04 (t, J = 4.1 Hz, 1H), -0.09 (dq, J = 11.4, 6.6, 5.4 Hz, 1H). [Example]

[0356] JPEG2024543127000097.jpg32105 Compound O (50 mg), 1-(dimethylamino)-2-propylamine (14 mg), Pd2(dba)3 (21 mg), 2-(di-t-butylphosphine)biphenyl (14 mg), and potassium t-butoxide (63 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, extracted with ethyl acetate (10 mL × 3), and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to obtain Example 62 (10 mg). ESI-MS: m / z = 557.45 [M+H] + .

[0357] 1 1H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.39 (s, 1H), 8.00 (s, 1H), 7.56 (s, 1H), 7.30 (d, J = 8.8 Hz, 1H), 6.85 (s, 1H), 6.64 (d, J = 8.6 Hz, 1H), 4.34 (s, 1H), 4.27 (d, J = 13.5 Hz, 1H), 4.04 (d, J = 22.0 Hz, 2H), 3.77 (s, 3H), 2.58 (s, 3H), 2.41 (d, J = 12.0 Hz, 1H), 2.22 (s, 6H), 2.15 (d, J = 10.1 Hz, 2H), 2.05 (d, J = 13.1 Hz, 2H), 1.84 (h, J = 7.3, 5.2 Hz, 1H), 1.75 (tt, J = 12.6, 5.9 Hz, 1H), 1.21 (d, J = 6.3 Hz, 3H), 0.91 (s, 1H), 0.65 (s dhept, J = 8.5, 5.0 Hz, 1H), 0.37 (tt, J = 9.1, 4.8 Hz, 1H), -0.01 (dq, J = 9.5, 5.3, 4.7 Hz, 1H), -0.09 (tt, J = 9.7, 4.8 Hz, 1H), -0.55 (dq, J = 9.7, 4.9 Hz, 1H).

Example

[0358] JPEG2024543127000098.jpg38113 Compound O-2 (50 mg), 1-(dimethylamino)-2-propylamine (14 mg), Pd2(dba)3 (21 mg), 2-(di-t-butylphosphine)biphenyl (14 mg), and potassium t-butoxide (63 mg) were added to t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 1M aqueous sodium bicarbonate solution (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 63 (10 mg). ESI-MS: m / z = 557.47 [M+H] + .

[0359] 1 H NMR (500 MHz, chloroform-d) δ 11.91 (s, 1H), 8.39 (s, 1H), 8.15 (s, 1H), 7.65 (s, 1H), 7.13 (dd, J = 8.5, 1.4 Hz, 1H), 6.63 (t, J = 2.6 Hz, 1H), 6.59 (dt, J = 8.7, 2.4 Hz, 1H), 4.36 (ddt, J = 14.1, 9.6, 4.9 Hz, 2H), 3.94 (ddt, J = 20.6, 13.4, 4.0 Hz, 2H), 3.78 (s, 3H), 3.58 - 3.48 (m, 1H), 2.64 (s, 4H), 2.33 (d, J = 7.3 Hz, 6H), 2.17 (qd, J = 7.4, 4.2 Hz, 2H), 2.01 (d, J = 6.5 Hz, 1H), 1.85 - 1.76 (m, 2H), 1.33 - 1.30 (m, 1H), 1.27 (d, J = 6.2 Hz, 3H), 0.60 - 0.51 (m, 1H), 0.45 (tq, J = 9.8, 5.3 Hz, 1H), 0.14 (tt, J = 9.2, 5.2 Hz, 1H), -0.02 (d, J = 5.7 Hz, 1H), -0.25 - -0.33 (m, 1H). [Example]

[0360] JPEG2024543127000099.jpg39119

[0361] (1) Manufacturing Method of Example 64 Compound O-2 (100 mg), (2-amino-1,1-dimethylethyl)dimethylamine dihydrochloride (42 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL). The mixture was purged with nitrogen gas three times and reacted at 95 °C for 2 h. The reaction was then completed. A 1M aqueous solution of sodium bicarbonate (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 64 (20 mg). ESI-MS: m / z = 571.42 [M+H] + . [Example]

[0362] JPEG2024543127000100.jpg21119(1) Method for producing compound 65-a Compound BOC-D-alanine (10.0 g) was dispersed in dichloromethane (150 mL), and dimethylamine hydrochloride (6.5 g), HATU (22.1 g), and N,N-diisopropylethylamine (20.5 g) were added in that order. The reaction was allowed to proceed at 25 °C for 16 h, after which TLC showed the reaction was complete. The reaction mixture was washed with aqueous NaHCO (1 M, 100 mL × 2), and the organic phase was retained, dried, and then evaporated to dryness. Compound 65-a (9.1 g) was obtained by column chromatography.

[0363] (2) Method for producing compound 65-b Compound 65-a (9.1 g) was dispersed in tetrahydrofuran (100 mL), cooled to 0-5°C, and a 1 M solution of LiAlH in tetrahydrofuran (105 mL) was added dropwise. The reaction was allowed to proceed at 0-5°C for 2 h. TLC showed that the reaction was complete. Water (7 mL), a 15% aqueous solution of NaOH (7 mL), and water (21 mL) were added dropwise to the reaction mixture, followed by filtration. The filtrate was dried, evaporated to dryness, and purified by column chromatography to give compound 65-b (4.5 g).

[0364] (3) Method for producing compound 65-c Compound 65-b (4.5 g) was dispersed in a hydrogen chloride / 1,4-dioxane solution (4 M, 56 mL) and reacted at 25 °C for 16 h, after which TLC showed the reaction was complete. The reaction mixture was concentrated, ethyl acetate (40 mL) was added, and the mixture was stirred at 25 °C for 1 h. The mixture was filtered, and the filter cake was baked to give compound 65-c (2.2 g).

[0365] (4) Manufacturing Method of Example 65 Compound O-2 (100 mg), compound 65-c (23 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 65 (8.6 mg). ESI-MS: m / z = 557.45 [M+H] + .

[0366] 1H NMR (500 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.37 (s, 1H), 7.93 (d, J = 7.0 Hz, 1H), 7.57 (d, J = 6.9 Hz, 1H), 7.28 (d, J = 8.2 Hz, 1H), 6.80 (s, 1H), 6.59 (d, J = 8.1 Hz, 1H), 5.36 (s, 1H), 4.34 - 4.24 (m, 2H), 4.10 - 4.03 (m, 2H), 3.76 (s, 3H), 3.63 (d, J = 6.7 Hz, 1H), 2.58 (s, 3H), 2.45 (t, J = 6.1 Hz, 1H), 2.36 - 2.31 (m, 1H), 2.27 (s, 6H), 2.03 (qd, J = 11.8, 6.8, 6.1 Hz, 3H), 1.85 (s, 1H), 1.79 - 1.71 (m, 1H), 1.14 (d, J = 6.3 Hz, 3H), 0.64 (dhept, J = 8.5, 5.0 Hz, 1H), 0.37 (tt, J = 9.1, 4.8 Hz, 1H), 0.00 (dq, J = 9.5, 5.3, 4.7 Hz, 1H), -0.07 (tt, J = 9.7, 4.8 Hz, 1H), -0.52 (dq, J = 9.7, 4.9 Hz, 1H). [Example]

[0367] JPEG2024543127000101.jpg20118(1) Manufacturing method of compound 66-a Compound N-tert-butoxycarbonyl-L-alanine (15.0 g) was dispersed in dichloromethane (200 mL), and dimethylamine hydrochloride (9.7 g), HATU (33.2 g), and N,N-diisopropylethylamine (30.7 g) were added in that order. The reaction was allowed to proceed at 25 °C for 16 h, after which TLC showed the reaction was complete. The reaction mixture was washed with aqueous NaHCO (1 M, 100 mL × 2), and the organic phase was retained, dried, and then evaporated to dryness. Compound 66-a (13.3 g) was obtained by column chromatography.

[0368] (2) Method for producing compound 66-b Compound 66-a (13.3 g) was dispersed in tetrahydrofuran (150 mL), cooled to 0-5°C, and a 1 M solution of LiAlH in tetrahydrofuran (154 mL) was added dropwise. The reaction was allowed to proceed at 0-5°C for 2 h. TLC showed that the reaction was complete. Water (11 mL), a 15% aqueous solution of NaOH (11 mL), and water (33 mL) were added dropwise to the reaction mixture, followed by filtration. The filtrate was dried, evaporated to dryness, and purified by column chromatography to give compound 66-b (5.7 g).

[0369] (3) Method for producing compound 66-c Compound 66-b (5.7 g) was dispersed in a 4 M hydrogen chloride / 1,4-dioxane solution (70 mL) and reacted at 25 °C for 16 h. TLC showed the reaction was complete. The reaction mixture was concentrated, ethyl acetate (50 mL) was added, and the mixture was stirred at 25 °C for 1 h. The mixture was filtered, and the filter cake was baked to give compound 66-c (3.0 g).

[0370] (4) Manufacturing Method of Example 66 Compound O-2 (100 mg), compound 66-c (23 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 66 (13 mg). ESI-MS: m / z = 557.45 [M+H] + .

[0371] 11H NMR (500 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.38 (s, 1H), 7.95 (s, 1H), 7.58 (s, 1H), 7.28 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 2.1 Hz, 1H), 6.58 (dd, J = 8.6, 2.0 Hz, 1H), 5.30 (d, J = 7.7 Hz, 1H), 4.33 (td, J = 8.6, 6.0 Hz, 1H), 4.26 (dd, J = 14.0, 3.6 Hz, 1H), 4.07 (td, J = 9.5, 4.1 Hz, 2H), 3.77 (s, 3H), 3.60 (p, J = 7.0 Hz, 1H), 2.58 (s, 3H), 2.33 (dd, J = 12.0, 5.5 Hz, 1H), 2.27 - 2.23 (m, 1H), 2.19 (s, 6H), 2.19 - 2.13 (m, 2H), 2.04 (ddt, J = 13.1, 8.8, 4.9 Hz, 1H), 1.86 (h, J = 7.3, 5.2 Hz, 1H), 1.75 (tt, J = 12.6, 5.9 Hz, 1H), 1.20 (d, J = 6.2 Hz, 3H), 0.64 (dhept, J = 8.5, 5.0 Hz, 1H), 0.36 (tt, J = 9.1, 4.8 Hz, 1H), 0.00 (dq, J = 9.5, 5.3, 4.7 Hz, 1H), -0.07 (tt, J = 9.7, 4.8 Hz, 1H), -0.53 (dq, J = 9.7, 4.9 Hz, 1H).

Example

[0372] JPEG2024543127000102.jpg32103 Compound O (100 mg), Compound 65-c (23 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 67 (10.1 mg). ESI-MS: m / z = 557.47 [M+H] + .

[0373] 11H NMR (500 MHz, DMSO-d6) δ 8.34 (s, 1H), 8.22 (s, 1H), 7.91 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.32 (d, J = 8.7 Hz, 1H), 6.79 (d, J = 2.2 Hz, 1H), 6.60 (dd, J = 8.7, 2.2 Hz, 1H), 4.31 - 4.26 (m, 1H), 4.22 (dd, J = 13.9, 3.6 Hz, 1H), 4.03 (ddd, J = 13.7, 9.7, 5.3 Hz, 2H), 3.73 (s, 3H), 3.46 (d, J = 6.7 Hz, 1H), 2.54 (s, 3H), 2.40 (dd, J = 12.1, 6.0 Hz, 1H), 2.23 (s, 6H), 2.22 - 2.19 (m, 1H), 2.14 (dp, J = 13.0, 7.4, 6.3 Hz, 1H), 1.98 (dq, J = 19.2, 7.5, 6.1 Hz, 1H), 1.80 (s, 1H), 1.74 - 1.65 (m, 1H), 1.25 (dd, J = 8.6, 5.0 Hz, 1H), 1.15 (d, J = 6.2 Hz, 3H), 0.59 (tt, J = 8.6, 3.7 Hz, 1H), 0.31 (tt, J = 9.2, 4.7 Hz, 1H), -0.05 (dq, J = 9.6, 4.9 Hz, 1H), -0.14 (tt, J = 9.2, 4.6 Hz, 1H), -0.58 (dq, J = 9.7, 4.9 Hz, 1H).

Example

[0374] JPEG2024543127000103.jpg32104 Compound O (100 mg), Compound 66-c (23 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 68 (15 mg). ESI-MS: m / z = 557.47 [M+H] + .

[0375] 1 H NMR (500 MHz, DMSO-d6) δ 12.44 (s, 1H), 8.39 (s, 1H), 7.96 (s, 1H), 7.59 (s, 1H), 7.37 (d, J = 8.8 Hz, 1H), 6.83 (s, 1H), 6.65 (d, J = 8.6 Hz, 1H), 4.34 (s, 1H), 4.27 (d, J = 13.5 Hz, 1H), 4.06 (d, J = 22.0 Hz, 2H), 3.78 (s, 3H), 2.59 (s, 3H), 2.40 (d, J = 12.0 Hz, 1H), 2.25 (s, 6H), 2.20 (d, J = 10.1 Hz, 2H), 2.05 (d, J = 13.1 Hz, 2H), 1.85 (h, J = 7.3, 5.2 Hz, 1H), 1.75 (tt, J = 12.6, 5.9 Hz, 1H), 1.21 (d, J = 6.3 Hz, 3H), 0.91 (s, 1H), 0.64 (s dhept, J = 8.5, 5.0 Hz, 1H), 0.36 (tt, J = 9.1, 4.8 Hz, 1H), -0.00 (dq, J = 9.5, 5.3, 4.7 Hz, 1H), -0.09 (tt, J = 9.7, 4.8 Hz, 1H), -0.53 (dq, J = 9.7, 4.9 Hz, 1H). [Example]

[0376] JPEG2024543127000104.jpg33108 Compound O (70 mg), N,N,2,2-tetramethyl-1,3-propylenediamine (20 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (19 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 95 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 69 (10 mg). ESI-MS: m / z = 585.41 [M+H] + .

[0377] 1 H NMR (500 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 7.54 (d, J = 1.3 Hz, 1H), 7.32 (d, J = 9.0 Hz, 1H), 6.80 (s, 1H), 6.72 - 6.62 (m, 2H), 4.29 (q, J = 7.7 Hz, 1H), 4.22 (dd, J = 14.0, 3.5 Hz, 1H), 4.06 - 4.00 (m, 2H), 3.73 (s, 3H), 3.51 (d, J = 3.0 Hz, 1H), 2.87 (s, 2H), 2.54 (s, 3H), 2.51 (s, 6H), 2.03 - 1.95 (m, 4H), 1.81 (d, J = 11.1 Hz, 1H), 1.73 - 1.68 (m, 1H), 0.96 (s, 6H), 0.61 - 0.56 (m, 1H), 0.30 (dd, J = 9.5, 5.5 Hz, 1H), -0.00 (m, 1H), -0.14 - -0.19 (m, 1H), -0.60 (dd, J = 9.5, 4.9 Hz, 1H). [Example]

[0378] JPEG2024543127000105.jpg32111 Compound O (75 mg), 1-(3-aminopropyl)pyrrolidine (36 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 70 (20 mg). ESI-MS: m / z = 583.40 [M+H] + .

[0379] 1 H NMR (500 MHz, chloroform-d) δ 12.09 (s, 1H), 8.41 (s, 1H), 8.15 (s, 1H), 7.71 (s, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.62 (d, J = 8.7 Hz, 1H), 6.49 (s, 1H), 4.41 - 4.31 (m, 2H), 3.93 (dq, J = 20.6, 6.0 Hz, 2H), 3.79 (s, 3H), 3.23 (q, J = 5.8 Hz, 2H), 2.96 (t, J = 5.9 Hz, 2H), 2.86 (s, 4H), 2.64 (s, 3H), 2.27 (d, J = 7.3 Hz, 1H), 2.21 - 2.14 (m, 2H), 2.00 (q, J = 7.0 Hz, 2H), 1.92 (s, 4H), 1.83 - 1.76 (m, 2H), 0.51 (s, 1H), 0.46 - 0.38 (m, 1H), 0.09 (t, J = 10.5 Hz, 1H), -0.02 - -0.10 (m, 1H), -0.34 (dd, J = 9.4, 5.1 Hz, 1H). [Example]

[0380] JPEG2024543127000106.jpg34111 Compound O (100 mg), 1-(3-aminopropyl)piperidine (54 mg), Pd2(dba)3 (35 mg), 2-(di-t-butylphosphine)biphenyl (23 mg), and potassium t-butoxide (128 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 71 (19 mg). ESI-MS: m / z = 597.42 [M+H] + .

[0381] 11H NMR (500 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.34 (s, 1H), 7.90 (s, 1H), 7.55 (d, J = 1.2 Hz, 1H), 7.32 (d, J = 8.8 Hz, 1H), 6.73 (d, J = 2.3 Hz, 1H), 6.56 (dd, J = 8.7, 2.2 Hz, 1H), 4.33 - 4.26 (m, 1H), 4.22 (dd, J = 13.9, 3.5 Hz, 1H), 4.07 - 3.97 (m, 2H), 3.73 (s, 3H), 3.02 (t, J = 6.9 Hz, 2H), 2.54 (s, 3H), 2.35 (t, J = 7.0 Hz, 3H), 2.32 (s, 2H), 2.21 (p, J = 6.6, 6.1 Hz, 1H), 2.13 (dq, J = 9.5, 4.3 Hz, 1H), 1.98 (dp, J = 13.2, 4.8, 4.3 Hz, 1H), 1.81 (d, J = 9.3 Hz, 1H), 1.71 (h, J = 6.3, 5.7 Hz, 3H), 1.51 (p, J = 5.6 Hz, 4H), 1.39 (q, J = 6.0 Hz, 2H), 1.25 (td, J = 10.8, 9.2, 4.7 Hz, 1H), 0.57 (tdd, J = 10.1, 6.5, 4.0 Hz, 1H), 0.30 (dp, J = 9.4, 4.6 Hz, 1H), -0.06 (dq, J = 9.5, 4.8 Hz, 1H), -0.16 (tt, J = 9.5, 4.6 Hz, 1H), -0.61 (dq, J = 9.7, 4.9 Hz, 1H).

Example

[0382] JPEG2024543127000107.jpg34111 Compound O (75 mg), 1-(2-aminoethyl)pyrrolidine (32 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 72 (16 mg). ESI-MS: m / z = 569.46 [M+H] + . 1 H NMR (500 MHz, chloroform-d) δ 12.09 (s, 1H), 8.41 (s, 1H), 8.15 (s, 1H), 7.71 (s, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.62 (d, J = 8.7 Hz, 1H), 6.49 (s, 1H), 4.41 - 4.31 (m, 2H), 3.93 (dq, J = 20.6, 6.0 Hz, 2H), 3.79 (s, 3H), 3.23 (q, J = 5.8 Hz, 2H), 2.96 (t, J = 5.9 Hz, 2H), 2.86 (s, 4H), 2.64 (s, 3H), 2.27 (d, J = 7.3 Hz, 1H), 2.21 - 2.14 (m, 2H), 1.92 (s, 4H), 1.83 - 1.76 (m, 2H), 0.51 (s, 1H), 0.46 - 0.38 (m, 1H), 0.09 (t, J = 10.5 Hz, 1H), -0.02 - -0.10 (m, 1H), -0.34 (dd, J = 9.4, 5.1 Hz, 1H). [Example]

[0383] JPEG2024543127000108.jpg33111 Compound O (75 mg), 1-(2-aminoethyl)piperidine (36 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 73 (31 mg). ESI-MS: m / z = 583.40 [M+H] + .

[0384] 1 H NMR (500 MHz, chloroform-d) δ 12.17 (s, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 8.16 (s, 1H), 7.75 (d, J = 1.4 Hz, 1H), 7.13 (d, J = 8.7 Hz, 1H), 6.65 (dd, J = 8.7, 2.1 Hz, 1H), 6.45 (d, J = 2.1 Hz, 1H), 4.35 (dd, J = 13.6, 3.9 Hz, 2H), 3.93 (ddt, J = 21.8, 13.8, 6.5 Hz, 2H), 3.79 (s, 3H), 3.18 (dq, J = 12.2, 6.7, 6.2 Hz, 2H), 2.95 (q, J = 6.8 Hz, 2H), 2.81 (s, 4H), 2.64 (s, 3H), 2.21 (ddt, J = 30.1, 22.6, 7.5 Hz, 3H), 1.80 (p, J = 5.9 Hz, 6H), 1.56 (s, 2H), 0.50 (d, J = 8.0 Hz, 1H), 0.42 (dq, J = 8.9, 4.7 Hz, 1H), 0.14 - 0.05 (m, 1H), -0.05 (dq, J = 10.0, 4.9 Hz, 1H), -0.35 (dq, J = 9.9, 5.1 Hz, 1H). [Example]

[0385] JPEG2024543127000109.jpg33115 Compound O (75 mg), N-(3-aminopropyl)morpholine (40 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 74 (31 mg). ESI-MS: m / z = 599.45 [M+H] + .

[0386] 1H NMR (500 MHz, クロロホルム-d) δ 12.03 (s, 1H), 8.44 - 8.38 (m, 1H), 8.15 (s, 1H), 7.68 (d, J = 1.3 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.58 (dd, J = 8.6, 2.1 Hz, 1H), 6.53 (d, J = 2.1 Hz, 1H), 4.40 - 4.32 (m, 2H), 3.94 (ddd, J = 16.7, 12.6, 6.5 Hz, 2H), 3.80 (d, J = 4.5 Hz, 4H), 3.78 (s, 3H), 3.16 (td, J = 6.4, 1.9 Hz, 2H), 2.64 (s, 3H), 2.62 (s, 2H), 2.60 (d, J = 7.1 Hz, 4H), 2.27 (q, J = 6.5 Hz, 1H), 2.20 - 2.11 (m, 2H), 1.87 (p, J = 6.6 Hz, 2H), 1.79 (td, J = 13.2, 12.2, 7.8 Hz, 2H), 0.51 (dq, J = 12.6, 3.6 Hz, 1H), 0.43 (dq, J = 8.8, 4.6 Hz, 1H), 0.10 (tt, J = 9.0, 5.2 Hz, 1H), -0.04 (q, J = 4.9 Hz, 1H), -0.33 (dq, J = 9.9, 5.1 Hz, 1H).

Example

[0387] JPEG2024543127000110.jpg17113(1) Manufacturing method of compound 75-a Compound O (1.0 g), carbamic acid t-butyl ester (437 mg), Pd2(dba)3 (430 mg), 2-(di-t-butylphosphine)biphenyl (280 mg), and potassium t-butoxide (1.26 g) were dispersed in t-amyl alcohol (20 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. The reaction was completed. Aqueous sodium bicarbonate solution (1 M, 100 mL) was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound 75-a (480 mg) was obtained by column chromatography. ESI-MS: m / z = 572.30 [M+H] + .

[0388] (2) Preparation of Compound 75-b Compound 75-a (480 mg) was dispersed in dichloromethane (10 mL) and trifluoroacetic acid (5 mL) was added dropwise at 25 °C. After the addition was complete, the mixture was allowed to react at 25 °C for 2 hours to complete the reaction. The reaction mixture was concentrated, and aqueous sodium bicarbonate solution (1 M, 20 mL) and ethyl acetate (30 mL) were added to the concentrate. The mixture was separated, and the organic phase was retained and concentrated until no liquid flowed out, yielding compound 75-b (350 mg). ESI-MS: m / z = 472.31 [M+H] + .

[0389] (3) Manufacturing Method of Example 75 Compound 75-b (30 mg) and N,N-dimethylglycine (7 mg) were dispersed in dichloromethane (5 mL), and HATU (29 mg) and triethylamine (19 mg) were added in that order. The reaction was allowed to proceed at 25 °C for 2 h, at which point the reaction was completed. The reaction mixture was washed with aqueous sodium bicarbonate (1 M, 5 mL), dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 75 (15 mg). ESI-MS: m / z = 557.32 [M+H] + .

[0390] 1H NMR (500 MHz, DMSO-d6) δ 9.84 (s, 1H), 8.36 (s, 1H), 8.09 (d, J = 1.9 Hz, 1H), 7.93 (s, 1H), 7.57 (dd, J = 8.7, 2.0 Hz, 1H), 7.50 - 7.37 (m, 2H), 4.32 - 4.25 (m, 2H), 4.9 - 4.01 (m, 2H), 3.75 (s, 3H), 3.13 (t, J = 7.1 Hz, 2H), 2.57 (s, 3H), 2.33 (s, 6H), 2.24 (q, J = 6.3 Hz, 1H), 2.14 (dt, J = 9.3, 4.9 Hz, 1H), 1.99 (td, J = 11.6, 8.9, 5.3 Hz, 1H), 1.86 - 1.70 (m, 2H), 0.60 (dq, J = 12.8, 7.9, 5.7 Hz, 1H), 0.37 (tt, J = 9.4, 4.8 Hz, 1H), -0.01 (dt, J = 9.8, 5.1 Hz, 1H), -0.05 (dp, J = 9.4, 4.7 Hz, 1H), -0.51 (dq, J = 9.6, 4.9 Hz, 1H). [Example]

[0391] Compound 75-b (30 mg) and 3-dimethylaminopropionic acid hydrochloride (9 mg) were dispersed in dichloromethane (5 mL), and HATU (29 mg) and triethylamine (19 mg) were added in sequence. The reaction was allowed to proceed at 25 °C for 2 h, at which point the reaction was completed. The reaction mixture was washed with aqueous sodium bicarbonate (1 M, 5 mL), dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 76 (14 mg). ESI-MS: m / z = 571.35 [M+H] + .

[0392] 1H NMR (500 MHz, DMSO-d6) δ 12.68 (s, 1H), 10.15 (s, 1H), 8.35 (s, 1H), 7.94 (d, J = 1.9 Hz, 1H), 7.91 (s, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.44 (dd, J = 8.7, 2.0 Hz, 1H), 4.32 - 4.25 (m, 2H), 4.13 - 4.08 (m, 1H), 4.05 - 4.01 (m, 1H), 3.73 (s, 3H), 2.70 (t, J = 7.1 Hz, 2H), 2.55 (s, 3H), 2.52 (d, J = 7.0 Hz, 2H), 2.28 (s, 6H), 2.21 (q, J = 6.3 Hz, 1H), 2.14 (dt, J = 9.3, 4.9 Hz, 1H), 1.99 (td, J = 11.6, 8.9, 5.3 Hz, 1H), 1.82 (d, J = 10.1 Hz, 1H), 1.76 - 1.68 (m, 1H), 0.60 (dq, J = 12.8, 7.9, 5.7 Hz, 1H), 0.29 (tt, J = 9.4, 4.8 Hz, 1H), -0.06 (dt, J = 9.8, 5.1 Hz, 1H), -0.23 (dp, J = 9.4, 4.7 Hz, 1H), -0.68 (dq, J = 9.6, 4.9 Hz, 1H). [Example]

[0393] JPEG2024543127000112.jpg32102 Compound 75-b (30 mg) and 4-dimethylaminobutyric acid hydrochloride (10 mg) were dispersed in dichloromethane (5 mL), and HATU (29 mg) and triethylamine (19 mg) were added in sequence. The reaction was allowed to proceed at 25 °C for 2 h, at which point the reaction was completed. The reaction mixture was washed with aqueous sodium bicarbonate (1 M, 5 mL), dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 77 (15 mg). ESI-MS: m / z = 585.35 [M+H] + . 1 1H NMR (500 MHz, DMSO-d6) δ 12.67 (s, 1H), 10.03 (s, 1H), 8.35 (s, 1H), 7.93 (d, J = 1.9 Hz, 1H), 7.91 (s, 1H), 7.55 (d, J = 9.1 Hz, 2H), 7.45 (dd, J = 8.7, 2.0 Hz, 1H), 4.32 - 4.24 (m, 2H), 4.13 - 4.08 (m, 1H), 4.04 (dt, J = 8.7, 5.8 Hz, 1H), 3.73 (s, 3H), 2.55 (s, 3H), 2.46 (t, J = 7.4 Hz, 2H), 2.36 (t, J = 7.4 Hz, 2H), 2.31 (s, 6H), 2.21 (t, J = 6.4 Hz, 1H), 2.14 (d, J = 6.0 Hz, 1H), 2.03 - 1.96 (m, 1H), 1.82 (d, J = 10.1 Hz, 1H), 1.79 (p, J = 7.4 Hz, 2H), 1.74 - 1.67 (m, 1H), 0.60 (dt, J = 9.1, 5.0 Hz, 1H), 0.30 (tt, J = 9.3, 4.8 Hz, 1H), -0.06 (dq, J = 9.7, 4.9 Hz, 1H), -0.23 (tt, J = 9.5, 4.8 Hz, 1H), -0.67 (dq, J = 9.6, 4.8 Hz, 1H).

Example

[0394] JPEG2024543127000113.jpg32111 Compound O (75 mg), 4-(2-aminoethyl)tetrahydropyran (36 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 78 (19 mg). ESI-MS: m / z = 584.44 [M+H] + .

[0395] 1 H NMR (500 MHz, chloroform-d) δ 11.97 (s, 1H), 8.39 (s, 1H), 8.15 (s, 1H), 7.66 (d, J = 1.2 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 6.58 (dd, J = 8.6, 2.2 Hz, 1H), 6.55 (d, J = 2.1 Hz, 1H), 4.35 (ddd, J = 11.4, 5.6, 3.0 Hz, 2H), 4.02 - 3.91 (m, 4H), 3.78 (s, 3H), 3.41 (td, J = 11.8, 1.9 Hz, 2H), 3.16 (t, J = 7.2 Hz, 2H), 2.64 (s, 3H), 2.33 - 2.24 (m, 1H), 2.23 - 2.13 (m, 2H), 1.80 - 1.77 (m, 1H), 1.68 - 1.61 (m, 8H), 0.56 - 0.49 (m, 1H), 0.44 (dq, J = 9.3, 4.8 Hz, 1H), 0.11 (tt, J = 9.1, 5.1 Hz, 1H), -0.03 (dd, J = 10.1, 5.3 Hz, 1H), -0.31 (dq, J = 10.0, 5.2 Hz, 1H).

[0396] [Example]

[0397] JPEG2024543127000114.jpg32111 Compound O (75 mg), cyclobutylamine (20 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 79 (30 mg). ESI-MS: m / z = 526.39 [M+H] + .

[0398] 1 H NMR (500 MHz, chloroform-d) δ 12.25 (s, 1H), 8.40 (s, 1H), 8.30 (s, 1H), 7.91 (s, 1H), 7.57 (s, 1H), 7.17 (d, J = 8.6 Hz, 1H), 7.03 - 6.96 (m, 1H), 4.41 (d, J = 13.9 Hz, 1H), 4.23 (d, J = 7.7 Hz, 1H), 4.09 (d, J = 7.9 Hz, 1H), 3.94 (d, J = 8.0 Hz, 1H), 3.88 (s, 3H), 2.49 (s, 3H), 2.33 (d, J = 25.2 Hz, 4H), 2.30 - 2.21 (m, 3H), 1.94 (q, J = 10.2 Hz, 3H), 1.75 (dt, J = 16.3, 7.9 Hz, 2H), 0.54 - 0.46 (m, 1H), 0.35 (dd, J = 9.2, 4.6 Hz, 1H), -0.12 (d, J = 3.0 Hz, 1H), -0.20 (dt, J = 9.8, 4.9 Hz, 1H), -0.65 (s, 1H). [Example]

[0399] JPEG2024543127000115.jpg34101 Compound O-2 (50 mg), 1-(3-aminopropyl)piperidine (16 mg), Pd2(dba)3 (20 mg), 2-(di-t-butylphosphine)biphenyl (13 mg), and potassium t-butoxide (61 mg) were dispersed in t-amyl alcohol (12 mL), purged with nitrogen gas three times, and reacted at 95 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 80 (25 mg). ESI-MS: m / z = 597.45 [M+H] + .

[0400] 11H NMR (500 MHz, DMSO-d6) δ 12.37 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.25 (d, J = 8.6 Hz, 1H), 6.68 (d, J = 2.1 Hz, 1H), 6.53 (dd, J = 8.6, 2.0 Hz, 1H), 4.28 (td, J = 8.6, 6.2 Hz, 1H), 4.22 (dd, J = 14.0, 3.6 Hz, 1H), 4.08 - 4.01 (m, 2H), 3.73 (s, 3H), 3.07 (t, J = 6.8 Hz, 2H), 2.54 (s, 3H), 2.36 (t, J = 7.1 Hz, 2H), 2.33 - 2.29 (m, 3H), 2.22 (p, J = 6.7, 6.3 Hz, 1H), 2.13 (tt, J = 8.6, 4.8 Hz, 1H), 2.00 (ddt, J = 13.7, 8.9, 3.9 Hz, 1H), 1.87 - 1.79 (m, 1H), 1.72 (p, J = 7.1 Hz, 3H), 1.50 (h, J = 5.1, 4.6 Hz, 4H), 1.39 (q, J = 5.9 Hz, 2H), 1.26 (dt, J = 17.5, 4.6 Hz, 1H), 0.65 - 0.55 (m, 1H), 0.32 (tt, J = 9.3, 4.6 Hz, 1H), -0.04 (dt, J = 9.4, 4.7 Hz, 1H), -0.11 (dp, J = 9.3, 4.5 Hz, 1H), -0.55 (dq, J = 9.6, 4.8 Hz, 1H).

Example

[0401] JPEG2024543127000116.jpg38107 Compound O-2 (70 mg), N-(3-aminopropyl)morpholine (22 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 95 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 81 (37 mg). ESI-MS: m / z = 599.42 [M+H] + .

[0402] 11H NMR (500 MHz, DMSO-d6) δ 12.30 (s, 1H), 7.91 (s, 1H), 7.54 (s, 1H), 7.25 (d, J = 8.5 Hz, 1H), 6.69 (d, J = 2.0 Hz, 1H), 6.53 (dd, J = 8.5, 2.1 Hz, 1H), 4.29 (q, J = 7.8 Hz, 1H), 4.22 (dd, J = 14.1, 3.6 Hz, 1H), 4.09 - 4.01 (m, 2H), 3.73 (s, 3H), 3.58 (t, J = 4.5 Hz, 4H), 3.09 (t, J = 6.8 Hz, 2H), 2.54 (s, 3H), 2.43 - 2.30 (m, 6H), 2.25 - 2.20 (m, 1H), 2.13 (dq, J = 14.5, 7.8, 6.2 Hz, 1H), 2.04 - 1.96 (m, 1H), 1.83 (d, J = 9.7 Hz, 1H), 1.73 (p, J = 7.3 Hz, 3H), 0.60 (tt, J = 8.5, 3.6 Hz, 1H), 0.32 (dp, J = 9.1, 4.6 Hz, 1H), -0.04 (dt, J = 9.8, 4.7 Hz, 1H), -0.12 (tt, J = 9.3, 4.6 Hz, 1H), -0.56 (dq, J = 9.7, 4.8 Hz, 1H).

Example

[0403] JPEG2024543127000117.jpg37102 Compound O-2 (75 mg), 1-(2-aminoethyl)pyrrolidine (32 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 82 (25 mg). ESI-MS: m / z = 569.40 [M+H] + .

[0404] 11H NMR (500 MHz, DMSO-d6) δ 12.44 (s, 1H), 8.39 (s, 1H), 8.30 (s, 1H), 7.96 (s, 1H), 7.59 (s, 1H), 7.31 (d, J = 8.6 Hz, 1H), 6.83 (s, 1H), 6.61 (dd, J = 8.5, 2.0 Hz, 1H), 4.34 (d, J = 7.8 Hz, 1H), 4.27 (dd, J = 13.9, 3.6 Hz, 1H), 4.13 - 4.07 (m, 2H), 3.78 (s, 3H), 3.29 (t, J = 6.7 Hz, 2H), 2.83 (t, J = 6.6 Hz, 2H), 2.71 (d, J = 5.9 Hz, 4H), 2.59 (s, 3H), 2.26 (q, J = 6.8 Hz, 1H), 2.18 (tt, J = 8.9, 4.8 Hz, 1H), 2.05 (ddd, J = 13.9, 9.2, 5.0 Hz, 1H), 1.91 - 1.86 (m, 1H), 1.80 (q, J = 3.4, 3.0 Hz, 4H), 1.75 (d, J = 14.2 Hz, 1H), 0.67 (tt, J = 8.5, 3.7 Hz, 1H), 0.37 (tt, J = 9.4, 4.9 Hz, 1H), 0.00 (dq, J = 9.7, 5.1 Hz, 1H), -0.08 (dq, J = 8.9, 4.6 Hz, 1H), -0.53 (dq, J = 9.8, 4.8 Hz, 1H).

Example

[0405] JPEG2024543127000118.jpg38101 Compound O-2 (60 mg), 1-(2-aminoethyl)piperidine (18 mg), Pd2(dba)3 (25 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (74 mg) were dispersed in t-amyl alcohol (15 mL), purged with nitrogen gas three times, and reacted at 95 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 83 (25 mg). ESI-MS: m / z = 583.41 [M+H] + .

[0406] 11H NMR (500 MHz, DMSO-d6) δ 12.38 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.54 (s, 1H), 7.26 (d, J = 8.6 Hz, 1H), 6.77 (d, J = 2.1 Hz, 1H), 6.56 (dd, J = 8.6, 2.0 Hz, 1H), 4.30 - 4.27 (m, 1H), 4.24 - 4.20 (m, 1H), 4.05 (dt, J = 9.1, 4.5 Hz, 2H), 3.73 (s, 3H), 3.20 (t, J = 6.7 Hz, 2H), 2.58 (t, J = 6.7 Hz, 2H), 2.54 (s, 3H), 2.28 (d, J = 6.6 Hz, 1H), 2.21 (q, J = 6.6, 6.1 Hz, 1H), 2.17 - 2.11 (m, 1H), 2.02 - 1.98 (m, 1H), 1.84 (q, J = 7.5 Hz, 1H), 1.72 (d, J = 13.5 Hz, 1H), 1.55 (p, J = 5.6 Hz, 4H), 1.44 - 1.39 (m, 3H), 1.24 (dd, J = 6.2, 3.6 Hz, 2H), 0.61 (qd, J = 10.4, 8.3, 5.1 Hz, 1H), 0.31 (dp, J = 8.7, 4.6 Hz, 1H), -0.03 - -0.07 (m, 1H), -0.13 (tt, J = 9.2, 4.5 Hz, 1H), -0.58 (dq, J = 9.6, 4.9 Hz, 1H).

Example

[0407] JPEG2024543127000119.jpg37103 Compound O-2 (50 mg), 1-(3-aminopropyl)pyrrolidine (14 mg), Pd2(dba)3 (20 mg), 2-(di-t-butylphosphine)biphenyl (13 mg), and potassium t-butoxide (61 mg) were dispersed in t-amyl alcohol (12 mL), purged with nitrogen gas three times, and reacted at 95 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 84 (25 mg). ESI-MS: m / z = 583.41 [M+H] + .

[0408] 1H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.36 (s, 1H), 8.25 (s, 1H), 7.99 (s, 1H), 7.59 (s, 1H), 7.36 (d, J = 8.6 Hz, 1H), 6.80 (s, 1H), 6.55 (dd, J = 8.5, 2.0 Hz, 1H), 4.37 (d, J = 7.8 Hz, 1H), 4.29 (dd, J = 13.9, 3.6 Hz, 1H), 4.17 - 4.01 (m, 2H), 3.77 (s, 3H), 3.25 (t, J = 6.7 Hz, 2H), 2.80 (t, J = 6.6 Hz, 2H), 2.71 (d, J = 5.9 Hz, 4H), 2.55 (s, 3H), 2.28 (q, J = 6.8 Hz, 1H), 2.20 (tt, J = 8.9, 4.8 Hz, 1H), 2.15 (q, J = 7.0 Hz, 2H), 2.03 (ddd, J = 13.9, 9.2, 5.0 Hz, 1H), 1.91 - 1.86 (m, 1H), 1.80 (q, J = 3.4, 3.0 Hz, 4H), 1.75 (d, J = 14.2 Hz, 1H), 0.67 (tt, J = 8.5, 3.7 Hz, 1H), 0.37 (tt, J = 9.4, 4.9 Hz, 1H), 0.00 (dq, J = 9.7, 5.1 Hz, 1H), -0.08 (dq, J = 8.9, 4.6 Hz, 1H), -0.53 (dq, J = 9.8, 4.8 Hz, 1H).

Example

[0409] JPEG2024543127000120.jpg20117(1) Manufacturing method of compound 85-a Compound BOC-N-methyl-L-alanine (10.0 g) was dispersed in dichloromethane (150 mL), and dimethylamine hydrochloride (6.0 g), HATU (20.6 g), and N,N-diisopropylethylamine (19.1 g) were added in that order. The reaction was allowed to proceed at 25 °C for 16 h, after which TLC showed the reaction was complete. The reaction mixture was washed with aqueous NaHCO (1 M, 100 mL × 2), and the organic phase was retained, dried, and then evaporated to dryness. Compound 85-a (9.3 g) was obtained by column chromatography.

[0410] (2) Preparation of Compound 85-b Compound 85-a (9.3 g) was dispersed in tetrahydrofuran (120 mL), cooled to 0-5°C, and a 1 M solution of LiAlH in tetrahydrofuran (101 mL) was added dropwise while maintaining the temperature. The reaction was allowed to proceed at 0-5°C for 2 h, and TLC showed that the reaction was complete. Water (10 mL), a 15% aqueous NaOH solution (10 mL), and water (30 mL) were added dropwise to the reaction mixture, followed by filtration. The filtrate was dried, evaporated to dryness, and then purified by column chromatography to give compound 85-b (4.6 g).

[0411] (3) Method for producing compound 85-c Compound 85-b (4.6 g) was dispersed in a hydrogen chloride / 1,4-dioxane solution (4 M, 53 mL) and reacted at 25°C for 16 h, after which TLC showed the reaction was complete. The reaction mixture was concentrated, ethyl acetate (50 mL) was added, and the mixture was stirred at 25°C for 1 h. The mixture was filtered, and the filter cake was baked to give compound 85-c (2.50 g).

[0412] (4) Manufacturing Method of Example 85 Compound O-2 (100 mg), compound 85-c (25 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 hours to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to obtain Example 85 (10 mg). ESI-MS: m / z = 571.35 [M+H] + .

[0413] 1H NMR (500 MHz, DMSO-d6) δ 12.55 (s, 1H), 8.41 (s, 1H), 7.96 (s, 1H), 7.60 (s, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.25 (d, J = 2.3 Hz, 1H), 6.96 (dd, J = 8.9, 2.3 Hz, 1H), 4.53 - 4.44 (m, 1H), 4.37 (dt, J = 8.6, 4.4 Hz, 1H), 4.33 - 4.23 (m, 2H), 4.08 (dt, J = 8.9, 5.7 Hz, 1H), 3.78 (s, 3H), 3.54 (dd, J = 13.5, 10.7 Hz, 1H), 3.20 (dd, J = 13.7, 4.3 Hz, 1H), 2.86 (s, 6H), 2.77 (s, 3H), 2.60 (s, 3H), 2.33 - 2.25 (m, 1H), 2.20 (tq, J = 8.9, 4.5 Hz, 1H), 2.08 (ddd, J = 15.5, 10.2, 6.0 Hz, 1H), 1.90 (td, J = 9.2, 4.8 Hz, 1H), 1.83 - 1.73 (m, 1H), 1.06 (d, J = 6.5 Hz, 3H), 0.69 (tq, J = 8.4, 4.3, 3.4 Hz, 1H), 0.35 (tt, J = 9.2, 4.7 Hz, 1H), -0.00 (dq, J = 9.6, 5.0 Hz, 1H), -0.19 (tt, J = 9.3, 4.7 Hz, 1H), -0.61 (dq, J = 9.6, 4.9 Hz, 1H).

Example

[0414] JPEG2024543127000121.jpg19112(1) Manufacturing method of compound 86-a Compound BOC-N-methyl-D-alanine (10.0 g) was dispersed in dichloromethane (150 mL), and dimethylamine hydrochloride (6.0 g), HATU (20.6 g), and N,N-diisopropylethylamine (19.1 g) were added in that order. The reaction was allowed to proceed at 25 °C for 16 h, after which TLC showed the reaction was complete. The reaction mixture was washed with aqueous NaHCO (1 M, 100 mL × 2), and the organic phase was retained, dried, and then evaporated to dryness. Compound 86-a (8.9 g) was obtained by column chromatography.

[0415] (2) Method for producing compound 86-b Compound 86-a (8.9 g) was dispersed in tetrahydrofuran (100 mL), cooled to 0-5°C, and a 1 M solution of LiAlH in tetrahydrofuran (103 mL) was added dropwise while maintaining the temperature. The reaction was allowed to proceed at 0-5°C for 2 h, and TLC showed that the reaction was complete. Water (7 mL), a 15% aqueous NaOH solution (7 mL), and water (21 mL) were added dropwise to the reaction mixture, followed by filtration. The filtrate was dried, evaporated to dryness, and then purified by column chromatography to give compound 86-b (4.2 g).

[0416] (3) Method for producing compound 86-c Compound 86-b (4.2 g) was dispersed in a hydrogen chloride / 1,4-dioxane solution (4 M, 52 mL) and reacted at 25°C for 16 h, after which TLC showed the reaction was complete. The reaction mixture was concentrated, ethyl acetate (40 mL) was added, and the mixture was stirred at 25°C for 1 h. The mixture was filtered, and the filter cake was baked to give compound 86-c (2.0 g).

[0417] (4) Manufacturing Method of Example 86 Compound O-2 (100 mg), compound 86-c (25 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 hours to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 86 (11 mg). ESI-MS: m / z = 571.35 [M+H] + . [Example]

[0418] JPEG2024543127000122.jpg32102 Compound O-2 (60 mg), cyclopentylamine (12 mg), Pd2(dba)3 (25 mg), 2-(di-t-butylphosphine)biphenyl (16 mg), and potassium t-butoxide (74 mg) were dispersed in t-amyl alcohol (17 mL), purged with nitrogen gas three times, and reacted at 95 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 87 (25 mg). ESI-MS: m / z = 540.45 [M+H] + .

[0419] 11H NMR (500 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.34 (d, J = 1.2 Hz, 1H), 7.90 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 6.68 (d, J = 2.0 Hz, 1H), 6.53 (dd, J = 8.6, 2.0 Hz, 1H), 5.57 (s, 1H), 4.28 (td, J = 8.5, 6.1 Hz, 1H), 4.23 (dd, J = 13.9, 3.6 Hz, 1H), 4.08 - 4.00 (m, 2H), 3.76 (t, J = 6.4 Hz, 1H), 3.73 (s, 3H), 2.54 (s, 3H), 2.27 - 2.19 (m, 1H), 2.13 (tt, J = 8.7, 4.9 Hz, 1H), 1.98 (dddd, J = 23.9, 12.4, 6.1, 1.9 Hz, 3H), 1.80 (dq, J = 9.1, 4.5 Hz, 1H), 1.70 (dp, J = 21.0, 7.3, 6.3 Hz, 3H), 1.57 (qd, J = 7.7, 3.5 Hz, 2H), 1.51 - 1.39 (m, 2H), 0.65 - 0.57 (m, 1H), 0.33 (tt, J = 9.1, 4.6 Hz, 1H), -0.04 (dt, J = 9.5, 4.7 Hz, 1H), -0.1' (td, J = 8.6, 4.3 Hz, 1H), -0.55 (dq, J = 9.5, 4.8 Hz, 1H).

Example

[0420] JPEG2024543127000123.jpg37117 Compound O (75 mg), 3-(trifluoromethyl)oxetan-3-amine (50 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 88 (6 mg). ESI-MS: m / z = 596.20 [M+H] + .

[0421] 1 H NMR (500 MHz, chloroform-d) δ 12.01 (s, 1H), 8.39 (d, J = 1.4 Hz, 1H), 8.15 (s, 1H), 7.65 (d, J = 1.4 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H), 6.54 - 6.47 (m, 2H), 4.95 (dd, J = 7.1, 1.2 Hz, 2H), 4.83 (d, J = 7.0 Hz, 2H), 4.35 (tt, J = 13.5, 4.8 Hz, 2H), 3.96 (dt, J = 8.4, 5.8 Hz, 2H), 3.78 (s, 3H), 3.35 - 3.27 (m, 2H), 2.64 (s, 3H), 2.26 (dt, J = 14.0, 6.1 Hz, 1H), 2.18 (td, J = 11.9, 11.0, 4.7 Hz, 2H), 0.52 (dt, J = 12.7, 5.6 Hz, 1H), 0.46 (dq, J = 8.2, 4.4, 3.5 Hz, 1H), 0.15 - 0.09 (m, 1H), -0.01 (d, J = 8.2 Hz, 1H), -0.31 (dq, J = 9.9, 5.1 Hz, 1H). [Example]

[0422] JPEG2024543127000124.jpg35105 Compound O (75 mg), 1-(3-methyloxetan-3-yl)ethan-1-amine hemioxalate (32 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 89 (16 mg). ESI-MS: m / z = 570.44 [M+H] + .

[0423] 1H NMR (500 MHz, クロロホルム-d) δ 11.95 (s, 1H), 8.40 (s, 1H), 8.16 (s, 1H), 7.67 (s, 1H), 7.17 (d, J = 8.5 Hz, 1H), 6.67 - 6.59 (m, 2H), 4.60 (dd, J = 6.2, 1.7 Hz, 1H), 4.55 (dd, J = 6.0, 2.6 Hz, 1H), 4.38 (dd, J = 6.2, 1.7 Hz, 2H), 4.36 - 4.33 (m, 1H), 3.95 (dt, J = 14.2, 7.5 Hz, 2H), 3.84 (q, J = 6.5 Hz, 1H), 3.78 (s, 3H), 3.72 (q, J = 7.0 Hz, 2H), 2.65 (s, 3H), 2.27 (q, J = 7.6 Hz, 1H), 2.19 (ddd, J = 12.3, 8.6, 5.3 Hz, 2H), 1.85 - 1.79 (m, 1H), 1.39 (s, 3H), 1.12 (dd, J = 6.4, 2.7 Hz, 3H), 0.58 - 0.49 (m, 1H), 0.45 (tt, J = 8.8, 4.2 Hz, 1H), 0.13 (tt, J = 8.9, 4.8 Hz, 1H), -0.00 - -0.04 (m, 1H), -0.29 (dt, J = 9.5, 4.9 Hz, 1H).

Example

[0424] JPEG2024543127000125.jpg36106 Compound O (75 mg), 3-ethyloxetan-3-amine hydrochloride (39 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 90 (10 mg). ESI-MS: m / z = 556.42 [M+H] + .

[0425] 1 H NMR (500 MHz, chloroform-d) δ 11.96 (s, 1H), 8.39 (s, 1H), 8.15 (s, 1H), 7.65 (s, 1H), 7.17 (d, J = 8.6 Hz, 1H), 6.45 (dd, J = 8.6, 2.2 Hz, 1H), 6.39 (d, J = 2.2 Hz, 1H), 4.77 (dd, J = 6.1, 2.7 Hz, 2H), 4.62 (d, J = 6.0 Hz, 2H), 4.34 (td, J = 13.0, 12.1, 5.3 Hz, 2H), 3.95 (dt, J = 18.1, 6.5 Hz, 2H), 3.78 (s, 3H), 2.64 (s, 3H), 2.28 (t, J = 6.9 Hz, 1H), 2.15 (dd, J = 13.9, 6.7 Hz, 3H), 1.82 (t, J = 7.5 Hz, 1H), 1.74 (s, 2H), 0.91 (t, J = 7.3 Hz, 3H), 0.52 (dq, J = 8.4, 4.2, 3.3 Hz, 1H), 0.46 (dq, J = 8.7, 4.4 Hz, 1H), 0.15 (tt, J = 9.4, 5.2 Hz, 1H), -0.02 (d, J = 5.2 Hz, 1H), -0.27 (dt, J = 9.6, 5.1 Hz, 1H). [Example]

[0426] JPEG2024543127000126.jpg36105 Compound O (75 mg), (2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidine hydrochloride (56 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 91 (31 mg). ESI-MS: m / z = 618.39 [M+H] + .

[0427] 1H NMR (500 MHz, クロロホルム-d) δ 12.01 (s, 1H), 8.39 (s, 1H), 8.15 (s, 1H), 7.67 (s, 1H), 7.20 (d, J = 8.6 Hz, 1H), 6.47 (dt, J = 8.5, 2.5 Hz, 1H), 6.44 (q, J = 2.8 Hz, 1H), 4.35 (td, J = 11.9, 9.8, 5.1 Hz, 2H), 4.25 (q, J = 8.0 Hz, 1H), 3.93 (dq, J = 14.0, 5.3, 4.5 Hz, 3H), 3.78 (s, 3H), 3.46 (dt, J = 14.0, 7.2 Hz, 1H), 3.28 (dq, J = 13.7, 5.7, 4.5 Hz, 2H), 3.00 - 2.96 (m, 1H), 2.95 (s, 3H), 2.63 (s, 3H), 2.27 (q, J = 6.4 Hz, 1H), 2.17 (dd, J = 16.8, 11.7 Hz, 2H), 1.79 (d, J = 15.3 Hz, 2H), 1.59 (d, J = 6.0 Hz, 3H), 0.56 - 0.48 (m, 1H), 0.43 (tt, J = 9.0, 5.0 Hz, 1H), 0.09 (tt, J = 9.1, 5.1 Hz, 1H), -0.04 (dt, J = 9.9, 4.8 Hz, 1H), -0.34 (dq, J = 9.9, 5.1 Hz, 1H).

Example

[0428] JPEG2024543127000127.jpg35104 Compound O (75 mg), (3-ethyloxetan-3-yl)methylamine (32 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 92 (10 mg). ESI-MS: m / z = 570.20 [M+H] + .

[0429] 1 H NMR (500 MHz, chloroform-d) δ 12.02 (s, 1H), 8.42 (s, 1H), 8.18 (s, 1H), 7.68 (s, 1H), 7.18 (d, J = 8.5 Hz, 1H), 6.65 (dd, J = 8.6, 2.2 Hz, 1H), 6.61 (d, J = 2.2 Hz, 1H), 4.51 (s, 4H), 4.35 (td, J = 12.0, 10.3, 5.2 Hz, 2H), 3.95 (dq, J = 9.3, 5.5 Hz, 2H), 3.79 (s, 3H), 3.31 (s, 2H), 2.65 (s, 3H), 2.21 (dtt, J = 30.7, 11.8, 5.6 Hz, 4H), 1.83 - 1.81 (m, 1H), 1.32 (d, J = 11.2 Hz, 1H), 0.95 (t, J = 7.4 Hz, 3H), 0.88 (t, J = 6.8 Hz, 1H), 0.52 (tt, J = 8.6, 3.9 Hz, 1H), 0.44 (tt, J = 9.2, 5.0 Hz, 1H), 0.11 (tt, J = 9.2, 5.1 Hz, 1H), -0.00 - -0.08 (m, 1H), -0.32 (dq, J = 10.1, 5.2 Hz, 1H). [Example]

[0430] JPEG2024543127000128.jpg36104 Compound O (75mg), N 1 ,N 1 A suspension of 32 mg of dimethylcyclobutane-1,3-diamine, 32 mg of Pd2(dba)3, 21 mg of 2-(di-t-butylphosphine)biphenyl, and 94 mg of potassium t-butoxide was dissolved in 5 mL of t-amyl alcohol. The mixture was purged with nitrogen three times and reacted at 90 °C for 2 h. The reaction was then completed. A 1 M aqueous solution of sodium bicarbonate (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 93 (25 mg). ESI-MS: m / z = 569.43 [M+H] + .

[0431] 1H NMR (500 MHz, Methanol-d4) δ 8.46 (s, 1H), 8.37 (d, J = 2.6 Hz, 1H), 8.02 (s, 1H), 7.57 (t, J = 8.5 Hz, 1H), 7.26 (t, J = 9.6 Hz, 1H), 6.67 - 6.57 (m, 2H), 4.31 (td, J = 18.0, 16.6, 11.1 Hz, 2H), 4.10 - 3.86 (m, 3H), 3.74 (s, 3H), 3.40 (t, J = 8.1 Hz, 1H), 2.94 - 2.84 (m, 1H), 2.76 (d, J = 10.0 Hz, 6H), 2.68 - 2.61 (m, 1H), 2.55 (s, 3H), 2.38 (dt, J = 14.3, 5.2 Hz, 1H), 2.20 (s, 2H), 2.05 (dt, J = 19.5, 10.0 Hz, 2H), 1.87 - 1.70 (m, 2H), 0.51 (d, J = 8.5 Hz, 1H), 0.34 (dq, J = 8.8, 4.7 Hz, 1H), -0.11 (dt, J = 18.2, 7.7 Hz, 2H), -0.58 (dt, J = 10.0, 5.3 Hz, 1H). [Example]

[0432] JPEG2024543127000129.jpg31105 Compound O (75 mg), 3-fluorocyclobutanamine (25 mg), Pd2(dba)3 (32 mg), 2-(di-t-butylphosphine)biphenyl (21 mg), and potassium t-butoxide (94 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 94 (15 mg). ESI-MS: m / z = 544.36 [M+H] + .

[0433] 1 H NMR (500 MHz, Methanol-d4) δ 8.46 (s, 1H), 8.15 (s, 1H), 7.70 (d, J = 4.5 Hz, 1H), 7.31 (d, J = 8.6 Hz, 1H), 6.71 (d, J = 8.3 Hz, 1H), 6.67 (s, 1H), 5.35 (ddt, J = 56.3, 6.6, 2.5 Hz, 1H), 4.47 - 4.30 (m, 2H), 4.19 - 4.05 (m, 2H), 3.95 (t, J = 11.1 Hz, 1H), 3.85 (s, 3H), 2.73 (ddd, J = 19.7, 10.0, 6.0 Hz, 2H), 2.66 (s, 3H), 2.51 - 2.39 (m, 2H), 2.34 - 2.24 (m, 2H), 2.15 - 2.03 (m, 1H), 1.85 (s, 2H), 0.67 - 0.53 (m, 1H), 0.44 (d, J = 8.5 Hz, 1H), 0.01 (q, J = 6.7, 6.1 Hz, 2H), -0.46 (q, J = 6.2, 5.6 Hz, 1H). [Example]

[0434] JPEG2024543127000130.jpg35105 Compound O (100 mg), 3,3-difluorocyclobutanamine (55 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 95 (18 mg). ESI-MS: m / z = 562.36 [M+H] + .

[0435] 1H NMR (500 MHz, Methanol-d4) δ 8.32 (s, 1H), 8.01 (s, 1H), 7.55 (s, 1H), 7.26 - 7.16 (m, 1H), 6.60 (d, J = 8.2 Hz, 2H), 4.33 - 4.26 (m, 1H), 4.22 (s, 1H), 3.95 (s, 1H), 3.88 - 3.74 (m, 2H), 3.71 (s, 3H), 3.01 (dt, J = 13.7, 7.1 Hz, 2H), 2.53 (s, 3H), 2.45 (d, J = 14.7 Hz, 2H), 2.22 - 2.09 (m, 2H), 1.96 (s, 1H), 1.72 (s, 2H), 0.46 (s, 1H), 0.31 (d, J = 8.8 Hz, 1H), -0.08 - -0.19 (m, 2H), -0.54 - -0.64 (m, 1H). [Example]

[0436] Compound O (100 mg), 3,3-difluorocyclopentylamine (46 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 96 (30 mg). ESI-MS: m / z = 576.38 [M+H] + .

[0437] 1H NMR (500 MHz, Methanol-d4) δ 8.35 (s, 1H), 8.02 (s, 1H), 7.58 (s, 1H), 7.20 (d, J = 8.4 Hz, 1H), 6.72 - 6.59 (m, 2H), 4.30 (q, J = 7.5, 6.9 Hz, 1H), 4.23 (d, J = 12.6 Hz, 1H), 4.02 - 3.89 (m, 2H), 3.85 (s, 1H), 3.72 (s, 3H), 2.59 (s, 1H), 2.54 (s, 3H), 2.32 - 2.22 (m, 2H), 2.21 - 2.06 (m, 3H), 1.98 (dt, J = 15.1, 7.3 Hz, 2H), 1.74 (dt, J = 24.0, 10.6 Hz, 3H), 0.47 (s, 1H), 0.32 (d, J = 9.3 Hz, 1H), -0.12 (t, J = 6.6 Hz, 2H), -0.58 (s, 1H). [Example]

[0438] JPEG2024543127000132.jpg35108 Compound O (100 mg), 4,4-difluorocyclohexylamine (51 mg), Pd2(dba)3 (35 mg), 2-(di-t-butylphosphine)biphenyl (23 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 90 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 97 (38 mg). ESI-MS: m / z = 590.42 [M+H] + .

[0439] 1H NMR (500 MHz, Methanol-d4) δ 8.47 (s, 1H), 8.15 (s, 1H), 7.70 (s, 1H), 7.30 (d, J = 8.6 Hz, 1H), 6.86 - 6.75 (m, 2H), 4.42 (q, J = 8.4, 7.4 Hz, 1H), 4.33 (d, J = 12.9 Hz, 1H), 4.09 (q, J = 6.4 Hz, 1H), 3.96 (t, J = 12.0 Hz, 1H), 3.84 (s, 3H), 3.48 (d, J = 11.6 Hz, 1H), 2.66 (s, 3H), 2.35 - 2.25 (m, 2H), 2.23 - 2.14 (m, 4H), 2.02 (dt, J = 42.9, 13.2 Hz, 3H), 1.84 (s, 2H), 1.69 (d, J = 12.0 Hz, 2H), 0.58 (d, J = 12.3 Hz, 1H), 0.44 (q, J = 7.3, 6.1 Hz, 1H), 0.04 - -0.05 (m, 2H), -0.45 (q, J = 6.6 Hz, 1H). [Example]

[0440] JPEG2024543127000133.jpg34107 Compound O-2 (100mg), N 1 ,N 1 A suspension of 25 mg of dimethylcyclobutane-1,3-diamine, 18 mg of Pd2(dba)3, 16 mg of 2-(di-t-butylphosphine)biphenyl, and 126 mg of potassium t-butoxide was dissolved in 4 mL of t-amyl alcohol. The mixture was purged with nitrogen three times and reacted at 95°C for 3 hours. The reaction mixture was then added with water and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 98 (13 mg). ESI-MS: m / z = 569.43 [M+H] + .

[0441] 1H NMR (500 MHz, DMSO-d6) δ 12.37 (s, 1H), 8.33 (s, 1H), 8.22 (s, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.24 (d, J = 8.5 Hz, 1H), 6.64 (d, J = 2.1 Hz, 1H), 6.50 (dd, J = 8.6, 2.1 Hz, 1H), 4.29 (d, J = 7.1 Hz, 1H), 4.22 (dd, J = 14.0, 3.7 Hz, 1H), 4.04 (td, J = 9.1, 4.0 Hz, 2H), 3.73 (s, 3H), 2.63 - 2.56 (m, 2H), 2.54 (s, 3H), 2.43 - 2.39 (m, 1H), 2.22 (dd, J = 12.8, 6.6 Hz, 1H), 2.14 (q, J = 5.4, 4.8 Hz, 1H), 2.06 (s, 6H), 2.00 - 1.97 (m, 1H), 1.81 (d, J = 8.6 Hz, 1H), 1.77 - 1.69 (m, 1H), 1.66 - 1.55 (m, 2H), 1.46 (t, J = 7.3 Hz, 1H), 0.61 (tt, J = 8.4, 3.5 Hz, 1H), 0.33 (dq, J = 9.0, 4.8 Hz, 1H), -0.05 (dq, J = 9.4, 4.8 Hz, 1H), -0.14 (tt, J = 9.4, 4.6 Hz, 1H), -0.58 (dq, J = 9.7, 4.9 Hz, 1H).

Example

[0442] JPEG2024543127000134.jpg36112 Compound O-2 (100mg), Sushi-N 1 ,N 1A suspension of 48 mg of dimethylcyclohexane-1,4-diamine dihydrochloride, 43 mg of Pd2(dba)3, 28 mg of 2-(di-t-butylphosphine)biphenyl, and 126 mg of potassium t-butoxide was added to 4 mL of t-amyl alcohol. The mixture was purged with nitrogen three times and reacted at 95°C for 3 hours. The reaction mixture was then added with water and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 99 (15 mg). ESI-MS: m / z = 597.49 [M+H] + .

[0443] 1 H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.38 (s, 1H), 8.31 (s, 1H), 7.95 (s, 1H), 7.58 (d, J = 1.1 Hz, 1H), 7.28 (d, J = 8.6 Hz, 1H), 6.79 (d, J = 2.0 Hz, 1H), 6.66 (dd, J = 8.7, 2.0 Hz, 1H), 4.32 (dd, J = 8.9, 2.8 Hz, 1H), 4.26 (dd, J = 14.0, 3.7 Hz, 1H), 4.11 - 4.04 (m, 2H), 3.77 (s, 3H), 2.58 (s, 3H), 2.39 - 2.36 (m, 1H), 2.33 (s, 6H), 2.26 (q, J = 6.7, 6.2 Hz, 1H), 2.17 (dq, J = 9.1, 4.7, 3.9 Hz, 1H), 2.04 (dq, J = 14.9, 5.0, 4.3 Hz, 2H), 1.87 - 1.72 (m, 6H), 1.66 - 1.57 (m, 4H), 0.68 - 0.61 (m, 1H), 0.37 (tt, J = 9.2, 4.6 Hz, 1H), 0.00 (dq, J = 9.5, 4.9 Hz, 1H), -0.08 (tt, J = 9.4, 4.6 Hz, 1H), -0.50 (dq, J = 9.5, 4.8 Hz, 1H). [Example]

[0444] JPEG2024543127000135.jpg35108 Compound O-2 (100 mg), trans-N 1 ,N 1 40 mg of dimethylcyclohexane-1,4-diamine hydrochloride, 43 mg of Pd2(dba)3, 28 mg of 2-(di-t-butylphosphine)biphenyl, and 126 mg of potassium t-butoxide were dispersed in 4 mL of t-amyl alcohol, purged with nitrogen gas three times, and then reacted at 95°C for 3 hours. The reaction mixture was then added with 30 mL of water and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 100 (20 mg). ESI-MS: m / z = 597.49 [M+H] + .

[0445] 11H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.37 (s, 1H), 8.31 (s, 1H), 7.94 (s, 1H), 7.58 (s, 1H), 7.26 (d, J = 8.6 Hz, 1H), 6.75 (d, J = 2.0 Hz, 1H), 6.56 (dd, J = 8.5, 2.0 Hz, 1H), 4.32 (td, J = 8.4, 5.8 Hz, 1H), 4.26 (dd, J = 14.0, 3.7 Hz, 1H), 4.08 (td, J = 9.0, 3.8 Hz, 2H), 3.77 (s, 3H), 2.58 (s, 3H), 2.48 - 2.39 (m, 1H), 2.35 (s, 6H), 2.26 (dt, J = 12.1, 5.9 Hz, 1H), 2.17 (dq, J = 8.8, 4.2, 3.5 Hz, 1H), 2.14 - 1.99 (m, 4H), 1.95 - 1.84 (m, 3H), 1.80 - 1.72 (m, 1H), 1.49 - 1.38 (m, 2H), 1.18 (ddt, J = 23.8, 13.0, 6.5 Hz, 2H), 0.68 - 0.58 (m, 1H), 0.37 (tt, J = 9.2, 4.6 Hz, 1H), -0.00 (dt, J = 9.5, 4.7 Hz, 1H), -0.08 (dp, J = 9.4, 4.7 Hz, 1H), -0.48 - -0.54 (m, 1H).

Example

[0446] JPEG2024543127000136.jpg35102 Compound 75-b (30 mg) and morpholin-4-ylacetic acid (8 mg) were dispersed in dichloromethane (5 mL), and HATU (29 mg) and triethylamine (19 mg) were added in sequence. The reaction was allowed to proceed at 25 °C for 2 h, at which point the reaction was completed. The reaction mixture was washed with aqueous sodium bicarbonate (1 M, 5 mL), dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 101 (12 mg). ESI-MS: m / z = 599.35 [M+H] + .

[0447] 1 H NMR (500 MHz, DMSO-d6) δ 12.69 (s, 1H), 9.84 (s, 1H), 8.35 (s, 1H), 7.98 (d, J = 2.0 Hz, 1H), 7.91 (s, 1H), 7.57 (d, J = 9.8 Hz, 2H), 7.45 (dd, J = 8.8, 2.0 Hz, 1H), 4.33 - 4.24 (m, 2H), 4.17 - 4.09 (m, 1H), 4.04 (dt, J = 8.9, 5.8 Hz, 1H), 3.73 (s, 3H), 3.65 (t, J = 4.5 Hz, 4H), 3.15 (s, 2H), 2.55 (s, 3H), 2.53 (t, J = 4.3 Hz, 4H), 2.25 - 2.18 (m, 1H), 2.18 - 2.11 (m, 1H), 2.03 - 1.96 (m, 1H), 1.84 (t, J = 8.9 Hz, 1H), 1.70 (q, J = 5.9 Hz, 1H), 0.60 (dq, J = 8.5, 5.0, 3.4 Hz, 1H), 0.30 (tt, J = 9.2, 4.9 Hz, 1H), -0.06 (dq, J = 9.8, 5.0 Hz, 1H), -0.23 (tt, J = 9.3, 4.8 Hz, 1H), -0.68 (dq, J = 9.6, 4.8 Hz, 1H). [Example]

[0448] JPEG2024543127000137.jpg32104 Compound O (70 mg), 3-aminocyclopentanol hydrochloride (22 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Purification by preparative liquid chromatography yielded Example 102 (10 mg). ESI-MS: m / z = 556.36 [M+H] + . [Example]

[0449] JPEG2024543127000138.jpg33103 Compound O (70 mg), 4-aminocyclohexanol (18 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to obtain Example 103 (12 mg). ESI-MS: m / z = 570.35 [M+H] + . [Example]

[0450] JPEG2024543127000139.jpg31103 Compound O (70 mg), 4-aminocyclohexanone hydrochloride (23 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Purification by preparative liquid chromatography yielded Example 104 (8 mg). ESI-MS: m / z = 568.35 [M+H] + .

[0451] 1 H NMR (500 MHz, chloroform-d) δ 12.11 (s, 1H), 8.61 (s, 1H), 8.40 (s, 1H), 8.17 (s, 1H), 7.71 (s, 1H), 7.15 (d, J = 8.5 Hz, 1H), 6.52 (d, J = 7.8 Hz, 2H), 4.45 - 4.37 (m, 2H), 3.98 (p, J = 5.9 Hz, 2H), 3.77 (s, 3H), 3.16 (d, J = 12.0 Hz, 1H), 2.92 (d, J = 12.4 Hz, 1H), 2.54 (s, 3H), 2.29 (ddd, J = 24.9, 15.6, 6.9 Hz, 2H), 2.17 - 2.09 (m, 2H), 2.02 (s, 2H), 1.83 - 1.74 (m, 2H), 1.48 (t, J = 10.5 Hz, 2H), 1.26 (t, J = 6.0 Hz, 2H), 0.47 - 0.39 (m, 1H), 0.28 (dq, J = 10.0, 5.1 Hz, 1H), 0.10 (dd, J = 10.2, 5.3 Hz, 1H), -0.07 (s, 1H), -0.51 (dq, J = 10.2, 5.0 Hz, 1H). [Example]

[0452] JPEG2024543127000140.jpg33100 Compound O (70 mg), (1R,2S)-2-fluorocyclopropylamine tosylate (39 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. 30 mL of water was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to obtain Example 105 (8 mg). ESI-MS: m / z = 530.31 [M+H] + . [Example]

[0453] JPEG2024543127000141.jpg32103 Compound O (100 mg), 3-aminocyclobutanol (20 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 106 (15 mg). ESI-MS: m / z = 542.30 [M+H] + . [Example]

[0454] JPEG2024543127000142.jpg31102 Compound O (100 mg), 3-aminocyclobutanone (20 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 107 (10 mg). ESI-MS: m / z = 540.31 [M+H] + . [Example]

[0455] JPEG2024543127000143.jpg31102 Compound O (100 mg), 1-methyl-4-(methylamino)piperidine (29 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 108 (15 mg). ESI-MS: m / z = 583.40 [M+H] + .

[0456] 1H NMR (500 MHz, chloroform-d) δ 12.18 (s, 1H), 8.41 (s, 1H), 8.15 (s, 1H), 7.69 (s, 1H), 7.22 (d, J = 9.1 Hz, 1H), 6.82 (dd, J = 6.5, 2.6 Hz, 2H), 4.42 - 4.32 (m, 2H), 3.95 (tt, J = 14.1, 6.4 Hz, 2H), 3.79 (s, 3H), 3.57 (td, J = 10.9, 4.7 Hz, 1H), 3.30 (d, J = 11.8 Hz, 2H), 2.79 (s, 3H), 2.62 (s, 3H), 2.58 (s, 3H), 2.52 (d, J = 12.0 Hz, 2H), 2.27 (q, J = 6.6 Hz, 1H), 2.22 - 2.08 (m, 4H), 1.82 (dd, J = 30.8, 9.5 Hz, 4H), 0.52 (dt, J = 12.6, 6.6 Hz, 1H), 0.44 (dq, J = 8.6, 4.7, 4.1 Hz, 1H), 0.10 (tt, J = 9.3, 5.2 Hz, 1H), -0.01 - -0.07 (m, 1H), -0.33 (dq, J = 9.9, 5.1 Hz, 1H). [Example]

[0457] JPEG2024543127000144.jpg33103 Compound O (100mg), N 1 ,N 1 29 mg of dimethylcyclopentane-1,3-diamine, 43 mg of Pd2(dba)3, 28 mg of 2-(di-t-butylphosphine)biphenyl, and 126 mg of potassium t-butoxide were dispersed in 3 mL of t-amyl alcohol. The mixture was purged with nitrogen three times and reacted at 100 °C for 2 h. The reaction was then completed. A 1 M aqueous solution of sodium bicarbonate (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 109 (23 mg). ESI-MS: m / z = 583.41 [M+H]+ . [Example]

[0458] JPEG2024543127000145.jpg32103 Compound O (100mg), N 1 ,N 1 ,N 4 A suspension of 35 mg of 1,4-trimethylcyclohexane-1,4-diamine, 43 mg of Pd2(dba)3, 28 mg of 2-(di-t-butylphosphine)biphenyl, and 126 mg of potassium t-butoxide was dissolved in 3 mL of t-amyl alcohol. The mixture was purged with nitrogen three times and reacted at 100°C for 2 hours. The reaction was then completed. A 1M aqueous solution of sodium bicarbonate (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 110 (10 mg). ESI-MS: m / z = 611.43 [M+H] + . [Example]

[0459] JPEG2024543127000146.jpg17111

[0460] (1) Method for producing compound 111-a Compound O-2 (1.0 g), carbamic acid t-butyl ester (437 mg), Pd2(dba)3 (430 mg), 2-(di-t-butylphosphine)biphenyl (280 mg), and potassium t-butoxide (1.26 g) were dispersed in t-amyl alcohol (20 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h. The reaction was completed. Aqueous sodium bicarbonate solution (1 M, 100 mL) was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. Compound 111-a (420 mg) was obtained by column chromatography. ESI-MS: m / z = 572.31 [M+H] + .

[0461] (2) Method for producing compound 111-b Compound 111-a (420 mg) was dispersed in dichloromethane (10 mL) and trifluoroacetic acid (5 mL) was added dropwise at 25 °C. After the addition was complete, the mixture was allowed to react at 25 °C for 2 hours to complete the reaction. The reaction mixture was concentrated, and aqueous sodium bicarbonate solution (1 M, 20 mL) and ethyl acetate (30 mL) were added to the concentrate. The mixture was separated, and the organic phase was retained and concentrated until no liquid flowed out, yielding compound 111-b (300 mg). ESI-MS: m / z = 472.32 [M+H] + .

[0462] (3) Manufacturing Method of Example 111 Compound 111-b (30 mg) and N,N-dimethylglycine (7 mg) were dispersed in dichloromethane (5 mL), and HATU (29 mg) and triethylamine (19 mg) were added in that order. The reaction was completed at 25 °C for 2 h. The reaction mixture was washed with aqueous sodium bicarbonate (1 M, 5 mL), dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 111 (13 mg). ESI-MS: m / z = 557.34 [M+H] + .

[0463] 1H NMR (500 MHz, DMSO-d6) δ 12.66 (s, 1H), 9.85 (s, 1H), 8.34 (s, 1H), 8.07 (d, J = 1.9 Hz, 1H), 7.91 (s, 1H), 7.56 (d, J = 1.2 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.40 (dd, J = 8.6, 1.8 Hz, 1H), 4.32 - 4.26 (m, 2H), 4.07 - 4.04 (m, 1H), 4.00 (dd, J = 13.9, 8.6 Hz, 1H), 3.73 (s, 3H), 3.15 (d, J = 1.3 Hz, 2H), 2.55 (s, 3H), 2.34 (s, 6H), 2.23 (dt, J = 13.2, 6.8 Hz, 1H), 2.13 (q, J = 6.7, 5.4 Hz, 1H), 2.02 (dq, J = 13.9, 7.6, 6.3 Hz, 1H), 1.76 (ddt, J = 20.9, 13.0, 4.8 Hz, 2H), 0.58 (q, J = 8.1, 7.2 Hz, 1H), 0.35 (tt, J = 8.7, 4.5 Hz, 1H), 0.01 - -0.04 (m, 1H), -0.07 (dt, J = 8.8, 4.4 Hz, 1H), -0.52 (dq, J = 9.5, 4.7 Hz, 1H). [Example]

[0464] Compound 111-b (30 mg) and 3-dimethylaminopropionic acid hydrochloride (9 mg) were dispersed in dichloromethane (5 mL), and HATU (29 mg) and triethylamine (19 mg) were added in that order. The reaction was allowed to proceed at 25 °C for 2 hours, at which point the reaction was complete. The reaction mixture was washed with aqueous sodium bicarbonate (1 M, 5 mL), dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 112 (15 mg). ESI-MS: m / z = 571.36 [M+H] + .

[0465] 1 1H NMR (500 MHz, DMSO-d6) δ 12.67 (s, 1H), 10.19 (s, 1H), 8.34 (s, 1H), 8.07 (d, J = 1.9 Hz, 1H), 7.91 (s, 1H), 7.56 (d, J = 1.2 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.23 (dd, J = 8.6, 1.8 Hz, 1H), 4.28 (dt, J = 14.7, 5.4 Hz, 2H), 4.06 (dt, J = 7.3, 5.0 Hz, 1H), 3.98 (dd, J = 14.0, 8.4 Hz, 1H), 3.73 (s, 3H), 2.70 (t, J = 7.1 Hz, 2H), 2.55 (s, 3H), 2.52 (d, J = 6.9 Hz, 2H), 2.28 (s, 6H), 2.22 (h, J = 6.1, 5.3 Hz, 1H), 2.12 (td, J = 8.8, 4.3 Hz, 1H), 2.06 - 2.00 (m, 1H), 1.76 (qd, J = 14.0, 13.1, 8.5 Hz, 2H), 0.55 (qd, J = 8.0, 4.0 Hz, 1H), 0.36 (dp, J = 8.9, 4.4 Hz, 1H), -0.00 (q, J = 5.1, 4.5 Hz, 1H), -0.06 (tt, J = 9.8, 5.1 Hz, 1H), -0.51 (dq, J = 9.5, 4.7 Hz, 1H).

Example

[0467] 1 H NMR (500 MHz, DMSO-d6) δ 12.82 - 12.47 (m, 1H), 10.05 (s, 1H), 8.34 (s, 1H), 8.08 (s, 1H), 7.91 (s, 1H), 7.56 (s, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.24 (d, J = 8.6 Hz, 1H), 4.28 (q, J = 8.7 Hz, 2H), 4.04 (d, J = 7.0 Hz, 1H), 3.98 (dd, J = 13.9, 8.3 Hz, 1H), 3.73 (s, 3H), 2.55 (s, 3H), 2.35 (dd, J = 16.8, 8.8 Hz, 4H), 2.20 (s, 6H), 2.13 (t, J = 7.5 Hz, 1H), 2.05 (s, 1H), 1.75 (d, J = 11.7 Hz, 5H), 0.56 (s, 1H), 0.39 - 0.33 (m, 1H), -0.01 (q, J = 4.9 Hz, 1H), -0.06 (s, 1H), -0.47 - -0.55 (m, 1H).

[0468] [Example]

[0469] JPEG2024543127000149.jpg35101 Compound 111-b (30 mg) and morpholin-4-ylacetic acid (8 mg) were dispersed in dichloromethane (5 mL), and HATU (29 mg) and triethylamine (19 mg) were added in sequence. The reaction was completed at 25 °C for 2 h. The reaction mixture was washed with aqueous sodium bicarbonate (1 M, 5 mL), dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 114 (15 mg). ESI-MS: m / z = 599.36 [M+H] + .

[0470] 1 H NMR (500 MHz, chloroform-d) δ 9.24 (s, 1H), 8.40 (d, J = 1.3 Hz, 1H), 8.30 (d, J = 1.9 Hz, 1H), 8.15 (s, 1H), 7.65 (d, J = 1.3 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 6.96 (dd, J = 8.5, 1.9 Hz, 1H), 4.41 (dd, J = 13.8, 3.2 Hz, 1H), 4.37 - 4.32 (m, 1H), 4.04 (dd, J = 13.9, 7.5 Hz, 1H), 3.98 - 3.94 (m, 1H), 3.81 (t, J = 4.6 Hz, 4H), 3.79 (s, 3H), 3.20 (d, J = 1.3 Hz, 2H), 2.67 (t, J = 4.7 Hz, 4H), 2.64 (s, 3H), 2.29 (dt, J = 13.3, 6.6 Hz, 1H), 2.21 - 2.16 (m, 2H), 1.84 - 1.78 (m, 2H), 0.58 (dq, J = 13.1, 7.3, 5.4 Hz, 1H), 0.44 (tt, J = 9.0, 4.9 Hz, 1H), 0.13 (tt, J = 9.0, 5.1 Hz, 1H), -0.04 (dt, J = 10.0, 4.9 Hz, 1H), -0.33 (dq, J = 9.9, 5.0 Hz, 1H). [Example]

[0471] JPEG2024543127000150.jpg31103 Compound O-2 (100mg), N 1 -cyclopropyl-N 2 ,N 2 A suspension of 45 mg of dimethylethane-1,2-diamine dihydrochloride, 43 mg of Pd(dba)(II), 28 mg of 2-(di-t-butylphosphine)biphenyl, and 126 mg of potassium t-butoxide was dissolved in 3 mL of t-amyl alcohol. The mixture was purged with nitrogen three times and reacted at 100°C for 2 hours. The reaction mixture was then cooled to room temperature and then heated to 100°C for 2 hours. The reaction mixture was then added to a 1M aqueous solution of sodium bicarbonate (20 mL), extracted with ethyl acetate, and the combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed. The mixture was purified by preparative liquid chromatography to give Example 115 (10 mg). ESI-MS: m / z = 583.40 [M+H] + .

[0472] 1 H NMR (500 MHz, DMSO-d6) δ 12.46 (s, 1H), 8.38 (s, 1H), 7.94 (s, 1H), 7.59 (s, 1H), 7.39 (d, J = 8.9 Hz, 2H), 7.17 (s, 1H), 6.95 (d, J = 9.0 Hz, 1H), 4.30 (d, J = 23.1 Hz, 2H), 4.11 (d, J = 27.2 Hz, 2H), 3.76 (s, 3H), 2.58 (s, 3H), 2.43 (s, 4H), 2.17 (s, 6H), 2.05 (s, 2H), 1.88 - 1.73 (m, 3H), 0.90 (s, 3H), 0.66 (s, 1H), 0.63 - 0.57 (m, 1H), 0.49 (s, 1H), 0.35 (s, 1H), 0.00 (s, 1H), -0.06 - -0.14 (m, 1H), -0.56 (s, 1H). [Example]

[0473] JPEG2024543127000151.jpg34106 Compound O-2 (100mg), N 1 ,N 1 A suspension of 34 mg of dimethyl-N2-(methyl-d3)ethane-1,2-ethylenediamine dihydrochloride, 43 mg of Pd2(dba)3, 28 mg of 2-(di-t-butylphosphine)biphenyl, and 126 mg of potassium t-butoxide was dissolved in 3 mL of t-amyl alcohol. The mixture was purged with nitrogen three times and reacted at 100 °C for 2 h. The reaction mixture was then cooled to room temperature and then cooled to room temperature. The reaction mixture was then added to 1 M aqueous sodium bicarbonate (20 mL), extracted with ethyl acetate, and the combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed. The mixture was purified by preparative liquid chromatography to give Example 116 (22 mg). ESI-MS: m / z = 560.42 [M+H] + .

[0474] 11H NMR (500 MHz, DMSO-d6) δ 12.45 (s, 1H), 8.39 (s, 1H), 7.96 (s, 1H), 7.60 (s, 1H), 7.39 (d, J = 8.8 Hz, 1H), 6.93 (d, J = 2.3 Hz, 1H), 6.70 (dd, J = 8.8, 2.3 Hz, 1H), 4.34 (q, J = 7.9 Hz, 1H), 4.28 (dd, J = 14.0, 3.6 Hz, 1H), 4.18 (dd, J = 13.9, 9.2 Hz, 1H), 4.08 (dt, J = 8.7, 5.7 Hz, 1H), 3.78 (s, 3H), 3.57 (s, 1H), 3.47 (d, J = 2.3 Hz, 1H), 2.59 (s, 3H), 2.44 (ddd, J = 15.3, 10.5, 6.1 Hz, 2H), 2.26 (dd, J = 9.5, 4.6 Hz, 1H), 2.23 (s, 6H), 2.19 (td, J = 9.2, 8.3, 3.7 Hz, 1H), 2.06 (td, J = 12.6, 9.3, 5.4 Hz, 1H), 1.87 (d, J = 10.0 Hz, 1H), 1.81 - 1.72 (m, 1H), 0.68 (tt, J = 8.3, 3.3 Hz, 1H), 0.36 (tt, J = 9.2, 4.7 Hz, 1H), 0.00 (dq, J = 9.6, 4.9 Hz, 1H), -0.11 (dp, J = 9.5, 4.8 Hz, 1H), -0.55 (dq, J = 9.6, 4.9 Hz, 1H).

Example

[0475] JPEG2024543127000152.jpg31104 Compound O-2 (100 mg), 1-methyl-4-(methylamino)piperidine (29 mg), Pd2(dba)3 (43 mg), 2-(di-t-butylphosphine)biphenyl (28 mg), and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 117 (12 mg). ESI-MS: m / z = 583.40 [M+H] + .

[0476] 1H NMR (500 MHz, DMSO-d6) δ 12.47 (s, 1H), 8.39 (s, 1H), 8.27 (s, 1H), 7.95 (s, 1H), 7.59 (s, 1H), 7.39 (d, J = 8.7 Hz, 1H), 7.06 (s, 1H), 6.84 (d, J = 8.9 Hz, 1H), 4.33 (q, J = 7.8 Hz, 1H), 4.28 (dd, J = 14.0, 3.4 Hz, 1H), 4.20 (dd, J = 13.9, 8.9 Hz, 1H), 4.10 - 4.05 (m, 1H), 3.77 (s, 3H), 3.03 - 2.93 (m, 2H), 2.78 (s, 3H), 2.58 (s, 3H), 2.31 (s, 3H), 2.27 - 2.14 (m, 4H), 2.06 (dq, J = 13.0, 4.7, 3.9 Hz, 1H), 1.90 - 1.73 (m, 4H), 1.71 - 1.61 (m, 2H), 1.27 (d, J = 10.5 Hz, 1H), 0.67 (dq, J = 9.4, 5.2, 4.4 Hz, 1H), 0.35 (tt, J = 9.4, 4.8 Hz, 1H), 0.03 - -0.04 (m, 1H), -0.14 (tt, J = 9.2, 4.7 Hz, 1H), -0.54 (dq, J = 9.7, 4.8 Hz, 1H).

Example

[0477] JPEG2024543127000153.jpg33104 Compound O-2 (100 mg), N 1 ,N 129 mg of dimethylcyclopentane-1,3-diamine, 43 mg of Pd2(dba)3, 28 mg of 2-(di-t-butylphosphine)biphenyl, and 126 mg of potassium t-butoxide were dispersed in 3 mL of t-amyl alcohol. The mixture was purged with nitrogen three times and reacted at 100 °C for 2 h. The reaction was then completed. A 1 M aqueous solution of sodium bicarbonate (20 mL) was added to the reaction mixture, which was then extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 118 (30 mg). ESI-MS: m / z = 583.41 [M+H] + . [Example]

[0478] JPEG2024543127000154.jpg33110 Compound O (70 mg), 3-(oxan-4-yl)propan-1-amine (22 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 100 °C for 2 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 119 (10 mg). ESI-MS: m / z = 598.39 [M+H] + . [Example]

[0479] JPEG2024543127000155.jpg33101 Compound O (70 mg), t-butylamine (30 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 60 °C for 5 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 120 (8 mg). ESI-MS: m / z = 528.36 [M+H] + . [Example]

[0480] JPEG2024543127000156.jpg33100 Compound O (70 mg), cyclopropylamine (25 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 60 °C for 5 h to complete the reaction. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 121 (6 mg). ESI-MS: m / z = 512.34 [M+H] + . [Example]

[0481] JPEG2024543127000157.jpg33100 Compound O-2 (70 mg), cyclopropylamine (25 mg), Pd2(dba)3 (30 mg), 2-(di-t-butylphosphine)biphenyl (20 mg), and potassium t-butoxide (88 mg) were dispersed in t-amyl alcohol (3 mL), purged with nitrogen gas three times, and reacted at 60 °C for 5 h. The reaction was then completed. Aqueous sodium bicarbonate solution (1 M, 20 mL) was added to the reaction mixture, extracted with ethyl acetate, and the combined organic phase was dried over anhydrous sodium sulfate and concentrated until no liquid flowed out. The mixture was purified by preparative liquid chromatography to give Example 122 (8 mg). ESI-MS: m / z = 512.34 [M+H] + . [Example]

[0482] JPEG2024543127000158.jpg22122

[0483] (1) Method for producing compound 123-a Compound N-benzyloxycarbonyl-L-alanine (3.82 g) was dispersed in dichloromethane (50 mL) and dimethyl-d6-amine hydrochloride (1.65 g), TBTU (6.05 g), and N,N-diisopropylethylamine (8.5 mL) were added sequentially at 0-5 °C. After the addition was completed, the reaction was allowed to proceed at 25 °C for 16 h. TLC showed that the reaction was complete. The reaction solution was washed with sodium hydroxide solution (1 M, 100 mL × 2), and the organic phase was retained, dried, and then evaporated to dryness. Compound 123-a (3.93 g) was obtained by column chromatography.

[0484] (2) Method for producing compound 123-b Compound 123-a (3.93 g) was dispersed in tetrahydrofuran (20 mL) and cooled to 0-5 °C. Borane (1 M in THF, 46 mL) was added dropwise while maintaining the temperature. The reaction was allowed to proceed at 0-5 °C for 2 h. TLC showed that the reaction of the starting material was complete. Hydrochloric acid (12 M, 3.0 mL) was slowly added dropwise to the reaction mixture at 0-5 °C. After the addition was complete, the mixture was heated at 60 °C for 2 h. TLC showed that the intermediate phase had disappeared. The reaction mixture was cooled to 20-25 °C, poured into water (50 mL), and the pH was adjusted to 9-10 with saturated sodium bicarbonate solution. The aqueous phase was extracted with ethyl acetate (20 mL × 2). The combined organic phases were dried, evaporated to dryness, and purified by column chromatography to give compound 123-b (1.52 g).

[0485] (3) Method for producing compound 123-c Compound 123-b (1.52 g) was dispersed in methanol (40 mL), hydrochloric acid (12 M, 3.8 mL) and Pd / C (10%, 0.15 g) were added, and the mixture was purged with hydrogen gas three times. The mixture was heated to 50 °C and reacted for 5 h, after which TLC showed completion of the reaction. The reaction mixture was filtered through diatomaceous earth, and the filtrate was evaporated to dryness to give colorless oily liquid 123-c (0.83 g).

[0486] (4) Manufacturing Method of Example 123 123-c (68 mg) and potassium t-butoxide (126 mg) were dispersed in t-amyl alcohol (5 mL) and stirred at 20-25 °C for 5 min. Compound O-2 (100 mg), Pd2(dba)3 (26 mg), and 2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-triisopropyl-1,1'-biphenyl (30 mg) were added. The mixture was purged with nitrogen gas three times and reacted at 100 °C for 2 h. LC-MS showed the reaction was complete. The reaction mixture was added with 30 mL of water and extracted with ethyl acetate (20 mL × 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 123 (25 mg). ESI-MS: m / z = 563.55 [M+H] + .

[0487] 1 1H NMR (500 MHz, DMSO-d6) δ 12.43 (s, 1H), 8.38 (s, 1H), 7.95 (s, 1H), 7.58 (s, 1H), 7.30 (d, J = 8.5 Hz, 1H), 6.86 (s, 1H), 6.61 (d, J = 8.5 Hz, 1H), 4.37 - 4.31 (m, 1H), 4.30 - 4.24 (m, 1H), 4.09 (dd, J = 13.7, 8.8 Hz, 2H), 3.77 (s, 3H), 3.55 (s, 2H), 2.58 (s, 3H), 2.26 (d, J = 9.8 Hz, 1H), 2.18 (s, 1H), 2.04 (d, J = 7.1 Hz, 2H), 1.87 (s, 1H), 1.75 (d, J = 12.4 Hz, 1H), 1.20 (d, J = 6.2 Hz, 3H), 0.64 (s, 1H), 0.35 (d, J = 10.2 Hz, 1H), 0.00 (q, J = 4.9 Hz, 1H), -0.09 (s, 1H), -0.51 - -0.58 (m, 1H).

Example

[0488] JPEG2024543127000159.jpg2990123-c (102 mg) and potassium t-butoxide (189 mg) were dispersed in t-amyl alcohol (5 mL) and stirred at 20-25 °C for 5 min. Compound O (100 mg), Pd2(dba)3 (26 mg), and 2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-triisopropyl-1,1'-biphenyl (30 mg) were added. The mixture was purged with nitrogen gas three times and incubated in an oil bath at 100 °C for 2 h. LC-MS showed the reaction was complete. 30 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (20 mL × 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to obtain Example 124 (22 mg). ESI-MS: m / z = 563.48 [M+H] + .

[0489] 1 H NMR (500 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.34 (s, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.34 (d, J = 8.8 Hz, 1H), 6.81 (s, 1H), 6.63 (d, J = 8.8 Hz, 1H), 4.29 (q, J = 7.8 Hz, 1H), 4.22 (dd, J = 14.2, 3.6 Hz, 1H), 4.04 (q, J = 6.2, 5.3 Hz, 2H), 3.73 (s, 3H), 3.50 (s, 2H), 2.54 (s, 3H), 2.20 (s, 1H), 2.14 (s, 1H), 2.00 (d, J = 13.8 Hz, 2H), 1.81 (s, 1H), 1.73 - 1.66 (m, 1H), 1.15 (d, J = 6.2 Hz, 3H), 0.59 (s, 1H), 0.30 (dq, J = 9.2, 4.6 Hz, 1H), -0.06 (dd, J = 9.5, 5.0 Hz, 1H), -0.16 (s, 1H), -0.59 (q, J = 5.1 Hz, 1H). [Example]

[0490] JPEG2024543127000160.jpg2592 Compound O (120 mg), cis-N 1 ,N 1 A suspension of 31 mg of dimethylcyclobutane-1,3-diamine, 30 mg of Pd2(dba)3, 35 mg of 2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-triisopropyl-1,1'-biphenyl, and 148 mg of potassium t-butoxide in 5 mL of t-amyl alcohol was purged with nitrogen three times and incubated in a 100 °C oil bath for 3.0 h. LC-MS analysis indicated the reaction was complete. The reaction mixture was added with 30 mL of water and extracted with ethyl acetate (20 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 125 (25 mg). ESI-MS: m / z = 569.44 [M+H]. + .

[0491] 1H NMR (500 MHz, DMSO-d6) δ 12.38 (s, 1H), 8.40 (s, 1H), 7.97 (s, 1H), 7.61 (s, 1H), 7.39 (d, J = 8.7 Hz, 1H), 6.77 (s, 1H), 6.59 (d, J = 8.6 Hz, 1H), 4.35 (q, J = 7.8 Hz, 1H), 4.28 (dd, J = 14.0, 3.5 Hz, 1H), 4.09 (dq, J = 14.0, 4.6 Hz, 2H), 3.81 (d, J = 9.8 Hz, 1H), 3.79 (s, 3H), 2.91 (d, J = 7.5 Hz, 1H), 2.61 (s, 3H), 2.48 (t, J = 7.5 Hz, 1H), 2.30 - 2.24 (m, 1H), 2.20 (d, J = 13.1 Hz, 1H), 2.12 (s, 6H), 2.05 (d, J = 7.7 Hz, 2H), 1.87 (t, J = 8.5 Hz, 1H), 1.81 - 1.74 (m, 1H), 1.69 (q, J = 9.9, 9.1 Hz, 2H), 0.64 (h, J = 8.5, 7.3 Hz, 1H), 0.37 (tt, J = 9.1, 4.8 Hz, 1H), 0.00 (dq, J = 9.8, 5.0 Hz, 1H), -0.09 (dq, J = 8.8, 4.5 Hz, 1H), -0.53 (dt, J = 9.9, 5.1 Hz, 1H).

Example

[0492] JPEG2024543127000161.jpg2484Compound O (120mg), Torotronsu-N 1 ,N 1A suspension of 31 mg of dimethylcyclobutane-1,3-diamine, 30 mg of Pd2(dba)3, 35 mg of 2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-triisopropyl-1,1'-biphenyl, and 148 mg of potassium t-butoxide in 5 mL of t-amyl alcohol was purged with nitrogen three times and incubated in a 100 °C oil bath for 3.0 h. LC-MS analysis indicated completion of the reaction. The reaction mixture was added with 30 mL of water and extracted with ethyl acetate (20 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 126 (20 mg). ESI-MS: m / z = 569.46 [M+H]. + .

[0493] 1H NMR (500 MHz, DMSO-d6) δ 12.42 (s, 1H), 8.40 (s, 1H), 7.97 (s, 1H), 7.61 (d, J = 1.2 Hz, 1H), 7.39 (d, J = 8.7 Hz, 1H), 6.72 (d, J = 2.1 Hz, 1H), 6.56 (dd, J = 8.6, 2.2 Hz, 1H), 6.01 (d, J = 5.3 Hz, 1H), 4.35 (q, J = 7.8 Hz, 1H), 4.28 (dd, J = 14.0, 3.5 Hz, 1H), 4.13 - 4.05 (m, 2H), 3.81 (d, J = 9.8 Hz, 1H), 3.79 (s, 3H), 2.85 (p, J = 6.6 Hz, 1H), 2.61 (s, 3H), 2.28 (ddd, J = 13.0, 7.5, 5.7 Hz, 3H), 2.20 (dq, J = 8.8, 4.3, 3.4 Hz, 1H), 2.14 (s, 6H), 2.07 - 1.99 (m, 3H), 1.88 (d, J = 9.3 Hz, 1H), 1.77 (dd, J = 11.3, 6.0 Hz, 1H), 0.65 (ddt, J = 13.0, 8.6, 4.6 Hz, 1H), 0.37 (tt, J = 9.3, 4.8 Hz, 1H), 0.00 (dq, J = 9.6, 5.0 Hz, 1H), -0.09 (dq, J = 9.4, 4.9 Hz, 1H), -0.53 (dq, J = 9.8, 5.0 Hz, 1H).

Example

[0494] JPEG2024543127000162.jpg3198 Compound O-2 (60mg), Sushi-N 1 ,N 1A suspension of 31 mg of dimethylcyclobutane-1,3-diamine, 30 mg of Pd(dba)(II), 35 mg of 2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-triisopropyl-1,1'-biphenyl, and 148 mg of potassium t-butoxide in 5 mL of t-amyl alcohol was purged with nitrogen three times and incubated in a 100 °C oil bath for 3.0 h. LC-MS analysis showed the reaction was complete. The reaction mixture was diluted with 30 mL of water and extracted with ethyl acetate (20 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 127 (50 mg). ESI-MS: m / z = 569.46 [M+H]. + .

[0495] 1H NMR (500 MHz, DMSO-d6) δ 12.38 (s, 1H), 8.40 (s, 1H), 8.30 (s, 1H), 7.97 (d, J = 1.2 Hz, 1H), 7.58 (d, J = 8.7 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 6.60 - 6.49 (m, 2H), 4.33 - 4.25 (m, 2H), 4.06 (d, J = 5.7 Hz, 2H), 3.81 (d, J = 9.8 Hz, 1H), 3.77 (s, 3H), 3.08 (p, J = 6.6 Hz, 1H), 2.61 (s, 3H), 2.28 (ddd, J = 13.0, 7.5, 5.7 Hz, 3H), 2.20 (dq, J = 8.8, 4.3, 3.4 Hz, 1H), 2.26 (s, 6H), 2.10 - 1.98 (m, 3H), 1.84 (q, J = 8.0, 7.6 Hz, 1H), 1.80 - 1.73 (m, 1H), 0.65 (dq, J = 17.8, 8.2, 6.6 Hz, 1H), 0.36 (tt, J = 9.3, 4.5 Hz, 1H), -0.01 (dq, J = 9.8, 5.0 Hz, 1H), -0.09 (dq, J = 9.1, 4.4 Hz, 1H), -0.55 (dt, J = 9.8, 4.8 Hz, 1H).

Example

[0496] JPEG2024543127000163.jpg31108 Compound O-2 (120mg), Toroンス-N 1 ,N 1A suspension of 31 mg of dimethylcyclobutane-1,3-diamine, 30 mg of Pd(dba)(II), 35 mg of 2-(dicyclohexylphosphino)-3,6-dimethoxy-2'-4'-6'-triisopropyl-1,1'-biphenyl, and 148 mg of potassium t-butoxide in 5 mL of t-amyl alcohol was purged with nitrogen three times and incubated in a 100 °C oil bath for 3 h. LC-MS analysis showed the reaction was complete. The reaction mixture was added with 30 mL of water and extracted with ethyl acetate (20 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 128 (35 mg). ESI-MS: m / z = 569.49 [M+H]. + .

[0497] 1H NMR (500 MHz, DMSO-d6) δ 12.42 (s, 1H), 8.38 (s, 1H), 8.32 (s, 1H), 7.95 (d, J = 1.2 Hz, 1H), 7.58 (d, J = 8.7 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 6.60 - 6.49 (m, 2H), 4.33 - 4.25 (m, 2H), 4.06 (d, J = 5.7 Hz, 2H), 3.81 (d, J = 9.8 Hz, 1H), 3.77 (s, 3H), 3.08 (p, J = 6.6 Hz, 1H), 2.61 (s, 3H), 2.28 (ddd, J = 13.0, 7.5, 5.7 Hz, 3H), 2.20 (dq, J = 8.8, 4.3, 3.4 Hz, 1H), 2.26 (s, 6H), 2.10 - 1.98 (m, 3H), 1.84 (q, J = 8.0, 7.6 Hz, 1H), 1.80 - 1.73 (m, 1H), 0.64 (dq, J = 17.8, 8.2, 6.6 Hz, 1H), 0.37 (tt, J = 9.3, 4.5 Hz, 1H), 0.00 (dq, J = 9.8, 5.0 Hz, 1H), -0.07 (dq, J = 9.1, 4.4 Hz, 1H), -0.50 (dt, J = 9.8, 4.8 Hz, 1H).

Example

[0498] JPEG2024543127000164.jpg21119

[0499] (1) Method for producing compound 129-a (1S,3R)-3-Aminocyclopentanol hydrochloride (500 mg) was dispersed in tetrahydrofuran (10 mL), and a solution of sodium hydroxide (363 mg) in water (3 mL) and di-t-butyl dicarbonate (833 mg) were added sequentially. The reaction was allowed to proceed at 20-25 °C for 3 h. TLC showed the reaction was complete. 20 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL × 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding compound 129-a (731 mg), which was used directly in the next step without further purification.

[0500] (2) Method for producing compound 129-b Compound 129-a (731 mg) was dispersed in ethyl acetate (20 mL). The temperature was controlled at 5-15°C. Triethylamine (735 mg) and ethylsulfonyl chloride (513 mg) were added sequentially to the reaction mixture. The mixture was incubated at 5-15°C for 0.5 h, and TLC showed the reaction was complete. The reaction mixture was washed with water (20 mL × 2), and the ethyl acetate phase was retained, dried over anhydrous sodium sulfate, and concentrated until no liquid flowed out. Compound 129-b (1.06 g) was obtained, which was used directly in the next step without further purification.

[0501] (3) Method for producing compound 129-c Compound 129-b (1.06 g) was dispersed in N,N-dimethylformamide (20 mL), potassium carbonate (1.51 g), 4-dimethylaminopyridine (44 mg), and dimethylamine hydrochloride (5.92 g) were added in that order, and the mixture was incubated at 80 °C for 6 h. TLC showed the reaction was complete. 100 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL × 2). The combined organic phases were washed with water (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and then subjected to column chromatography to obtain liquid 129-c (238 mg).

[0502] (4) Preparation of Compound 129-d Compound 129-c (238 mg) was dispersed in a 4 M solution of hydrochloric acid in methanol (15 mL) and stirred at 20-25 °C for 1 h. TLC showed the reaction was complete. The reaction mixture was concentrated until no more liquid flowed out, redissolved in methanol (15 mL), and further concentrated until no more liquid flowed out to give compound 129-d (150 mg).

[0503] (5) Manufacturing Method of Example 129 Compound O (50 mg), 129-d (25 mg), Pd2(dba)3 (29 mg), 2-di-t-butylphosphino-2',4',6'-triisopropylbiphenyl (27 mg), and potassium t-butoxide (141 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and incubated in a 100 °C oil bath for 2 h. LC-MS showed the reaction was complete. 30 mL of water was added to the reaction mixture, followed by extraction with ethyl acetate (20 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, concentrated until no liquid flowed, and purified by preparative liquid chromatography to give Example 129 (22 mg). ESI-MS: m / z = 583.51 [M+H] + .

[0504] 1H NMR (500 MHz, chloroform-d) δ 12.05 (s, 1H), 8.39 (s, 1H), 8.15 (s, 1H), 7.67 (s, 1H), 7.16 (d, J = 8.5 Hz, 1H), 6.55 (d, J = 9.4 Hz, 2H), 4.37 - 4.33 (m, 2H), 3.99 - 3.93 (m, 2H), 3.78 (s, 3H), 3.42 (t, J = 8.6 Hz, 1H), 2.73 (s, 1H), 2.71 - 2.66 (m, 6H), 2.63 (s, 3H), 2.38 (dt, J = 15.9, 7.9 Hz, 2H), 2.28 (dd, J = 13.9, 6.9 Hz, 1H), 2.21 - 2.12 (m, 3H), 2.02 - 1.93 (m, 2H), 1.82 - 1.73 (m, 2H), 1.59 (p, J = 6.8 Hz, 1H), 0.51 (d, J = 9.6 Hz, 1H), 0.43 (tt, J = 8.8, 4.7 Hz, 1H), 0.11 (d, J = 10.1 Hz, 1H), -0.01 - -0.07 (m, 1H), -0.32 (dt, J = 10.2, 5.2 Hz, 1H). [Example]

[0505] JPEG2024543127000165.jpg4099 Compound O-2 (50 mg), 129-d (25 mg), Pd2(dba)3 (29 mg), 2-di-t-butylphosphino-2',4',6'-triisopropylbiphenyl (27 mg), and potassium t-butoxide (141 mg) were dispersed in t-amyl alcohol (5 mL), purged with nitrogen gas three times, and reacted in an oil bath at 100 °C for 2 h. LC-MS showed the reaction was complete. 30 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL × 2). The combined organic phase was dried over anhydrous sodium sulfate, concentrated until no liquid flowed out, and purified by preparative liquid chromatography to obtain Example 130 (20 mg). ESI-MS: m / z = 583.53 [M+H] + .

[0506] 1 H NMR (500 MHz, クロロホルム-d) δ 8.39 (d, J = 4.4 Hz, 3H), 8.15 (s, 1H), 7.64 (s, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.59 (s, 1H), 6.51 (d, J = 8.5 Hz, 1H), 4.35 (tt, J = 8.7, 4.4 Hz, 2H), 4.05 (h, J = 6.1, 5.4 Hz, 1H), 4.00 - 3.91 (m, 2H), 3.78 (s, 3H), 3.46 (t, J = 8.5 Hz, 1H), 2.74 (d, J = 13.9 Hz, 6H), 2.63 (s, 3H), 2.42 (q, J = 9.2, 8.2 Hz, 2H), 2.30 - 2.11 (m, 4H), 2.08 - 1.94 (m, 2H), 1.86 - 1.75 (m, 2H), 1.65 - 1.55 (m, 1H), 0.55 (dq, J = 12.8, 6.6 Hz, 1H), 0.42 (tq, J = 9.0, 4.5 Hz, 1H), 0.06 (td, J = 8.6, 4.6 Hz, 1H), -0.05 (dq, J = 9.1, 4.7 Hz, 1H), -0.37 (ddt, J = 32.8, 9.7, 5.0 Hz, 1H).

[0507]

Example

[0508] JPEG2024543127000166.jpg19113

[0509] (1) Method for producing compound 131-a (1S,3S)-3-Aminocyclopentanol hydrochloride (500 mg) was dispersed in tetrahydrofuran (10 mL), and a solution of sodium hydroxide (363 mg) in water (3 mL) and di-t-butyl dicarbonate (833 mg) were added sequentially. The reaction was allowed to proceed at 20-25 °C for 3 h. TLC showed the reaction was complete. 20 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL × 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated until no liquid flowed out, yielding...

Claims

1. The compound of formula I″ shown below: (In the formula, R 1 is C 3~5 Cycloalkyl, C 3~5 Cycloalkyl-C 1~3 Alkyl-, haloC 1~6 Alkyl, or C 1~6 Selected from alkyl, R 2 is hydrogen, halogen, OH, NH 2 , C 1~8 Alkyl, or C 1~8 alkoxy, where C 1~8 Alkyl or C 1~8 The alkoxy is optionally substituted by one or more R'; R' is halogen, OH, cyano, NH 2 , or nitro, R 3 is halogen, cyano, nitro, NH 2 , O.H., C. 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3- to 10-membered heterocyclyl, C 6~10 Aryl, 5- to 10-membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH 2 , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O) 2 H, -S(O) 2 R a , -S(O) 2 N.H. 2 , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a or -NHC(O)NHR a and C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3- to 10-membered heterocyclyl, C 6~10 The aryl or 5- to 10-membered heteroaryl may optionally be one or more R c is replaced by The R c is oxo, OH, NH 2 , halogen, cyano, nitro, C 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 Alkyl) 2 , -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O) 2 R a , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -C 1~6 Alkyl-S(O) 2 -C 1~6 Alkyl, or optionally OH, halogen or C 1~6 3-8 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; R a and R b each independently represents a group optionally substituted by one or more R″: 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3- to 10-membered heterocycloalkyl, C 6~10 aryl, or 5- to 10-membered heteroaryl; R″ is independently halogen, NH 2 , OH, oxo, deuterium, cyano, nitro, C 1~8 Alkyl, C 1~8 Alkoxy, HaloC 1~8 Alkyl, -N(C 1~8 Alkyl) 2 , -NH(C 1~8 Alkyl), C 3~6 cycloalkyl, or optionally C 1~8 3-10 membered heterocycloalkyl substituted by alkyl; n is selected from 0, 1, 2, 3, or 4; R 4 is C 1~6 Alkyl or C 3~5 cycloalkyl, However, R 1 C 1~6 When selected from alkyl, R 4 is C 3~5 cycloalkyl.), a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

2. The following formula I': (In the formula, R 1 is C 3~5 Cycloalkyl, C 3~5 Cycloalkyl-C 1~3 Alkyl-, haloC 1~6 Alkyl, or C 1~6 Selected from alkyl, R 2 is hydrogen, C 1~8 Alkyl, or C 1~8 alkoxy, where C 1~8 Alkyl or C 1~8 The alkoxy is optionally substituted by one or more R'; R' is selected from halogen, hydroxy, cyano, amino, or nitro; R 3 is halogen, cyano, nitro, NH 2 , O.H., C. 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3- to 10-membered heterocyclyl, C 6~10 Aryl, 5- to 10-membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH 2 , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O) 2 H, -S(O) 2 R a , -S(O) 2 N.H. 2 , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -NHC(O)OR a , or -N(C 1~4 alkyl)C(O)OR a and C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3- to 10-membered heterocyclyl, C 6~10 The aryl or 5- to 10-membered heteroaryl may optionally be one or more R c is replaced by The R c is oxo, halogen, cyano, nitro, C 1~8 Alkoxy, -N(C 1~8Alkyl) 2 , -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O) 2 R a , -S(O) 2 N.R. a R b , -NHS(O) 2 R a or optionally hydroxy, halogen or C 1~6 3-8 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; R a and R b each independently represents a group optionally substituted by one or more R″: 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~10 Cycloalkyl, 3- to 10-membered heterocycloalkyl, C 6~10 aryl, or 5- to 10-membered heteroaryl; R″ is independently halogen, NH 2 , OH, cyano, nitro, C 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 Alkyl) 2 , -NH(C 1~8 Alkyl), C 3~6 cycloalkyl, or 3- to 10-membered heterocycloalkyl; n is selected from 0, 1, 2, 3, or 4; R 4 is C 1~6 Alkyl or C 3~5 cycloalkyl, However, R 1 C 1~6 When selected from alkyl, R 4 is C 3~5cycloalkyl; a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof; 2. A compound of formula I'' according to claim 1, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

3. The R 1 is C 3~4 Cycloalkyl, C 3~4 Cycloalkyl-C 1~2 Alkyl-, haloC 1~3 Alkyl, or C 1~3 Selected from alkyl, Optionally, said R 1 is cyclopropyl, cyclopropyl-CH 2 -, halomethyl, or methyl; Optionally, said R 1 is cyclopropyl, cyclopropyl-CH 2 -, methyl substituted by one or more fluorines, or methyl; The compound according to any one of claims 1 to 2, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

4. R 2 is hydrogen, halogen, OH, NH 2 , C 1~6 Alkyl, or C 1~6 alkoxy, where C 1~6 Alkyl or C 1~6 The alkoxy is optionally substituted by one or more R'; Optionally, R 2 is hydrogen, halogen, OH, NH 2 , C 1~3 Alkyl, or C 1~3 alkoxy, where C 1~3 Alkyl or C 1~3 The alkoxy is optionally substituted by one or more R'; Optionally, R 2 is hydrogen, fluorine, chlorine, bromine, C 1~3 Alkyl, or C 1~3selected from alkoxy, Optionally, R 2 is fluorine, chlorine, bromine, or C 1~3 Selected from alkyl, Optionally, R 2 is selected from fluorine or methyl; Or, R 2 is hydrogen, C 1~6 Alkyl, or C 1~6 alkoxy, where C 1~6 Alkyl or C 1~6 The alkoxy is optionally substituted by one or more R'; Optionally, R 2 is hydrogen, C 1~3 Alkyl, or C 1~3 alkoxy, where C 1~3 Alkyl or C 1~3 The alkoxy is optionally substituted by one or more R'; Optionally, R 2 is hydrogen, C 1~3 Alkyl, or C 1~3 selected from alkoxy, Optionally, R 2 is C 1~3 Selected from alkyl, Optionally, R 2 is selected from methyl; The compound according to any one of claims 1 to 3, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

5. The compound according to any one of claims 1 to 4, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R' is selected from halogen.

6. R 3 is halogen, cyano, nitro, NH 2 , O.H., C. 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3-8 membered heterocyclyl, C 6~10Aryl, 5- to 6-membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH 2 , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O) 2 H, -S(O) 2 R a , -S(O) 2 N.H. 2 , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a or -NHC(O)NHR a and C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3-8 membered heterocyclyl, C 6~10 The aryl or 5- to 6-membered heteroaryl may optionally be one or more R c is replaced by Optionally, R 3 is halogen, cyano, nitro, NH 2 , O.H., C. 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a, -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH 2 , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O) 2 H, -S(O) 2 R a , -S(O) 2 N.H. 2 , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a or -NHC(O)NHR a and C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl are optionally joined by one or more R c is replaced by Optionally, R 3 is halogen, cyano, NH 2 , O.H., C. 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3- to 8-membered heterocyclyl, -NHR b , -NR a R b , -OR a , -SR a , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -NHS(O) 2 R a , -NHC(O)OR a, -N(C 1~4 alkyl)C(O)OR a or -NHC(O)NHR a and C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl or 3- to 8-membered heterocyclyl optionally includes one or more R c is replaced by Optionally, said R 3 is fluorine, chlorine, bromine, C 1~4 Alkyl, C 2~4 alkenyl, 4-6 membered heterocyclyl, -NHR b , -NR a R b , -OR a , -SR a , -OC(O)R a , -NHC(O)R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a or -NHC(O)NHR a and C 1~4 Alkyl, C 2~4 The alkenyl or 4- to 6-membered heterocyclyl may optionally be one or more R c is replaced by Optionally, said R 3 is fluorine, chlorine, bromine, C 1~3 Alkyl, C 2~4 alkenyl, 4-5 membered azacycloalkyl, -NHR b , -NR a R b , -OR a , -SR a , -OC(O)R a , -NHC(O)R a , -NHC(O)OR a , -N(C 1~4 alkyl)C(O)OR a or -NHC(O)NHR a and C 1~3 Alkyl, C 2~4The alkenyl or 4- to 5-membered azacycloalkyl may optionally be one or more R c is replaced by Optionally, said R 3 is bromine, methyl, butenyl, azetidinyl, pyrrolidinyl, -NHR b , -NR a R b , -OR a , -NHC(O)R a or -NHC(O)NHR a wherein said methyl, butenyl, azetidinyl, or pyrrolidinyl is optionally selected from one or more R c is replaced by Optionally, said R 3 is bromine, -N.H.R. b , -NR a R b , -OR a , -NHC(O)R a or -NHC(O)NHR a Selected from Optionally, said R 3 is -NHR b , -NR a R b , -OR a , -NHC(O)R a or -NHC(O)NHR a Selected from Optionally, said R 3 is -NHR b or -NR a R b Selected from Optionally, said R 3 is -OR a Selected from Optionally, said R 3 is -NHC(O)R a or -NHC(O)NHR a Selected from Or, R 3 is halogen, cyano, nitro, NH 2 , O.H., C. 1~6 Alkyl, C 2~6Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3-8 membered heterocyclyl, C 6~10 Aryl, 5- to 6-membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH 2 , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O) 2 H, -S(O) 2 R a , -S(O) 2 N.H. 2 , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -NHC(O)OR a , or -N(C 1~4 alkyl)C(O)OR a and C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 3-8 membered heterocyclyl, C 6~10 The aryl or 5- to 6-membered heteroaryl may optionally be one or more R c is replaced by Optionally, R 3 is halogen, cyano, nitro, NH 2 , O.H., C. 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH 2 , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~4 alkyl)C(O)R a , -S(O) 2 H, -S(O) 2 R a , -S(O) 2 N.H. 2 , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -NHC(O)OR a , or -N(C 1~4 alkyl)C(O)OR a and C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl may optionally be one or more R c is replaced by Optionally, R 3 is halogen, cyano, nitro, NH 2 , O.H., C. 1~3 Alkyl, C 2~3 Alkenyl, C 2~3 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl, -NHR b , -NR a R b , -OR a , -SR a , -C(O)H, -C(O)R a , COOH, -C(O)OR a , -C(O)NH 2 , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -N(C 1~3 alkyl)C(O)R a , -S(O) 2 H, -S(O) 2 R a , -S(O) 2 N.H. 2 , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -NHC(O)OR a , or -N(C 1~3 alkyl)C(O)OR a and C 1~3 Alkyl, C 2~3 Alkenyl, C 2~3 Alkynyl, C 3~6 Cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl may optionally be one or more R c is replaced by Optionally, R 3 is halogen, cyano, NH 2 , OH, or -NHR b Selected from Optionally, R 3 is fluorine, chlorine, bromine, or -NHR b Selected from Optionally, R 3 is bromine, Selected from The compound according to any one of claims 1 to 5, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

7. The R c OH, NH 2 , oxo, halogen, cyano, nitro, C 1~6 Alkyl, C 1~6 Alkoxy, -N(C 1~6 Alkyl) 2 , -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O) 2 R a , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -C 1~6 Alkyl-S(O) 2 -C 1~6 Alkyl, or optionally OH, halogen or C 1~4 3-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; Optionally, the R c OH, NH 2 , oxo, halogen, cyano, nitro, C 1~4 Alkyl, C 1~4 Alkoxy, -N(C 1~4 Alkyl) 2 , -NH(C 1~4 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O) 2 R a , -S(O) 2 N.R. a R b , -NHS(O) 2 R a , -C 1~4 Alkyl-S(O) 2 -C 1~4 Alkyl, or optionally OH, halogen or C 1~3 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; Optionally, the R c OH, NH 2 , halogen, cyano, C 1~4 Alkyl, C 1~4Alkoxy, -N(C 1~4 Alkyl) 2 , -NH(C 1~4 Alkyl), -C 1~4 Alkyl-S(O) 2 -C 1~4 Alkyl, or optionally OH, halogen or C 1~3 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; Optionally, the R c OH, C 1~3 Alkyl, -N(C 1~3 Alkyl) 2 , -C 1~3 Alkyl-S(O) 2 -C 1~3 Alkyl, or optionally OH, halogen or C 1~3 6-membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; Optionally, the R c OH, C 1~3 Alkyl, -N(C 1~3 Alkyl) 2 , -C 1~3 Alkyl-S(O) 2 -C 1~3 Alkyl, or optionally one or more C 1~3 piperazinyl substituted by alkyl; Optionally, the R c is OH, methyl, Selected from Alternatively, the R c is oxo, OH, NH 2 , halogen, cyano, nitro, C 1~8 Alkoxy, -N(C 1~8 Alkyl) 2 , -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O) 2 R a , -S(O) 2 N.R. a R b , -NHS(O) 2 R a or optionally OH, halogen or C 1~6 3-8 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; Optionally, the R c is oxo, halogen, cyano, nitro, C 1~6 Alkoxy, -N(C 1~6 Alkyl) 2 , -NH(C 1~8 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O) 2 R a , -S(O) 2 N.R. a R b , -NHS(O) 2 R a or optionally hydroxy, halogen or C 1~4 3-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; Optionally, the R c is oxo, halogen, cyano, nitro, C 1~4 Alkoxy, -N(C 1~4 Alkyl) 2 , -NH(C 1~4 alkyl), -C(O)R a , -C(O)OR a , -C(O)NR a R b , -OC(O)R a , -NHC(O)R a , -S(O) 2 R a , -S(O) 2 N.R. a R b , -NHS(O) 2 R a or optionally hydroxy, halogen or C 1~3 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; Optionally, said R c is oxo, halogen, cyano, C 1~4 Alkoxy, -N(C 1~4 Alkyl) 2 , -NH(C 1~4 alkyl), or optionally hydroxy, halogen or C 1~3 4-6 membered heterocycloalkyl substituted by one or more groups independently selected from alkyl; The compound according to any one of claims 1 to 6, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

8. The R a and R b each independently represents a group optionally substituted by one or more R″: 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, 3-8 membered heterocycloalkyl, C 6~10 aryl, or 5- to 6-membered heteroaryl; Optionally, said R a and R b each independently represents a group optionally substituted by one or more R″: 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, or 3- to 8-membered heterocycloalkyl; Optionally, said R a and R b each independently represents a group optionally substituted by one or more R″: 1~8 Alkyl, C 3~8 cycloalkyl, or 3- to 8-membered heterocycloalkyl; Optionally, said R a and R b each independently represents a group optionally substituted by one or more R″: 1~5 Alkyl, C 3~6 cycloalkyl, or 4- to 6-membered heterocycloalkyl; Optionally, said R a and R b are each independently selected from the group: methyl, ethyl, propyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydropyranyl, or piperidinyl, optionally substituted with one or more R″; Alternatively, the R a and R b each independently represents a group optionally substituted by one or more R″: 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 selected from cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl; Optionally, said R a and R b each independently represents a group optionally substituted by one or more R″: 3~6 cycloalkyl, or 4- to 6-membered heterocycloalkyl; The compound according to any one of claims 1 to 7, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

9. R″ is independently halogen, oxo, deuterium, NH 2 , OH, cyano, nitro, C 1~8 Alkyl, haloC 1~8 Alkyl, C 1~8 Alkoxy, -N(C 1~8 Alkyl) 2 , -N(deuterated C 1~8 Alkyl) 2 , -NH(C 1~8 Alkyl), C 3~6 cycloalkyl, or optionally C 1~8 3-10 membered heterocycloalkyl substituted by alkyl; Optionally, each R″ is independently selected from halogen, oxo, deuterium, NH 2 , OH, cyano, nitro, haloC 1~6 Alkyl, C 1~6 Alkyl, C 1~6 Alkoxy, -N(C 1~6 Alkyl) 2 , -N(deuterated C 1~6 Alkyl) 2 , -NH(C 1~6 Alkyl), C 3~6 cycloalkyl, or optionally C 1~6 3-6 membered heterocycloalkyl substituted by alkyl; Optionally, each R″ is independently selected from halogen, oxo, deuterium, NH 2 , OH, cyano, nitro, C 1~3 Alkyl, haloC 1~3 Alkyl, C 1~3 Alkoxy, -N(C 1~3 Alkyl) 2 , -N(deuterated C 1~3 Alkyl) 2 , -NH(C 1~3 Alkyl), C 4~6 cycloalkyl, or optionally C 1~3 3-6 membered heterocycloalkyl substituted by alkyl; Optionally, each R″ is independently selected from fluorine, chlorine, bromine, oxo, deuterium, NH 2 , OH, Cyano, C 1~4 Alkyl, Fluoro C 1~4 Alkyl, C 1~4 Alkoxy, -N(C 1~4 Alkyl) 2 , -N(deuterated C 1~4 Alkyl) 2 , -NH(C 1~4 Alkyl), C 5~6 cycloalkyl, or optionally C 1~44-6 membered heterocycloalkyl substituted by alkyl; Optionally, each R″ is independently selected from fluorine, OH, oxo, deuterium, —NH 2 , methyl, ethyl, propyl, trifluoromethyl, -N(CH 3 ) 2 , -N(CD 3 ) 2 , -N(CH 2 CH 3 ) 2 , -NHCH 3 , morpholinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, 1,4-dioxanyl, or oxetanyl optionally substituted by methyl or ethyl; Alternatively, each R" is independently selected from halogen or 3- to 6-membered heterocycloalkyl; Optionally, each R″ is independently selected from fluorine, chlorine, bromine, or 6-membered heterocycloalkyl; Optionally, each R″ is independently selected from fluorine, or morpholinyl; The compound according to any one of claims 1 to 8, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

10. n is selected from 0, 1, 2, or 3; Optionally, n is selected from 0, 1, or 2; Optionally, n is selected from 1 or 2; Optionally, n is selected from 1, The compound according to any one of claims 1 to 9, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

11. R 4 is C 1~3 Alkyl or C 3~4 cycloalkyl, Optionally, R 4 is selected from methyl, ethyl, cyclopropyl, or cyclobutyl; Optionally, R 4 is selected from methyl, or cyclopropyl; Optionally, R 4 is selected from cyclopropyl, Optionally, R 4 is selected from methyl; The compound according to any one of claims 1 to 10, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

12. Formula I'' compounds include I'A compounds, Formula I'B compounds, Formula I compounds, Formula IA compounds, Formula IB compounds, Formula I-1 compounds, Formula I-1A compounds, Formula I-1B compounds, Formula I-2 compounds, Formula I- 2A compound, formula I-2B compound, formula II compound, formula IIA compound, formula IIB compound, formula II-1 compound, formula II-1A compound, formula II-1B compound, formula II-2 compound, formula II-2 A compound, formula II-2B compound, formula III-1 compound, formula III-1A compound, formula III-1B compound, formula III-2 compound, formula III-2A compound, formula III-2B compound, formula I V compound, Formula IVA compound, Formula IVB compound, Formula IV-1 compound, Formula IV-1A compound, Formula IV-1B compound, Formula IV-2 compound, Formula IV-2A compound, or Formula IV-2B compound, Selected from The compound according to any one of claims 1 to 11, its stereoisomer, or a pharma- ceutically acceptable salt thereof.

13. The following compound: Represented by A compound, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

14. A pharmaceutical composition comprising the compound according to any one of claims 1 to 13, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

15. Use of the compound according to any one of claims 1 to 13, its stereoisomer, or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition according to claim 14, in the manufacture of a medicament for preventing or treating cancer, comprising: Optionally, the cancer is selected from lung cancer; Optionally, the cancer is selected from non-small cell lung cancer.

Citation Information

Patent Citations

  • Macrocyclic compounds as EGFR (epidermal growth factor receptor) inhibitors and application thereof

    CN113527335A